evidence_id	assertion_id	disorder_id	disorder_name	source_file	section	section_index	path	evidence_index	reference	supports	evidence_source	snippet	explanation	raw_json
40	71	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	has_subtypes	0	evidence	0	PMID:25604431	SUPPORT		Transthyretin (ATTR) amyloidosis is a life-threatening, gain-of-toxic-function disease characterised by extracellular deposition of amyloid fibrils composed of transthyretin (TTR). TTR protein destabilised by TTR gene mutation is prone to dissociate from its native tetramer to monomer, and to then misfold and aggregate into amyloid fibrils, resulting in autosomal dominant hereditary amyloidosis.	The literature clearly states that mutations in the TTR gene lead to the misfolding of transthyretin proteins, which then aggregate into amyloid fibrils, supporting the statement.	"{""explanation"": ""The literature clearly states that mutations in the TTR gene lead to the misfolding of transthyretin proteins, which then aggregate into amyloid fibrils, supporting the statement."", ""reference"": ""PMID:25604431"", ""snippet"": ""Transthyretin (ATTR) amyloidosis is a life-threatening, gain-of-toxic-function disease characterised by extracellular deposition of amyloid fibrils composed of transthyretin (TTR). TTR protein destabilised by TTR gene mutation is prone to dissociate from its native tetramer to monomer, and to then misfold and aggregate into amyloid fibrils, resulting in autosomal dominant hereditary amyloidosis."", ""supports"": ""SUPPORT""}"
41	71	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	has_subtypes	0	evidence	1	PMID:34518987	SUPPORT		Heritable cardiac amyloidosis (CA) ... results from the accumulation of the misfolded protein transthyretin within the myocardium, resulting in amyloid transthyretin-associated cardiomyopathy (ATTR-CM).	The literature confirms that hereditary cardiac amyloidosis results from the misfolding and accumulation of transthyretin due to mutations in the TTR gene.	"{""explanation"": ""The literature confirms that hereditary cardiac amyloidosis results from the misfolding and accumulation of transthyretin due to mutations in the TTR gene."", ""reference"": ""PMID:34518987"", ""snippet"": ""Heritable cardiac amyloidosis (CA) ... results from the accumulation of the misfolded protein transthyretin within the myocardium, resulting in amyloid transthyretin-associated cardiomyopathy (ATTR-CM)."", ""supports"": ""SUPPORT""}"
42	71	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	has_subtypes	0	evidence	2	PMID:30486687	SUPPORT		Hereditary transthyretin (ATTRm) amyloidosis, formerly known as familial amyloid polyneuropathy, is a major type of hereditary systemic amyloidosis, in which the disease is caused by mutant transthyretin (TTR).	The literature supports that hereditary ATTRm amyloidosis is caused by mutations in the TTR gene, which leads to the disease.	"{""explanation"": ""The literature supports that hereditary ATTRm amyloidosis is caused by mutations in the TTR gene, which leads to the disease."", ""reference"": ""PMID:30486687"", ""snippet"": ""Hereditary transthyretin (ATTRm) amyloidosis, formerly known as familial amyloid polyneuropathy, is a major type of hereditary systemic amyloidosis, in which the disease is caused by mutant transthyretin (TTR)."", ""supports"": ""SUPPORT""}"
43	71	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	has_subtypes	0	evidence	3	PMID:22094129	SUPPORT		Familial amyloid polyneuropathies (FAPs) are a group of life-threatening multisystem disorders transmitted as an autosomal dominant trait. Nerve lesions are induced by deposits of amyloid fibrils, most commonly due to mutated transthyretin (TTR).	The literature confirms that familial amyloid polyneuropathies, a form of hereditary ATTR amyloidosis, are caused by mutated TTR leading to amyloid deposits.	"{""explanation"": ""The literature confirms that familial amyloid polyneuropathies, a form of hereditary ATTR amyloidosis, are caused by mutated TTR leading to amyloid deposits."", ""reference"": ""PMID:22094129"", ""snippet"": ""Familial amyloid polyneuropathies (FAPs) are a group of life-threatening multisystem disorders transmitted as an autosomal dominant trait. Nerve lesions are induced by deposits of amyloid fibrils, most commonly due to mutated transthyretin (TTR)."", ""supports"": ""SUPPORT""}"
44	72	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	has_subtypes	1	evidence	0	PMID:31731233	SUPPORT		Wild-type ATTR amyloidosis (ATTR-wt) is characterized by the accumulation of amyloid in the heart, leading to fatal heart failure and arrhythmia.	The study confirms that ATTR-wt occurs without mutations in the TTR gene and primarily affects the heart in older individuals.	"{""explanation"": ""The study confirms that ATTR-wt occurs without mutations in the TTR gene and primarily affects the heart in older individuals."", ""reference"": ""PMID:31731233"", ""snippet"": ""Wild-type ATTR amyloidosis (ATTR-wt) is characterized by the accumulation of amyloid in the heart, leading to fatal heart failure and arrhythmia."", ""supports"": ""SUPPORT""}"
45	72	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	has_subtypes	1	evidence	1	PMID:26048914	SUPPORT		The non-hereditary form (ATTRwt) is caused by native or wild-type TTR and was previously referred to as senile systemic amyloidosis. ... The predominant effect of ATTRwt amyloidosis is on the heart	The literature supports that ATTRwt occurs without mutations in the TTR gene and primarily affects the heart, commonly in older individuals.	"{""explanation"": ""The literature supports that ATTRwt occurs without mutations in the TTR gene and primarily affects the heart, commonly in older individuals."", ""reference"": ""PMID:26048914"", ""snippet"": ""The non-hereditary form (ATTRwt) is caused by native or wild-type TTR and was previously referred to as senile systemic amyloidosis. ... The predominant effect of ATTRwt amyloidosis is on the heart"", ""supports"": ""SUPPORT""}"
46	72	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	has_subtypes	1	evidence	2	PMID:34390072	SUPPORT		Cardiac ATTR deposition occurred after age 75 years and increased in an age-dependent manner.	The study confirms that ATTRwt affects older individuals and involves amyloid deposits in the heart.	"{""explanation"": ""The study confirms that ATTRwt affects older individuals and involves amyloid deposits in the heart."", ""reference"": ""PMID:34390072"", ""snippet"": ""Cardiac ATTR deposition occurred after age 75 years and increased in an age-dependent manner."", ""supports"": ""SUPPORT""}"
47	72	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	has_subtypes	1	evidence	3	PMID:32441155	SUPPORT		Tissue accumulation of misfolded transthyretin (TTR) may occur because of TTR gene mutations (variant amyloid TTR amyloidosis, ATTRv), or as an age-related phenomenon (wild-type ATTR, ATTRwt).	The literature supports that ATTRwt occurs without TTR gene mutations and is age-related, affecting the heart.	"{""explanation"": ""The literature supports that ATTRwt occurs without TTR gene mutations and is age-related, affecting the heart."", ""reference"": ""PMID:32441155"", ""snippet"": ""Tissue accumulation of misfolded transthyretin (TTR) may occur because of TTR gene mutations (variant amyloid TTR amyloidosis, ATTRv), or as an age-related phenomenon (wild-type ATTR, ATTRwt)."", ""supports"": ""SUPPORT""}"
48	72	4	ATTR_Amyloidosis	ATTR_Amyloidosis.yaml	has_subtypes	1	evidence	4	PMID:28329248	SUPPORT		Wild-type transthyretin amyloidosis (ATTRwt) is mostly considered a disease predominantly of elderly male, characterized by concentric LV hypertrophy, preserved LVEF, and low QRS voltages.	The study supports that ATTRwt commonly affects older individuals and involves the heart.	"{""explanation"": ""The study supports that ATTRwt commonly affects older individuals and involves the heart."", ""reference"": ""PMID:28329248"", ""snippet"": ""Wild-type transthyretin amyloidosis (ATTRwt) is mostly considered a disease predominantly of elderly male, characterized by concentric LV hypertrophy, preserved LVEF, and low QRS voltages."", ""supports"": ""SUPPORT""}"
217	216	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	has_subtypes	0	evidence	0	PMID:3608570	SUPPORT		Aside from opportunistic infections, several neoplasms have been identified as part of the spectrum of acquired immunodeficiency syndrome (AIDS) as defined by the Centers for Disease Control.	The reference explicitly mentions that opportunistic infections and certain cancers (neoplasms) are part of the spectrum of AIDS, fitting the definition of AIDS-defining conditions provided in the statement.	"{""explanation"": ""The reference explicitly mentions that opportunistic infections and certain cancers (neoplasms) are part of the spectrum of AIDS, fitting the definition of AIDS-defining conditions provided in the statement."", ""reference"": ""PMID:3608570"", ""snippet"": ""Aside from opportunistic infections, several neoplasms have been identified as part of the spectrum of acquired immunodeficiency syndrome (AIDS) as defined by the Centers for Disease Control."", ""supports"": ""SUPPORT""}"
218	216	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	has_subtypes	0	evidence	1	PMID:18366449	SUPPORT		The three most frequent initial ADIs were Pneumocystis carinii (jirovecii) pneumonia (PCP) (15.6%), oesophageal candidiasis (14.3%) and Kaposi's sarcoma (13.9%) in the pre-cART period.	This reference discusses specific opportunistic infections and cancers as initial AIDS-defining illnesses (ADIs), supporting the assertion that these conditions signal progression to AIDS.	"{""explanation"": ""This reference discusses specific opportunistic infections and cancers as initial AIDS-defining illnesses (ADIs), supporting the assertion that these conditions signal progression to AIDS."", ""reference"": ""PMID:18366449"", ""snippet"": ""The three most frequent initial ADIs were Pneumocystis carinii (jirovecii) pneumonia (PCP) (15.6%), oesophageal candidiasis (14.3%) and Kaposi's sarcoma (13.9%) in the pre-cART period."", ""supports"": ""SUPPORT""}"
219	216	9	Acquired Immunodeficiency Syndrome	Acquired_Immunodeficiency_Syndrome.yaml	has_subtypes	0	evidence	2	PMID:19584497	SUPPORT		Opportunistic parasitic infection can cause severe morbidity and mortality.	This reference highlights the role of opportunistic infections in patients with HIV/AIDS, which supports the statement about specific opportunistic infections being AIDS-defining conditions.	"{""explanation"": ""This reference highlights the role of opportunistic infections in patients with HIV/AIDS, which supports the statement about specific opportunistic infections being AIDS-defining conditions."", ""reference"": ""PMID:19584497"", ""snippet"": ""Opportunistic parasitic infection can cause severe morbidity and mortality."", ""supports"": ""SUPPORT""}"
386	284	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	has_subtypes	0	evidence	0	PMID:1751370	SUPPORT		MST was 6.2 months for acute type	Shimoyama classification study confirms acute ATLL has median survival of 6.2 months, supporting the poor prognosis described.	"{""explanation"": ""Shimoyama classification study confirms acute ATLL has median survival of 6.2 months, supporting the poor prognosis described."", ""reference"": ""PMID:1751370"", ""snippet"": ""MST was 6.2 months for acute type"", ""supports"": ""SUPPORT""}"
387	285	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	has_subtypes	1	evidence	0	PMID:1751370	SUPPORT		Lymphoma type, no lymphocytosis, 1% or less abnormal T-lymphocytes, and histologically-proven lymphadenopathy with or without extranodal lesions.	Shimoyama classification defines lymphoma type by lymphadenopathy without significant blood involvement.	"{""explanation"": ""Shimoyama classification defines lymphoma type by lymphadenopathy without significant blood involvement."", ""reference"": ""PMID:1751370"", ""snippet"": ""Lymphoma type, no lymphocytosis, 1% or less abnormal T-lymphocytes, and histologically-proven lymphadenopathy with or without extranodal lesions."", ""supports"": ""SUPPORT""}"
388	286	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	has_subtypes	2	evidence	0	PMID:1751370	SUPPORT		24.3 months for chronic type	Shimoyama study shows chronic type has median survival of 24.3 months, supporting the better prognosis described.	"{""explanation"": ""Shimoyama study shows chronic type has median survival of 24.3 months, supporting the better prognosis described."", ""reference"": ""PMID:1751370"", ""snippet"": ""24.3 months for chronic type"", ""supports"": ""SUPPORT""}"
389	287	11	Adult T-Cell Leukemia/Lymphoma	Adult_T_Cell_Leukemia_Lymphoma.yaml	has_subtypes	3	evidence	0	PMID:1751370	SUPPORT		Smouldering type, 5% or more abnormal lymphocytes of T-cell nature in PB, normal lymphocyte level (less than 4 x 10(9)/l), no hypercalcaemia	Shimoyama classification defines smoldering type by low abnormal cell counts and absence of hypercalcemia.	"{""explanation"": ""Shimoyama classification defines smoldering type by low abnormal cell counts and absence of hypercalcemia."", ""reference"": ""PMID:1751370"", ""snippet"": ""Smouldering type, 5% or more abnormal lymphocytes of T-cell nature in PB, normal lymphocyte level (less than 4 x 10(9)/l), no hypercalcaemia"", ""supports"": ""SUPPORT""}"
442	384	15	Akinetopsia	Akinetopsia.yaml	has_subtypes	0	evidence	0	PMID:31036340	SUPPORT	HUMAN_CLINICAL	Two types of akinetopsia have been reported: one is cinematographic vision, and the other is invisibility of moving objects.	This report describes cinematographic vision as one of two reported akinetopsia subtypes.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This report describes cinematographic vision as one of two reported akinetopsia subtypes."", ""reference"": ""PMID:31036340"", ""snippet"": ""Two types of akinetopsia have been reported: one is cinematographic vision, and the other is invisibility of moving objects."", ""supports"": ""SUPPORT""}"
443	385	15	Akinetopsia	Akinetopsia.yaml	has_subtypes	1	evidence	0	PMID:31036340	SUPPORT	HUMAN_CLINICAL	Two types of akinetopsia have been reported: one is cinematographic vision, and the other is invisibility of moving objects.	This report describes invisibility of moving objects as the second akinetopsia subtype.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This report describes invisibility of moving objects as the second akinetopsia subtype."", ""reference"": ""PMID:31036340"", ""snippet"": ""Two types of akinetopsia have been reported: one is cinematographic vision, and the other is invisibility of moving objects."", ""supports"": ""SUPPORT""}"
502	418	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	has_subtypes	0	evidence	0	PMID:30707186	SUPPORT		Early-onset Alzheimer disease (AD) is defined as having an age of onset younger than 65 years. ... Early-onset AD comprises about 5% to 6% of cases of AD and includes a substantial percentage of phenotypic variants that differ from the usual amnestic presentation of typical AD. Characteristics of early-onset AD in comparison to late-onset AD include a larger genetic predisposition (familial mutations and summed polygenic risk)	This reference clearly supports the definition of Early-Onset Alzheimer's Disease as occurring in individuals younger than 65 and being often associated with genetic factors.	"{""explanation"": ""This reference clearly supports the definition of Early-Onset Alzheimer's Disease as occurring in individuals younger than 65 and being often associated with genetic factors."", ""reference"": ""PMID:30707186"", ""snippet"": ""Early-onset Alzheimer disease (AD) is defined as having an age of onset younger than 65 years. ... Early-onset AD comprises about 5% to 6% of cases of AD and includes a substantial percentage of phenotypic variants that differ from the usual amnestic presentation of typical AD. Characteristics of early-onset AD in comparison to late-onset AD include a larger genetic predisposition (familial mutations and summed polygenic risk)"", ""supports"": ""SUPPORT""}"
503	418	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	has_subtypes	0	evidence	1	PMID:25998117	SUPPORT		Young-onset dementia is hereditary, multifactorial, or sporadic. The most common hereditary dementias include Alzheimer disease.	This reference supports the idea that early-onset Alzheimer's disease can be hereditary, aligning with the statement's mention of genetic factors.	"{""explanation"": ""This reference supports the idea that early-onset Alzheimer's disease can be hereditary, aligning with the statement's mention of genetic factors."", ""reference"": ""PMID:25998117"", ""snippet"": ""Young-onset dementia is hereditary, multifactorial, or sporadic. The most common hereditary dementias include Alzheimer disease."", ""supports"": ""SUPPORT""}"
504	419	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	has_subtypes	1	evidence	0	PMID:24429902	SUPPORT		In both cases, the disease results in severe cognitive dysfunction, among other problems, and the late-onset form of the disease is now considered to be the most common cause of dementia among the elderly.	The literature confirms that late-onset Alzheimer's Disease is the most common form of Alzheimer's and primarily affects those aged 65 and older.	"{""explanation"": ""The literature confirms that late-onset Alzheimer's Disease is the most common form of Alzheimer's and primarily affects those aged 65 and older."", ""reference"": ""PMID:24429902"", ""snippet"": ""In both cases, the disease results in severe cognitive dysfunction, among other problems, and the late-onset form of the disease is now considered to be the most common cause of dementia among the elderly."", ""supports"": ""SUPPORT""}"
505	419	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	has_subtypes	1	evidence	1	PMID:34120901	SUPPORT		BACKGROUND: Young onset dementia is associated with a longer time to diagnosis compared to late onset dementia.	The study differentiates between young onset and late onset Alzheimer's Disease, with late onset typically affecting older adults.	"{""explanation"": ""The study differentiates between young onset and late onset Alzheimer's Disease, with late onset typically affecting older adults."", ""reference"": ""PMID:34120901"", ""snippet"": ""BACKGROUND: Young onset dementia is associated with a longer time to diagnosis compared to late onset dementia."", ""supports"": ""SUPPORT""}"
506	419	17	Alhzeimer_Disease	Alhzeimer_Disease.yaml	has_subtypes	1	evidence	2	PMID:18667359	SUPPORT		Alzheimer's disease accounts for 60% whereas vascular dementia accounts for approximately 30% of the prevalence. Early-onset familial forms of dementia with single-gene defects occur in Latin America, Asia, and Africa.	The literature indicates that late-onset Alzheimer's Disease is more prevalent compared to early-onset forms.	"{""explanation"": ""The literature indicates that late-onset Alzheimer's Disease is more prevalent compared to early-onset forms."", ""reference"": ""PMID:18667359"", ""snippet"": ""Alzheimer's disease accounts for 60% whereas vascular dementia accounts for approximately 30% of the prevalence. Early-onset familial forms of dementia with single-gene defects occur in Latin America, Asia, and Africa."", ""supports"": ""SUPPORT""}"
712	582	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	has_subtypes	0	evidence	0	PMID:16338214	SUPPORT		the condition can exist on its own. APS appears to represent a clinical spectrum, both in terms of APS features and the presence of other autoimmune conditions. The clinical and serological characteristics of 'primary' APS (PAPS) are similar to those of secondary APS, although the clinical features are more commonly recognised in the presence of another autoimmune or inflammatory condition.	The passage supports the statement by indicating that APS can exist on its own without other related diseases, defining it as primary APS (PAPS).	"{""explanation"": ""The passage supports the statement by indicating that APS can exist on its own without other related diseases, defining it as primary APS (PAPS)."", ""reference"": ""PMID:16338214"", ""snippet"": ""the condition can exist on its own. APS appears to represent a clinical spectrum, both in terms of APS features and the presence of other autoimmune conditions. The clinical and serological characteristics of 'primary' APS (PAPS) are similar to those of secondary APS, although the clinical features are more commonly recognised in the presence of another autoimmune or inflammatory condition."", ""supports"": ""SUPPORT""}"
713	582	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	has_subtypes	0	evidence	1	PMID:27550302	SUPPORT		APS can be isolated (primary APS) or associated with other autoimmune diseases.	This snippet reinforces that APS can exist independently as primary APS.	"{""explanation"": ""This snippet reinforces that APS can exist independently as primary APS."", ""reference"": ""PMID:27550302"", ""snippet"": ""APS can be isolated (primary APS) or associated with other autoimmune diseases."", ""supports"": ""SUPPORT""}"
714	583	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	has_subtypes	1	evidence	0	PMID:11014973	SUPPORT		APS may be associated with another autoimmune disease (secondary APS), particularly systemic lupus erythematosus (SLE).	This reference states that APS can occur with other autoimmune diseases, particularly systemic lupus erythematosus, which supports the statement regarding the subtype Secondary APS.	"{""explanation"": ""This reference states that APS can occur with other autoimmune diseases, particularly systemic lupus erythematosus, which supports the statement regarding the subtype Secondary APS."", ""reference"": ""PMID:11014973"", ""snippet"": ""APS may be associated with another autoimmune disease (secondary APS), particularly systemic lupus erythematosus (SLE)."", ""supports"": ""SUPPORT""}"
715	583	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	has_subtypes	1	evidence	1	PMID:15507265	SUPPORT		Primary utilized when there is no associated disorder, secondary with an associated autoimmune disorder such as systemic lupus erythematosus (SLE).	This reference explains that secondary APS is associated with another autoimmune disorder, specifically mentioning systemic lupus erythematosus (SLE), thus supporting the statement.	"{""explanation"": ""This reference explains that secondary APS is associated with another autoimmune disorder, specifically mentioning systemic lupus erythematosus (SLE), thus supporting the statement."", ""reference"": ""PMID:15507265"", ""snippet"": ""Primary utilized when there is no associated disorder, secondary with an associated autoimmune disorder such as systemic lupus erythematosus (SLE)."", ""supports"": ""SUPPORT""}"
716	583	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	has_subtypes	1	evidence	2	PMID:19593144	SUPPORT		Although originally described in the context of systemic lupus erythematosus, antiphospholipid syndrome was then recognized as a primary antiphospholipid syndrome without any underlying autoimmune disease in almost half of the cases.	This reference provides context for primary APS being without other autoimmune diseases and implies that secondary APS, in contrast, involves other autoimmune disorders such as systemic lupus erythematosus.	"{""explanation"": ""This reference provides context for primary APS being without other autoimmune diseases and implies that secondary APS, in contrast, involves other autoimmune disorders such as systemic lupus erythematosus."", ""reference"": ""PMID:19593144"", ""snippet"": ""Although originally described in the context of systemic lupus erythematosus, antiphospholipid syndrome was then recognized as a primary antiphospholipid syndrome without any underlying autoimmune disease in almost half of the cases."", ""supports"": ""SUPPORT""}"
717	583	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	has_subtypes	1	evidence	3	PMID:35896399	SUPPORT		Systemic lupus erythematosus (SLE) and secondary anti-phospholipid syndrome (APS II) can cause increased morbidity and mortality of the fetus.	This article mentions secondary antiphospholipid syndrome in conjunction with systemic lupus erythematosus, supporting the existence of Secondary APS as a subtype of APS.	"{""explanation"": ""This article mentions secondary antiphospholipid syndrome in conjunction with systemic lupus erythematosus, supporting the existence of Secondary APS as a subtype of APS."", ""reference"": ""PMID:35896399"", ""snippet"": ""Systemic lupus erythematosus (SLE) and secondary anti-phospholipid syndrome (APS II) can cause increased morbidity and mortality of the fetus."", ""supports"": ""SUPPORT""}"
718	583	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	has_subtypes	1	evidence	4	PMID:10866096	SUPPORT		We retrospectively studied patients with APS and systemic lupus erythematosus (SLE)...39 patients had primary antiphospholipid syndrome (PAPS) and 69 secondary antiphospholipid syndrome (SAPS).	This article gives data on secondary APS occurring along with systemic lupus erythematosus, thus supporting the statement about the existence of the Secondary APS subtype.	"{""explanation"": ""This article gives data on secondary APS occurring along with systemic lupus erythematosus, thus supporting the statement about the existence of the Secondary APS subtype."", ""reference"": ""PMID:10866096"", ""snippet"": ""We retrospectively studied patients with APS and systemic lupus erythematosus (SLE)...39 patients had primary antiphospholipid syndrome (PAPS) and 69 secondary antiphospholipid syndrome (SAPS)."", ""supports"": ""SUPPORT""}"
719	583	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	has_subtypes	1	evidence	5	PMID:26939208	SUPPORT		BACKGROUND: The antiphospholipid syndrome (APS) is one of the most encountered autoimmunity in systemic lupus erythematosus (SLE) patients and pathogenesis of these two seems to be intricate	This article states that APS is common in SLE patients, indicating the close relationship between APS and SLE and supporting the subtype of Secondary APS.	"{""explanation"": ""This article states that APS is common in SLE patients, indicating the close relationship between APS and SLE and supporting the subtype of Secondary APS."", ""reference"": ""PMID:26939208"", ""snippet"": ""BACKGROUND: The antiphospholipid syndrome (APS) is one of the most encountered autoimmunity in systemic lupus erythematosus (SLE) patients and pathogenesis of these two seems to be intricate"", ""supports"": ""SUPPORT""}"
720	584	24	Antiphospholipid Syndrome	Antiphospholipid_Syndrome.yaml	has_subtypes	2	evidence	0	PMID:17145604	SUPPORT		Antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS) are increasingly being recognized in children. Transient non-pathogenic aPL are often seen after childhood infections, while thrombotic events seem rare in those with true aPL.	The reference supports the existence of individuals with antiphospholipid antibodies but no clinical symptoms, which align with the description of Asymptomatic APS.	"{""explanation"": ""The reference supports the existence of individuals with antiphospholipid antibodies but no clinical symptoms, which align with the description of Asymptomatic APS."", ""reference"": ""PMID:17145604"", ""snippet"": ""Antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS) are increasingly being recognized in children. Transient non-pathogenic aPL are often seen after childhood infections, while thrombotic events seem rare in those with true aPL."", ""supports"": ""SUPPORT""}"
895	690	28	Asthma	Asthma.yaml	has_subtypes	0	evidence	0	PMID:32037107	SUPPORT		Allergic asthma is defined as asthma associated with sensitization to aeroallergens, which leads to asthma symptoms and airway inflammation.	The literature explicitly states that allergic asthma is triggered by allergens.	"{""explanation"": ""The literature explicitly states that allergic asthma is triggered by allergens."", ""reference"": ""PMID:32037107"", ""snippet"": ""Allergic asthma is defined as asthma associated with sensitization to aeroallergens, which leads to asthma symptoms and airway inflammation."", ""supports"": ""SUPPORT""}"
896	690	28	Asthma	Asthma.yaml	has_subtypes	0	evidence	1	PMID:24925403	SUPPORT		Allergic diseases triggered by mite allergens include allergic rhinoconjunctivitis, asthma, atopic dermatitis and other skin diseases.	This literature confirms asthma can be triggered by mite allergens, consistent with the definition of allergic asthma.	"{""explanation"": ""This literature confirms asthma can be triggered by mite allergens, consistent with the definition of allergic asthma."", ""reference"": ""PMID:24925403"", ""snippet"": ""Allergic diseases triggered by mite allergens include allergic rhinoconjunctivitis, asthma, atopic dermatitis and other skin diseases."", ""supports"": ""SUPPORT""}"
897	690	28	Asthma	Asthma.yaml	has_subtypes	0	evidence	2	PMID:32589303	SUPPORT		Respiratory health can be particularly affected by climate change, which contributes to the development of allergic respiratory diseases and asthma.	The document indicates that climate change contributes to the development of asthma, supporting the statement.	"{""explanation"": ""The document indicates that climate change contributes to the development of asthma, supporting the statement."", ""reference"": ""PMID:32589303"", ""snippet"": ""Respiratory health can be particularly affected by climate change, which contributes to the development of allergic respiratory diseases and asthma."", ""supports"": ""SUPPORT""}"
898	690	28	Asthma	Asthma.yaml	has_subtypes	0	evidence	3	PMID:30725285	SUPPORT		Asthma is a heterogeneous chronic inflammatory disease of the airways. The most prevalent form is atopic asthma, which is initiated by the exposure to (inhaled) allergens.	This literature identifies atopic (allergic) asthma as initiated by allergens, which supports the statement.	"{""explanation"": ""This literature identifies atopic (allergic) asthma as initiated by allergens, which supports the statement."", ""reference"": ""PMID:30725285"", ""snippet"": ""Asthma is a heterogeneous chronic inflammatory disease of the airways. The most prevalent form is atopic asthma, which is initiated by the exposure to (inhaled) allergens."", ""supports"": ""SUPPORT""}"
899	691	28	Asthma	Asthma.yaml	has_subtypes	1	evidence	0	PMID:11678516	PARTIAL		Asthmatic attack in exercise-induced asthma is brought about by hyperventilation (not necessarily to exercise), cold air, and low humidity of the air breathed.	The reference discusses asthma subtypes triggered by exercise, cold air, and respiratory conditions, but does not explicitly mention stress or classify it specifically as 'Non-Allergic Asthma'.	"{""explanation"": ""The reference discusses asthma subtypes triggered by exercise, cold air, and respiratory conditions, but does not explicitly mention stress or classify it specifically as 'Non-Allergic Asthma'."", ""reference"": ""PMID:11678516"", ""snippet"": ""Asthmatic attack in exercise-induced asthma is brought about by hyperventilation (not necessarily to exercise), cold air, and low humidity of the air breathed."", ""supports"": ""PARTIAL""}"
900	691	28	Asthma	Asthma.yaml	has_subtypes	1	evidence	1	PMID:25439356	PARTIAL		First, asthma phenotypes that are associated with environmental exposures (occupational agents, cigarette smoke, air pollution, cold dry air)...	The reference mentions environmental exposures like cold dry air and non-allergic triggers, but does not explicitly identify stress or exercise specifically in relation to 'Non-Allergic Asthma'.	"{""explanation"": ""The reference mentions environmental exposures like cold dry air and non-allergic triggers, but does not explicitly identify stress or exercise specifically in relation to 'Non-Allergic Asthma'."", ""reference"": ""PMID:25439356"", ""snippet"": ""First, asthma phenotypes that are associated with environmental exposures (occupational agents, cigarette smoke, air pollution, cold dry air)..."", ""supports"": ""PARTIAL""}"
901	691	28	Asthma	Asthma.yaml	has_subtypes	1	evidence	2	PMID:20176257	SUPPORT		Indoor and outdoor air pollutants trigger airway inflammation and increase the severity of asthma.	The reference corroborates that environmental pollutants are triggers for asthma exacerbations.	"{""explanation"": ""The reference corroborates that environmental pollutants are triggers for asthma exacerbations."", ""reference"": ""PMID:20176257"", ""snippet"": ""Indoor and outdoor air pollutants trigger airway inflammation and increase the severity of asthma."", ""supports"": ""SUPPORT""}"
902	692	28	Asthma	Asthma.yaml	has_subtypes	2	evidence	0	PMID:36833767	SUPPORT		Only a few previous studies have investigated the subtypes of adult-onset asthma. No previous study has assessed whether these subtypes are different between men and women, or whether these subtypes have different risk factors.	The reference discusses subtypes of adult-onset asthma and emphasizes the importance of different risk factors, which supports that adult-onset asthma could have environmental triggers.	"{""explanation"": ""The reference discusses subtypes of adult-onset asthma and emphasizes the importance of different risk factors, which supports that adult-onset asthma could have environmental triggers."", ""reference"": ""PMID:36833767"", ""snippet"": ""Only a few previous studies have investigated the subtypes of adult-onset asthma. No previous study has assessed whether these subtypes are different between men and women, or whether these subtypes have different risk factors."", ""supports"": ""SUPPORT""}"
903	692	28	Asthma	Asthma.yaml	has_subtypes	2	evidence	1	PMID:30240884	SUPPORT		Adult-onset asthma is an important asthma phenotype and, in contrast to childhood asthma, is often associated with specific triggers of onset.	This study indicates that adult-onset asthma is often associated with specific triggers of onset, which aligns with the statement that it is often triggered by environmental factors.	"{""explanation"": ""This study indicates that adult-onset asthma is often associated with specific triggers of onset, which aligns with the statement that it is often triggered by environmental factors."", ""reference"": ""PMID:30240884"", ""snippet"": ""Adult-onset asthma is an important asthma phenotype and, in contrast to childhood asthma, is often associated with specific triggers of onset."", ""supports"": ""SUPPORT""}"
904	692	28	Asthma	Asthma.yaml	has_subtypes	2	evidence	2	PMID:20176257	SUPPORT		Exposure to unusual substances at work causes occupational asthma, accounting for about 5% of asthma in adults. Indoor and outdoor air pollutants trigger airway inflammation and increase the severity of asthma.	The literature specifies that environmental factors such as pollutants can trigger adult asthma, further supporting the statement about environmental triggers.	"{""explanation"": ""The literature specifies that environmental factors such as pollutants can trigger adult asthma, further supporting the statement about environmental triggers."", ""reference"": ""PMID:20176257"", ""snippet"": ""Exposure to unusual substances at work causes occupational asthma, accounting for about 5% of asthma in adults. Indoor and outdoor air pollutants trigger airway inflammation and increase the severity of asthma."", ""supports"": ""SUPPORT""}"
905	693	28	Asthma	Asthma.yaml	has_subtypes	3	evidence	0	PMID:26398072	SUPPORT		Although in textbooks asthma and chronic obstructive pulmonary disease (COPD) are viewed as distinct disorders, there is increasing awareness that many patients have features of both. This article reviews the asthma-COPD overlap syndrome.	The article explicitly refers to the Asthma-COPD Overlap Syndrome, which indicates the presence of subtypes sharing features of both asthma and COPD.	"{""explanation"": ""The article explicitly refers to the Asthma-COPD Overlap Syndrome, which indicates the presence of subtypes sharing features of both asthma and COPD."", ""reference"": ""PMID:26398072"", ""snippet"": ""Although in textbooks asthma and chronic obstructive pulmonary disease (COPD) are viewed as distinct disorders, there is increasing awareness that many patients have features of both. This article reviews the asthma-COPD overlap syndrome."", ""supports"": ""SUPPORT""}"
906	693	28	Asthma	Asthma.yaml	has_subtypes	3	evidence	1	PMID:24507842	SUPPORT		Asthma in childhood and COPD in smokers have their own phenotypic expression with underlying pathophysiological mechanisms that differ importantly. In older adults, asthma and COPD are more difficult to differentiate and there exists a bronchodilator response in most but not all patients with asthma and persistent airway obstruction in most but not all patients with COPD where even up to 50% have been reported to have some bronchodilator response as assessed with FEV1.	The article acknowledges overlapping phenotypes between asthma and COPD, supporting the existence of a subtype with features of both diseases.	"{""explanation"": ""The article acknowledges overlapping phenotypes between asthma and COPD, supporting the existence of a subtype with features of both diseases."", ""reference"": ""PMID:24507842"", ""snippet"": ""Asthma in childhood and COPD in smokers have their own phenotypic expression with underlying pathophysiological mechanisms that differ importantly. In older adults, asthma and COPD are more difficult to differentiate and there exists a bronchodilator response in most but not all patients with asthma and persistent airway obstruction in most but not all patients with COPD where even up to 50% have been reported to have some bronchodilator response as assessed with FEV1."", ""supports"": ""SUPPORT""}"
907	693	28	Asthma	Asthma.yaml	has_subtypes	3	evidence	2	PMID:29713158	SUPPORT		Asthma and COPD are heterogeneous diseases. Patients with both disease features (asthma-COPD overlap ...) are common.	This article clearly supports that there is an overlap between asthma and COPD, validating the statement about the Asthma-COPD Overlap subtype with shared features.	"{""explanation"": ""This article clearly supports that there is an overlap between asthma and COPD, validating the statement about the Asthma-COPD Overlap subtype with shared features."", ""reference"": ""PMID:29713158"", ""snippet"": ""Asthma and COPD are heterogeneous diseases. Patients with both disease features (asthma-COPD overlap ...) are common."", ""supports"": ""SUPPORT""}"
908	694	28	Asthma	Asthma.yaml	has_subtypes	4	evidence	0	PMID:22794682	SUPPORT		patients with asthma may be classified as allergic (IgE mediated), nonallergic (often triggered by viral upper respiratory tract infections or no apparent cause), occupational, aspirin-exacerbated respiratory disease, potentially (near) fatal, exercise induced, and cough variant asthma.	This reference explicitly lists exercise-induced asthma as a subtype of asthma, supporting the statement.	"{""explanation"": ""This reference explicitly lists exercise-induced asthma as a subtype of asthma, supporting the statement."", ""reference"": ""PMID:22794682"", ""snippet"": ""patients with asthma may be classified as allergic (IgE mediated), nonallergic (often triggered by viral upper respiratory tract infections or no apparent cause), occupational, aspirin-exacerbated respiratory disease, potentially (near) fatal, exercise induced, and cough variant asthma."", ""supports"": ""SUPPORT""}"
909	694	28	Asthma	Asthma.yaml	has_subtypes	4	evidence	1	PMID:5002114	SUPPORT		This study indicates that swimming should be recommended in preference to running or cycling as an exercise programme for adults and children with asthma.	This study highlights exercise-induced asthma and provides insights into managing physical activities for those with this subtype.	"{""explanation"": ""This study highlights exercise-induced asthma and provides insights into managing physical activities for those with this subtype."", ""reference"": ""PMID:5002114"", ""snippet"": ""This study indicates that swimming should be recommended in preference to running or cycling as an exercise programme for adults and children with asthma."", ""supports"": ""SUPPORT""}"
910	694	28	Asthma	Asthma.yaml	has_subtypes	4	evidence	2	PMID:22157157	SUPPORT		Exercise-induced bronchoconstriction (EIB) refers to acute airflow obstruction that is triggered by a period of physical exertion.	This study details the pathology of exercise-induced bronchoconstriction, commonly referred to as exercise-induced asthma, supporting the statement.	"{""explanation"": ""This study details the pathology of exercise-induced bronchoconstriction, commonly referred to as exercise-induced asthma, supporting the statement."", ""reference"": ""PMID:22157157"", ""snippet"": ""Exercise-induced bronchoconstriction (EIB) refers to acute airflow obstruction that is triggered by a period of physical exertion."", ""supports"": ""SUPPORT""}"
911	694	28	Asthma	Asthma.yaml	has_subtypes	4	evidence	3	PMID:37086818	SUPPORT		Exercise is one of the most commonly reported symptom triggers for people with asthma.	This reference recognizes the role of physical exertion as a trigger for asthma symptoms, aligning with the concept of exercise-induced asthma as a subtype.	"{""explanation"": ""This reference recognizes the role of physical exertion as a trigger for asthma symptoms, aligning with the concept of exercise-induced asthma as a subtype."", ""reference"": ""PMID:37086818"", ""snippet"": ""Exercise is one of the most commonly reported symptom triggers for people with asthma."", ""supports"": ""SUPPORT""}"
1067	807	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	has_subtypes	0	evidence	0	PMID:22199394	SUPPORT		Recent advances in molecular genetics have identified two major genes, PITX2 and FOXC1, demonstrating a wide spectrum of mutations, which aids in the molecular diagnosis of the disease.	The literature confirms that Axenfeld-Rieger syndrome is associated with mutations in the PITX2 gene and is characterized by ocular abnormalities and extra-ocular symptoms.	"{""explanation"": ""The literature confirms that Axenfeld-Rieger syndrome is associated with mutations in the PITX2 gene and is characterized by ocular abnormalities and extra-ocular symptoms."", ""reference"": ""PMID:22199394"", ""snippet"": ""Recent advances in molecular genetics have identified two major genes, PITX2 and FOXC1, demonstrating a wide spectrum of mutations, which aids in the molecular diagnosis of the disease."", ""supports"": ""SUPPORT""}"
1068	807	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	has_subtypes	0	evidence	1	PMID:31341655	SUPPORT		The PITX2 gene may be responsible for a significant portion of ARS with additional systemic defects in the Chinese population.	This reference supports the statement by indicating that mutations in the PITX2 gene are linked to Axenfeld-Rieger syndrome, which includes ocular and systemic manifestations.	"{""explanation"": ""This reference supports the statement by indicating that mutations in the PITX2 gene are linked to Axenfeld-Rieger syndrome, which includes ocular and systemic manifestations."", ""reference"": ""PMID:31341655"", ""snippet"": ""The PITX2 gene may be responsible for a significant portion of ARS with additional systemic defects in the Chinese population."", ""supports"": ""SUPPORT""}"
1069	807	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	has_subtypes	0	evidence	2	PMID:11092457	SUPPORT		Rieger syndrome (RIEG 1; MIM 180500) is an autosomal dominant disorder of morphogenesis. It is a phenotypically heterogeneous disorder characterized by malformations of the eyes, teeth, and umbilicus.	This reference confirms that Rieger syndrome, also known as Axenfeld-Rieger Syndrome Type 1 (RIEG1), involves ocular and extra-ocular abnormalities.	"{""explanation"": ""This reference confirms that Rieger syndrome, also known as Axenfeld-Rieger Syndrome Type 1 (RIEG1), involves ocular and extra-ocular abnormalities."", ""reference"": ""PMID:11092457"", ""snippet"": ""Rieger syndrome (RIEG 1; MIM 180500) is an autosomal dominant disorder of morphogenesis. It is a phenotypically heterogeneous disorder characterized by malformations of the eyes, teeth, and umbilicus."", ""supports"": ""SUPPORT""}"
1070	808	33	Axenfeld-Rieger_syndrome	Axenfeld-Rieger_syndrome.yaml	has_subtypes	1	evidence	0	PMID:32741584	SUPPORT		Axenfeld-Rieger syndrome (ARS) type 3 is a rare autosomal dominant disease, characterized by anterior segment dysgenesis of the eye, hearing loss, and cardiac defects. ARS type 3 is highly associated with FOXC1 mutations, which induces developmental disorders of neural crest cells.	This reference directly supports the statement that Axenfeld-Rieger Syndrome Type 3 (RIEG3) is caused by mutations in the FOXC1 gene and has similar phenotypic features.	"{""explanation"": ""This reference directly supports the statement that Axenfeld-Rieger Syndrome Type 3 (RIEG3) is caused by mutations in the FOXC1 gene and has similar phenotypic features."", ""reference"": ""PMID:32741584"", ""snippet"": ""Axenfeld-Rieger syndrome (ARS) type 3 is a rare autosomal dominant disease, characterized by anterior segment dysgenesis of the eye, hearing loss, and cardiac defects. ARS type 3 is highly associated with FOXC1 mutations, which induces developmental disorders of neural crest cells."", ""supports"": ""SUPPORT""}"
1306	972	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	has_subtypes	0	evidence	0	PMID:37612261	SUPPORT		This study reports variants in BBS1 and BBS7 in patients with Bardet-Biedl syndrome from the Canadian Maritime provinces. The BBS1 variant NM_024649.5:c.1169T>G was identified as a recurrent variant in Prince Edward Island.	This supports the claim that mutations in the BBS1 gene are a common subtype of Bardet-Biedl syndrome.	"{""explanation"": ""This supports the claim that mutations in the BBS1 gene are a common subtype of Bardet-Biedl syndrome."", ""reference"": ""PMID:37612261"", ""snippet"": ""This study reports variants in BBS1 and BBS7 in patients with Bardet-Biedl syndrome from the Canadian Maritime provinces. The BBS1 variant NM_024649.5:c.1169T>G was identified as a recurrent variant in Prince Edward Island."", ""supports"": ""SUPPORT""}"
1307	972	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	has_subtypes	0	evidence	1	PMID:32759308	SUPPORT		More than half of BBS patients carry mutations in one of eight genes encoding for subunits of a protein complex, the BBSome, which mediates trafficking of ciliary cargoes. ... We show that the pre-BBSome is nucleated by BBS4 and assembled at pericentriolar satellites, followed by the translocation of the BBSome into the ciliary base mediated by BBS1.	This explains the critical role of BBS1 in the assembly of the BBSome, further implicating it in Bardet-Biedl syndrome.	"{""explanation"": ""This explains the critical role of BBS1 in the assembly of the BBSome, further implicating it in Bardet-Biedl syndrome."", ""reference"": ""PMID:32759308"", ""snippet"": ""More than half of BBS patients carry mutations in one of eight genes encoding for subunits of a protein complex, the BBSome, which mediates trafficking of ciliary cargoes. ... We show that the pre-BBSome is nucleated by BBS4 and assembled at pericentriolar satellites, followed by the translocation of the BBSome into the ciliary base mediated by BBS1."", ""supports"": ""SUPPORT""}"
1308	973	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	has_subtypes	1	evidence	0	PMID:36672825	SUPPORT		Patient 3 had Bardet-Biedl syndrome and carried a heterozygous mutation (c.389_390delAC; p.Asn130ThrfsTer4) in BBS7 and a homozygous mutation in BBS2 (c.209G>A; p.Ser70Asn). Her clinical findings included global developmental delay, disproportionate short stature, myopia, retinitis pigmentosa, obesity, pyometra with vaginal atresia, bilateral hydronephrosis with ureteropelvic junction obstruction, bilateral genu valgus, post-axial polydactyly feet, and small and thin fingernails and toenails, tooth agenesis, microdontia, taurodontism, and impaired dentin formation.	The study shows that a mutation in the BBS2 gene can indeed cause Bardet-Biedl syndrome and the associated phenotypic variability in clinical findings.	"{""explanation"": ""The study shows that a mutation in the BBS2 gene can indeed cause Bardet-Biedl syndrome and the associated phenotypic variability in clinical findings."", ""reference"": ""PMID:36672825"", ""snippet"": ""Patient 3 had Bardet-Biedl syndrome and carried a heterozygous mutation (c.389_390delAC; p.Asn130ThrfsTer4) in BBS7 and a homozygous mutation in BBS2 (c.209G>A; p.Ser70Asn). Her clinical findings included global developmental delay, disproportionate short stature, myopia, retinitis pigmentosa, obesity, pyometra with vaginal atresia, bilateral hydronephrosis with ureteropelvic junction obstruction, bilateral genu valgus, post-axial polydactyly feet, and small and thin fingernails and toenails, tooth agenesis, microdontia, taurodontism, and impaired dentin formation."", ""supports"": ""SUPPORT""}"
1309	973	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	has_subtypes	1	evidence	1	PMID:34364070	SUPPORT		Bardet-Biedl syndrome is a autosomal recessive hereditary disorder characterized by polydactyly, multiple renal cysts, retinal cone-rod dystrophy, obesity, and variable neural development or cognitive impairment	This study supports that mutations in the BBS2 gene can cause Bardet-Biedl syndrome, along with a spectrum of associated features, reinforcing the idea of phenotypic variability.	"{""explanation"": ""This study supports that mutations in the BBS2 gene can cause Bardet-Biedl syndrome, along with a spectrum of associated features, reinforcing the idea of phenotypic variability."", ""reference"": ""PMID:34364070"", ""snippet"": ""Bardet-Biedl syndrome is a autosomal recessive hereditary disorder characterized by polydactyly, multiple renal cysts, retinal cone-rod dystrophy, obesity, and variable neural development or cognitive impairment"", ""supports"": ""SUPPORT""}"
1310	974	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	has_subtypes	2	evidence	0	PMID:12876834	SUPPORT		BBS is defined by the association of retinopathy, obesity, hypogonadism, renal dysfunction, postaxial polydactyly and mental retardation. This clinically complex syndrome is genetically heterogeneous with linkage to more than 6 loci, and 4 genes have been cloned so far.	This reference acknowledges the genetic heterogeneity of Bardet-Biedl Syndrome and mentions multiple BBS genes.	"{""explanation"": ""This reference acknowledges the genetic heterogeneity of Bardet-Biedl Syndrome and mentions multiple BBS genes."", ""reference"": ""PMID:12876834"", ""snippet"": ""BBS is defined by the association of retinopathy, obesity, hypogonadism, renal dysfunction, postaxial polydactyly and mental retardation. This clinically complex syndrome is genetically heterogeneous with linkage to more than 6 loci, and 4 genes have been cloned so far."", ""supports"": ""SUPPORT""}"
1311	974	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	has_subtypes	2	evidence	1	PMID:27170093	SUPPORT		Bardet-Biedl Syndrome (BBS) is an autosomal recessive disorder and is classified as one of the ciliopathy.	Although this reference focuses on BBS3, it contributes to the recognition of different BBS subtypes caused by mutations in various BBS genes.	"{""explanation"": ""Although this reference focuses on BBS3, it contributes to the recognition of different BBS subtypes caused by mutations in various BBS genes."", ""reference"": ""PMID:27170093"", ""snippet"": ""Bardet-Biedl Syndrome (BBS) is an autosomal recessive disorder and is classified as one of the ciliopathy."", ""supports"": ""SUPPORT""}"
1312	974	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	has_subtypes	2	evidence	2	PMID:32165602	SUPPORT		Bardet-Biedl syndrome (BBS) is a rare heterogenous autosomal recessive disease due to defects in primary cilia which until now, up to 21 types have been detected.	The reference highlights the heterogeneity of BBS and mentions the existence of multiple types of the syndrome, caused by different genetic mutations.	"{""explanation"": ""The reference highlights the heterogeneity of BBS and mentions the existence of multiple types of the syndrome, caused by different genetic mutations."", ""reference"": ""PMID:32165602"", ""snippet"": ""Bardet-Biedl syndrome (BBS) is a rare heterogenous autosomal recessive disease due to defects in primary cilia which until now, up to 21 types have been detected."", ""supports"": ""SUPPORT""}"
1313	974	40	Bardet-Biedl Syndrome	Bardet-Biedl_Syndrome.yaml	has_subtypes	2	evidence	3	PMID:36325687	SUPPORT		Mutation screening demonstrated four novel mutations: c.613C>T; p.Q205* in the BBS5 gene, c.1391C>G; p.S464* in the BBS10 gene, and c.155delC; p.S52* and c.1584T>G; p.Y528* in the BBS12 gene.	This study identifies mutations in multiple BBS genes, supporting the statement that BBS comprises various subtypes caused by different genetic mutations.	"{""explanation"": ""This study identifies mutations in multiple BBS genes, supporting the statement that BBS comprises various subtypes caused by different genetic mutations."", ""reference"": ""PMID:36325687"", ""snippet"": ""Mutation screening demonstrated four novel mutations: c.613C>T; p.Q205* in the BBS5 gene, c.1391C>G; p.S464* in the BBS10 gene, and c.155delC; p.S52* and c.1584T>G; p.Y528* in the BBS12 gene."", ""supports"": ""SUPPORT""}"
1444	1142	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	has_subtypes	0	evidence	0	PMID:12839317	SUPPORT	HUMAN_CLINICAL	One subgroup of patients develops interstitial pulmonary fibrosis after recurrent acute episodes (recurrent BFL)	The abstract defines a recurrent chronic BFL subtype marked by recurrent acute episodes and fibrotic progression.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The abstract defines a recurrent chronic BFL subtype marked by recurrent acute episodes and fibrotic progression."", ""reference"": ""PMID:12839317"", ""snippet"": ""One subgroup of patients develops interstitial pulmonary fibrosis after recurrent acute episodes (recurrent BFL)"", ""supports"": ""SUPPORT""}"
1445	1143	47	Bird Fancier's Lung	Bird_Fanciers_Lung.yaml	has_subtypes	1	evidence	0	PMID:12839317	SUPPORT	HUMAN_CLINICAL	the other subgroup of patients has no history of acute episodes but has slowly progressive chronic respiratory disease (insidious BFL).	The abstract defines an insidious subtype with slow progression and no acute episode history.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The abstract defines an insidious subtype with slow progression and no acute episode history."", ""reference"": ""PMID:12839317"", ""snippet"": ""the other subgroup of patients has no history of acute episodes but has slowly progressive chronic respiratory disease (insidious BFL)."", ""supports"": ""SUPPORT""}"
1832	1582	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	has_subtypes	0	evidence	0	PMID:23204254	SUPPORT		Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD).	The article clearly states that Chronic Bronchitis (CB) is a subtype of COPD, characterized by inflammation of the bronchial tubes leading to increased mucus production and chronic cough.	"{""explanation"": ""The article clearly states that Chronic Bronchitis (CB) is a subtype of COPD, characterized by inflammation of the bronchial tubes leading to increased mucus production and chronic cough."", ""reference"": ""PMID:23204254"", ""snippet"": ""Chronic bronchitis (CB) is a common but variable phenomenon in chronic obstructive pulmonary disease (COPD)."", ""supports"": ""SUPPORT""}"
1833	1582	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	has_subtypes	0	evidence	1	PMID:27264777	SUPPORT		Chronic obstructive pulmonary disease (COPD) is an umbrella term that covers many clinical subtypes with clearly different pulmonary and extra-pulmonary characteristics.	The article supports that COPD has multiple subtypes with differing characteristics, encompassing conditions like Chronic Bronchitis.	"{""explanation"": ""The article supports that COPD has multiple subtypes with differing characteristics, encompassing conditions like Chronic Bronchitis."", ""reference"": ""PMID:27264777"", ""snippet"": ""Chronic obstructive pulmonary disease (COPD) is an umbrella term that covers many clinical subtypes with clearly different pulmonary and extra-pulmonary characteristics."", ""supports"": ""SUPPORT""}"
1834	1582	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	has_subtypes	0	evidence	2	PMID:22753831	SUPPORT		Chronic cough and sputum production: a clinical COPD phenotype?	The article discusses the phenotype of COPD which includes chronic cough and sputum production, indicative of conditions like Chronic Bronchitis.	"{""explanation"": ""The article discusses the phenotype of COPD which includes chronic cough and sputum production, indicative of conditions like Chronic Bronchitis."", ""reference"": ""PMID:22753831"", ""snippet"": ""Chronic cough and sputum production: a clinical COPD phenotype?"", ""supports"": ""SUPPORT""}"
1835	1583	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	has_subtypes	1	evidence	0	PMID:33926668	SUPPORT		Chronic obstructive pulmonary usually is subcategorized into 2 groups: chronic bronchitis and emphysema.	This reference reiterates the point that emphysema is a recognized subtype of COPD.	"{""explanation"": ""This reference reiterates the point that emphysema is a recognized subtype of COPD."", ""reference"": ""PMID:33926668"", ""snippet"": ""Chronic obstructive pulmonary usually is subcategorized into 2 groups: chronic bronchitis and emphysema."", ""supports"": ""SUPPORT""}"
1836	1583	67	Chronic_Obstructive_Pulmonary_Disease	Chronic_Obstructive_Pulmonary_Disease.yaml	has_subtypes	1	evidence	1	PMID:21178627	SUPPORT		Latest studies further support the association of emphysema and COPD with coal dust exposure.	This confirms that emphysema is considered a subtype of COPD, further supporting the statement.	"{""explanation"": ""This confirms that emphysema is considered a subtype of COPD, further supporting the statement."", ""reference"": ""PMID:21178627"", ""snippet"": ""Latest studies further support the association of emphysema and COPD with coal dust exposure."", ""supports"": ""SUPPORT""}"
2063	1822	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	0	evidence	0	PMID:37377591	SUPPORT		In CD, the ileum is frequently affected and about one third of patients presents with a pure ileal type.	This reference supports the statement that Crohn's disease involves inflammation of the ileum, and specifies this subtype as Ileal Crohn's Disease.	"{""explanation"": ""This reference supports the statement that Crohn's disease involves inflammation of the ileum, and specifies this subtype as Ileal Crohn's Disease."", ""reference"": ""PMID:37377591"", ""snippet"": ""In CD, the ileum is frequently affected and about one third of patients presents with a pure ileal type."", ""supports"": ""SUPPORT""}"
2064	1822	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	0	evidence	1	PMID:30882291	SUPPORT		Gastroscopy revealed severe aphthous pangastritis with biopsies showing a focal active and chronic gastritis with presence of granulomas... coloscopy showing an aphthous terminal ileum... concordant with a slightly active, mildly chronic terminal ileitis typical for Crohn's disease.	This reference supports the claim that Crohn's disease can involve the ileum, characterizing it distinctly as terminal ileitis which is a known feature of Ileal Crohn's Disease.	"{""explanation"": ""This reference supports the claim that Crohn's disease can involve the ileum, characterizing it distinctly as terminal ileitis which is a known feature of Ileal Crohn's Disease."", ""reference"": ""PMID:30882291"", ""snippet"": ""Gastroscopy revealed severe aphthous pangastritis with biopsies showing a focal active and chronic gastritis with presence of granulomas... coloscopy showing an aphthous terminal ileum... concordant with a slightly active, mildly chronic terminal ileitis typical for Crohn's disease."", ""supports"": ""SUPPORT""}"
2065	1822	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	0	evidence	2	PMID:31960900	SUPPORT		Crohn''s disease patients with unequivocal imaging findings of ileal inflammation at enterography despite negative ileoscopy and biopsy are likely to have active inflammatory Crohn''s disease.	This reference highlights that Crohn's disease can manifest as inflammation of the ileum, aligning with the subtype of Ileal Crohn's Disease.	"{""explanation"": ""This reference highlights that Crohn's disease can manifest as inflammation of the ileum, aligning with the subtype of Ileal Crohn's Disease."", ""reference"": ""PMID:31960900"", ""snippet"": ""Crohn''s disease patients with unequivocal imaging findings of ileal inflammation at enterography despite negative ileoscopy and biopsy are likely to have active inflammatory Crohn''s disease."", ""supports"": ""SUPPORT""}"
2066	1823	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	1	evidence	0	PMID:38437854	PARTIAL		Commonly affecting the terminal ileum and proximal colon, Crohn's disease inflammation is often discontinuous and patchy, segmental, and transmural.	The literature indicates that Crohn's disease can affect the colon and often presents with discontinuous, patchy inflammation. However, it is typically not limited to the colon and often involves the terminal ileum.	"{""explanation"": ""The literature indicates that Crohn's disease can affect the colon and often presents with discontinuous, patchy inflammation. However, it is typically not limited to the colon and often involves the terminal ileum."", ""reference"": ""PMID:38437854"", ""snippet"": ""Commonly affecting the terminal ileum and proximal colon, Crohn's disease inflammation is often discontinuous and patchy, segmental, and transmural."", ""supports"": ""PARTIAL""}"
2067	1823	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	1	evidence	1	PMID:11271896	SUPPORT		The site of involvement was the ileum in three patients, the colon in one patient and both the ileum and the colon in one patient. Typical small intestinal CD occurred in four of seven patients with marked aphthous lesions of the small intestine, whereas colonic CD occurred in two of eight patients with such aphthous lesions of the colon.	This study shows that Crohn's disease can indeed affect the colon specifically, supporting the subtype known as Colonic Crohn's Disease.	"{""explanation"": ""This study shows that Crohn's disease can indeed affect the colon specifically, supporting the subtype known as Colonic Crohn's Disease."", ""reference"": ""PMID:11271896"", ""snippet"": ""The site of involvement was the ileum in three patients, the colon in one patient and both the ileum and the colon in one patient. Typical small intestinal CD occurred in four of seven patients with marked aphthous lesions of the small intestine, whereas colonic CD occurred in two of eight patients with such aphthous lesions of the colon."", ""supports"": ""SUPPORT""}"
2068	1823	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	1	evidence	2	PMID:26906301	PARTIAL		Although ileitis can be seen in HSP, terminal ileitis is virtually pathognomonic for Crohn disease.	The focus is on terminal ileitis, commonly seen in Crohns disease. It suggests that Crohn's disease frequently involves the ileum, but does not refute that the colon can also be involved.	"{""explanation"": ""The focus is on terminal ileitis, commonly seen in Crohns disease. It suggests that Crohn's disease frequently involves the ileum, but does not refute that the colon can also be involved."", ""reference"": ""PMID:26906301"", ""snippet"": ""Although ileitis can be seen in HSP, terminal ileitis is virtually pathognomonic for Crohn disease."", ""supports"": ""PARTIAL""}"
2069	1823	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	1	evidence	3	PMID:33278326	PARTIAL		Changes in absorptive capacity and first-pass metabolism in the small intestine affect oral drug bioavailability.	This study focuses on small intestine involvement in Crohn's disease but does not refute colonic involvement with skip lesions.	"{""explanation"": ""This study focuses on small intestine involvement in Crohn's disease but does not refute colonic involvement with skip lesions."", ""reference"": ""PMID:33278326"", ""snippet"": ""Changes in absorptive capacity and first-pass metabolism in the small intestine affect oral drug bioavailability."", ""supports"": ""PARTIAL""}"
2070	1823	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	1	evidence	4	PMID:28379745	SUPPORT		Nearly half (36/73, 49%) of the patients with normal or nonspecific findings at ileocolonoscopy had radiologically active disease with a median length of SB involvement of 20 cm (range, 1 to > 100 cm).	Findings indicate that Crohn's Disease can have varying and discontinuous involvement, including potentially just the colon, thereby supporting the subtype.	"{""explanation"": ""Findings indicate that Crohn's Disease can have varying and discontinuous involvement, including potentially just the colon, thereby supporting the subtype."", ""reference"": ""PMID:28379745"", ""snippet"": ""Nearly half (36/73, 49%) of the patients with normal or nonspecific findings at ileocolonoscopy had radiologically active disease with a median length of SB involvement of 20 cm (range, 1 to > 100 cm)."", ""supports"": ""SUPPORT""}"
2071	1824	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	2	evidence	0	PMID:33712743	PARTIAL		Crohn's disease can affect any part of the gastrointestinal tract; however, current European and national guidelines worldwide do not differentiate between small-intestinal and colonic Crohn's disease for medical treatment.	Although the literature acknowledges different manifestations of Crohn's disease involving the ileum and colon, it primarily discusses the broader differentiation between small-intestinal and colonic Crohn's Disease without naming or detailing specific subtypes such as Ileocolonic Crohn's Disease.	"{""explanation"": ""Although the literature acknowledges different manifestations of Crohn's disease involving the ileum and colon, it primarily discusses the broader differentiation between small-intestinal and colonic Crohn's Disease without naming or detailing specific subtypes such as Ileocolonic Crohn's Disease."", ""reference"": ""PMID:33712743"", ""snippet"": ""Crohn's disease can affect any part of the gastrointestinal tract; however, current European and national guidelines worldwide do not differentiate between small-intestinal and colonic Crohn's disease for medical treatment."", ""supports"": ""PARTIAL""}"
2072	1824	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	2	evidence	1	PMID:11271896	PARTIAL		The site of involvement was the ileum in three patients, the colon in one patient and both the ileum and the colon in one patient.	This provides clinical evidence of Crohn's Disease affecting both the ileum and colon in patients but does not explicitly label it as Ileocolonic Crohn's Disease.	"{""explanation"": ""This provides clinical evidence of Crohn's Disease affecting both the ileum and colon in patients but does not explicitly label it as Ileocolonic Crohn's Disease."", ""reference"": ""PMID:11271896"", ""snippet"": ""The site of involvement was the ileum in three patients, the colon in one patient and both the ileum and the colon in one patient."", ""supports"": ""PARTIAL""}"
2073	1824	77	Crohn Disease	Crohn_Disease.yaml	has_subtypes	2	evidence	2	PMID:38294885	SUPPORT		The terminal ileum and small bowel (SB) are involved in 30-45% of patients with Crohn's disease, while 20% have both small and large bowel involvement.	This literature reference supports the statement by noting that 20% of Crohn's disease cases involve both the small and large intestines, which corresponds to the description of Ileocolonic Crohn's Disease.	"{""explanation"": ""This literature reference supports the statement by noting that 20% of Crohn's disease cases involve both the small and large intestines, which corresponds to the description of Ileocolonic Crohn's Disease."", ""reference"": ""PMID:38294885"", ""snippet"": ""The terminal ileum and small bowel (SB) are involved in 30-45% of patients with Crohn's disease, while 20% have both small and large bowel involvement."", ""supports"": ""SUPPORT""}"
2332	2212	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	has_subtypes	0	evidence	0	PMID:19436038	SUPPORT		Luminal B tumors have higher proliferation and poorer prognosis than luminal A tumors.	Study establishes that luminal A tumors have lower proliferation and better prognosis than luminal B, supporting the subtype distinction.	"{""explanation"": ""Study establishes that luminal A tumors have lower proliferation and better prognosis than luminal B, supporting the subtype distinction."", ""reference"": ""PMID:19436038"", ""snippet"": ""Luminal B tumors have higher proliferation and poorer prognosis than luminal A tumors."", ""supports"": ""SUPPORT""}"
2333	2213	99	ER-Positive Breast Cancer	ER_Positive_Breast_Cancer.yaml	has_subtypes	1	evidence	0	PMID:19436038	SUPPORT		the 10-year breast cancer-specific survival was 79% (95% CI = 76% to 83%) for luminal A, 64% (95% CI = 59% to 70%) for luminal B	Study demonstrates significantly worse 10-year survival for luminal B (64%) compared to luminal A (79%) with tamoxifen monotherapy.	"{""explanation"": ""Study demonstrates significantly worse 10-year survival for luminal B (64%) compared to luminal A (79%) with tamoxifen monotherapy."", ""reference"": ""PMID:19436038"", ""snippet"": ""the 10-year breast cancer-specific survival was 79% (95% CI = 76% to 83%) for luminal A, 64% (95% CI = 59% to 70%) for luminal B"", ""supports"": ""SUPPORT""}"
2352	2236	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	0	evidence	0	PMID:8800808	SUPPORT		The reemergence of Ebola, subtype Zaire, in Kikwit 1995 caused a worldwide sensation, since it struck after a sensibilization on the danger of Ebola virus disease.	The Zaire ebolavirus is indeed one of the subtypes of Ebola virus. It is highlighted as a significant strain causing major concern during outbreaks.	"{""explanation"": ""The Zaire ebolavirus is indeed one of the subtypes of Ebola virus. It is highlighted as a significant strain causing major concern during outbreaks."", ""reference"": ""PMID:8800808"", ""snippet"": ""The reemergence of Ebola, subtype Zaire, in Kikwit 1995 caused a worldwide sensation, since it struck after a sensibilization on the danger of Ebola virus disease."", ""supports"": ""SUPPORT""}"
2353	2236	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	0	evidence	1	PMID:23327370	SUPPORT		The re-emergence of EHF outbreaks in Gabon and Republic of the Congo were concomitant with an increase in mortality amongst gorillas and chimpanzees infected with ZEBOV.	This reference highlights the re-emergence of outbreaks in the specified locations and underscores the high mortality rates associated with the Zaire strain of the Ebola virus.	"{""explanation"": ""This reference highlights the re-emergence of outbreaks in the specified locations and underscores the high mortality rates associated with the Zaire strain of the Ebola virus."", ""reference"": ""PMID:23327370"", ""snippet"": ""The re-emergence of EHF outbreaks in Gabon and Republic of the Congo were concomitant with an increase in mortality amongst gorillas and chimpanzees infected with ZEBOV."", ""supports"": ""SUPPORT""}"
2354	2236	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	0	evidence	2	PMID:24795448	SUPPORT		The causative agent has now been identified as an outlier strain of Zaire Ebola virus.	This reference confirms that the virus responsible for the outbreak is a strain of Zaire Ebola virus, supporting the statement's claim about the locations and the strain.	"{""explanation"": ""This reference confirms that the virus responsible for the outbreak is a strain of Zaire Ebola virus, supporting the statement's claim about the locations and the strain."", ""reference"": ""PMID:24795448"", ""snippet"": ""The causative agent has now been identified as an outlier strain of Zaire Ebola virus."", ""supports"": ""SUPPORT""}"
2355	2237	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	1	evidence	0	PMID:37750724	SUPPORT		Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized.	This reference indicates that Sudan virus disease (SVD), one of the strains of Ebola Virus Disease (EVD), is associated with outbreaks in Uganda.	"{""explanation"": ""This reference indicates that Sudan virus disease (SVD), one of the strains of Ebola Virus Disease (EVD), is associated with outbreaks in Uganda."", ""reference"": ""PMID:37750724"", ""snippet"": ""Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized."", ""supports"": ""SUPPORT""}"
2356	2237	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	1	evidence	1	PMID:28643203	SUPPORT		Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Ta Forest virus	This reference confirms that the Sudan virus (SUDV) is a known subtype of Ebola virus disease.	"{""explanation"": ""This reference confirms that the Sudan virus (SUDV) is a known subtype of Ebola virus disease."", ""reference"": ""PMID:28643203"", ""snippet"": ""Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Ta Forest virus"", ""supports"": ""SUPPORT""}"
2357	2237	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	1	evidence	2	PMID:31806422	SUPPORT		The genus Ebolavirus from the family Filoviridae is composed of five species including Sudan ebolavirus.	This reference lists Sudan ebolavirus as one of the species in the genus Ebolavirus, supporting the statement that it is a subtype.	"{""explanation"": ""This reference lists Sudan ebolavirus as one of the species in the genus Ebolavirus, supporting the statement that it is a subtype."", ""reference"": ""PMID:31806422"", ""snippet"": ""The genus Ebolavirus from the family Filoviridae is composed of five species including Sudan ebolavirus."", ""supports"": ""SUPPORT""}"
2358	2237	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	1	evidence	3	PMID:37355146	SUPPORT		In 1976, the disease emerged in two simultaneous outbreaks in Sudan and the Democratic Republic of Congo.	This reference supports the history of outbreaks in Sudan, correlating with the Sudan ebolavirus strain.	"{""explanation"": ""This reference supports the history of outbreaks in Sudan, correlating with the Sudan ebolavirus strain."", ""reference"": ""PMID:37355146"", ""snippet"": ""In 1976, the disease emerged in two simultaneous outbreaks in Sudan and the Democratic Republic of Congo."", ""supports"": ""SUPPORT""}"
2359	2237	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	1	evidence	4	PMID:34420499	SUPPORT		The second largest Ebola virus disease (EVD) epidemic occurred in the Democratic Republic of the Congo (DRC) from 2018-20.	Although this reference does not specifically mention Sudan ebolavirus, it alludes to significant EVD outbreaks in Africa, indirectly supporting the assertion about large outbreaks.	"{""explanation"": ""Although this reference does not specifically mention Sudan ebolavirus, it alludes to significant EVD outbreaks in Africa, indirectly supporting the assertion about large outbreaks."", ""reference"": ""PMID:34420499"", ""snippet"": ""The second largest Ebola virus disease (EVD) epidemic occurred in the Democratic Republic of the Congo (DRC) from 2018-20."", ""supports"": ""SUPPORT""}"
2360	2238	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	2	evidence	0	PMID:21122234	SUPPORT		The first known Ebola hemorrhagic fever (EHF) outbreak caused by Bundibugyo Ebola virus occurred in Bundibugyo District, Uganda, in 2007. Fifty-six cases of EHF were laboratory confirmed.	This reference supports the statement by confirming the occurrence of a Bundibugyo Ebola virus outbreak in Uganda.	"{""explanation"": ""This reference supports the statement by confirming the occurrence of a Bundibugyo Ebola virus outbreak in Uganda."", ""reference"": ""PMID:21122234"", ""snippet"": ""The first known Ebola hemorrhagic fever (EHF) outbreak caused by Bundibugyo Ebola virus occurred in Bundibugyo District, Uganda, in 2007. Fifty-six cases of EHF were laboratory confirmed."", ""supports"": ""SUPPORT""}"
2361	2238	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	2	evidence	1	PMID:34467242	SUPPORT		Bundibugyo virus (BDBV) is one of four ebolaviruses known to cause disease in humans. Bundibugyo virus disease (BVD) outbreaks occurred in 2007-2008 in Bundibugyo District, Uganda, and in 2012 in Isiro, Province Orientale, Democratic Republic of the Congo.	This reference also supports the statement by citing outbreaks of Bundibugyo Ebola virus in Uganda.	"{""explanation"": ""This reference also supports the statement by citing outbreaks of Bundibugyo Ebola virus in Uganda."", ""reference"": ""PMID:34467242"", ""snippet"": ""Bundibugyo virus (BDBV) is one of four ebolaviruses known to cause disease in humans. Bundibugyo virus disease (BVD) outbreaks occurred in 2007-2008 in Bundibugyo District, Uganda, and in 2012 in Isiro, Province Orientale, Democratic Republic of the Congo."", ""supports"": ""SUPPORT""}"
2362	2239	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	3	evidence	0	PMID:28643203	SUPPORT		Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Ta Forest virus	The literature states that Tai Forest virus is indeed one of the ebolaviruses and mentions its association with human Ebola virus disease (EVD), supporting the claim of a known outbreak in Ivory Coast.	"{""explanation"": ""The literature states that Tai Forest virus is indeed one of the ebolaviruses and mentions its association with human Ebola virus disease (EVD), supporting the claim of a known outbreak in Ivory Coast."", ""reference"": ""PMID:28643203"", ""snippet"": ""Ebola virus disease (EVD) in humans is associated with four ebolaviruses: Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), and Ta Forest virus"", ""supports"": ""SUPPORT""}"
2363	2239	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	3	evidence	1	PMID:31806422	SUPPORT		The genus Ebolavirus from the family Filoviridae is composed of five species including Sudan ebolavirus, Reston ebolavirus, Bundibugyo ebolavirus, Ta Forest ebolavirus, and Ebola virus (previously known as Zaire ebolavirus)	The reference lists Tai Forest ebolavirus as one of the species within the genus Ebolavirus, supporting the claim that it is a subtype of Ebola virus disease.	"{""explanation"": ""The reference lists Tai Forest ebolavirus as one of the species within the genus Ebolavirus, supporting the claim that it is a subtype of Ebola virus disease."", ""reference"": ""PMID:31806422"", ""snippet"": ""The genus Ebolavirus from the family Filoviridae is composed of five species including Sudan ebolavirus, Reston ebolavirus, Bundibugyo ebolavirus, Ta Forest ebolavirus, and Ebola virus (previously known as Zaire ebolavirus)"", ""supports"": ""SUPPORT""}"
2364	2239	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	3	evidence	2	PMID:37750724	NO_EVIDENCE		Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized, and the genetic relatedness of the new variant is evaluated.	This reference discusses the Sudan virus disease outbreak in Uganda in 2022 and does not mention the Tai Forest ebolavirus or outbreaks in Ivory Coast.	"{""explanation"": ""This reference discusses the Sudan virus disease outbreak in Uganda in 2022 and does not mention the Tai Forest ebolavirus or outbreaks in Ivory Coast."", ""reference"": ""PMID:37750724"", ""snippet"": ""Here, the 2022 Sudan virus disease (SVD) outbreak in Mubende District, Uganda, is summarized, and the genetic relatedness of the new variant is evaluated."", ""supports"": ""NO_EVIDENCE""}"
2365	2240	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	4	evidence	0	PMID:21987747	PARTIAL		Reston ebolavirus infection event in domestic pigs has triggered continuing epidemiologic investigations among Philippine health and veterinary agencies... The first one in 1989 was the first-ever Ebola virus that emerged outside of Africa and was also the first known natural infection of Ebola virus in nonhuman primates.	The reference supports that Reston ebolavirus was identified outside of Africa in the Philippines and that it had not caused disease in humans, but it does not affirmatively state that it is the only strain identified outside of Africa.	"{""explanation"": ""The reference supports that Reston ebolavirus was identified outside of Africa in the Philippines and that it had not caused disease in humans, but it does not affirmatively state that it is the only strain identified outside of Africa."", ""reference"": ""PMID:21987747"", ""snippet"": ""Reston ebolavirus infection event in domestic pigs has triggered continuing epidemiologic investigations among Philippine health and veterinary agencies... The first one in 1989 was the first-ever Ebola virus that emerged outside of Africa and was also the first known natural infection of Ebola virus in nonhuman primates."", ""supports"": ""PARTIAL""}"
2366	2240	100	Ebola Virus Disease (EVD)	Ebola_Virus_Disease_EVD.yaml	has_subtypes	4	evidence	1	PMID:28643203	SUPPORT		To date, no documented cases of human disease have been associated with Reston virus.	This reference supports the claim that Reston ebolavirus has not caused disease in humans.	"{""explanation"": ""This reference supports the claim that Reston ebolavirus has not caused disease in humans."", ""reference"": ""PMID:28643203"", ""snippet"": ""To date, no documented cases of human disease have been associated with Reston virus."", ""supports"": ""SUPPORT""}"
2442	2286	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	0	evidence	0	PMID:28192633	SUPPORT		Classical EDS is a heritable disorder of connective tissue. Patients are affected with joint hypermobility, skin hyperextensibilty, and skin fragility leading to atrophic scarring and significant bruising.	This reference directly supports the claim that Classical EDS (cEDS) is characterized by joint hypermobility, skin hyperextensibility, and atrophic scarring.	"{""explanation"": ""This reference directly supports the claim that Classical EDS (cEDS) is characterized by joint hypermobility, skin hyperextensibility, and atrophic scarring."", ""reference"": ""PMID:28192633"", ""snippet"": ""Classical EDS is a heritable disorder of connective tissue. Patients are affected with joint hypermobility, skin hyperextensibilty, and skin fragility leading to atrophic scarring and significant bruising."", ""supports"": ""SUPPORT""}"
2443	2287	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	1	evidence	0	PMID:20301456	PARTIAL		Hypermobile Ehlers-Danlos syndrome (hEDS) is characterized by generalized joint hypermobility, joint instability, pain, soft and hyperextensible skin with atrophic scars and easy bruising...	While hEDS is characterized by generalized joint hypermobility and chronic pain, the provided literature does not emphasize recurrent joint dislocations as a defining characteristic.	"{""explanation"": ""While hEDS is characterized by generalized joint hypermobility and chronic pain, the provided literature does not emphasize recurrent joint dislocations as a defining characteristic."", ""reference"": ""PMID:20301456"", ""snippet"": ""Hypermobile Ehlers-Danlos syndrome (hEDS) is characterized by generalized joint hypermobility, joint instability, pain, soft and hyperextensible skin with atrophic scars and easy bruising..."", ""supports"": ""PARTIAL""}"
2444	2287	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	1	evidence	1	PMID:31582002	SUPPORT		Symptomatic joint hypermobility can result from soft tissue injury or muscular strain caused by muscular imbalance	This article supports the characterization of hEDS with generalized joint hypermobility, recurrent joint dislocations, and chronic pain.	"{""explanation"": ""This article supports the characterization of hEDS with generalized joint hypermobility, recurrent joint dislocations, and chronic pain."", ""reference"": ""PMID:31582002"", ""snippet"": ""Symptomatic joint hypermobility can result from soft tissue injury or muscular strain caused by muscular imbalance"", ""supports"": ""SUPPORT""}"
2445	2287	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	1	evidence	2	PMID:28145611	SUPPORT		"The hypermobile type of Ehlers-Danlos syndrome (hEDS) is likely the most common hereditary disorder of connective tissue. It has been described largely in those with musculoskeletal complaints including joint hypermobility, joint subluxations/dislocations, as well as skin and soft tissue manifestations."""	This provides direct support for the statement, noting joint hypermobility, recurrent dislocations, and associated chronic pain in hEDS.	"{""explanation"": ""This provides direct support for the statement, noting joint hypermobility, recurrent dislocations, and associated chronic pain in hEDS."", ""reference"": ""PMID:28145611"", ""snippet"": ""The hypermobile type of Ehlers-Danlos syndrome (hEDS) is likely the most common hereditary disorder of connective tissue. It has been described largely in those with musculoskeletal complaints including joint hypermobility, joint subluxations/dislocations, as well as skin and soft tissue manifestations.\"""", ""supports"": ""SUPPORT""}"
2446	2288	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	2	evidence	0	PMID:33650410	SUPPORT		The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences.	This excerpt directly supports the statement by confirming that vEDS is characterized by thin, translucent skin, and fragility of arteries, intestines, and uterus.	"{""explanation"": ""This excerpt directly supports the statement by confirming that vEDS is characterized by thin, translucent skin, and fragility of arteries, intestines, and uterus."", ""reference"": ""PMID:33650410"", ""snippet"": ""The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences."", ""supports"": ""SUPPORT""}"
2447	2288	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	2	evidence	1	PMID:32941194	SUPPORT		Vascular Ehlers-Danlos syndrome (vEDS) is the most severe form of EDS, affecting the synthesis of type III collagen. It is notable for decreased life expectancy and morbidity, including spontaneous vessel rupture.	This excerpt supports the statement by indicating that vEDS is the most severe form of EDS and is associated with significant arterial fragility.	"{""explanation"": ""This excerpt supports the statement by indicating that vEDS is the most severe form of EDS and is associated with significant arterial fragility."", ""reference"": ""PMID:32941194"", ""snippet"": ""Vascular Ehlers-Danlos syndrome (vEDS) is the most severe form of EDS, affecting the synthesis of type III collagen. It is notable for decreased life expectancy and morbidity, including spontaneous vessel rupture."", ""supports"": ""SUPPORT""}"
2448	2288	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	2	evidence	2	PMID:29709596	SUPPORT		Life-threatening arterial aneurysms, dissections and ruptures of medium-sized and large arteries are a hallmark of the vascular subtype of EDS, caused by a molecular defect in collagen type III, an important constituent of blood vessel walls and hollow organs.	This excerpt supports the statement by mentioning the severe arterial fragility associated with vEDS.	"{""explanation"": ""This excerpt supports the statement by mentioning the severe arterial fragility associated with vEDS."", ""reference"": ""PMID:29709596"", ""snippet"": ""Life-threatening arterial aneurysms, dissections and ruptures of medium-sized and large arteries are a hallmark of the vascular subtype of EDS, caused by a molecular defect in collagen type III, an important constituent of blood vessel walls and hollow organs."", ""supports"": ""SUPPORT""}"
2449	2288	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	2	evidence	3	PMID:30534875	SUPPORT		Ehlers Danlos Syndrome comprises a heterogeneous group of genetic disorders of the connective tissue, due to defects in collagen or its modifying enzymes. We report a 21 years old male presenting with translucent skin revealing the subcutaneous venous pattern.	This excerpt indirectly supports the statement by describing a patient with vEDS having translucent skin, which aligns with the defining characteristics of vEDS mentioned in the statement.	"{""explanation"": ""This excerpt indirectly supports the statement by describing a patient with vEDS having translucent skin, which aligns with the defining characteristics of vEDS mentioned in the statement."", ""reference"": ""PMID:30534875"", ""snippet"": ""Ehlers Danlos Syndrome comprises a heterogeneous group of genetic disorders of the connective tissue, due to defects in collagen or its modifying enzymes. We report a 21 years old male presenting with translucent skin revealing the subcutaneous venous pattern."", ""supports"": ""SUPPORT""}"
2450	2289	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	3	evidence	0	PMID:18155911	SUPPORT		The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) (OMIM 225400) is an inherited connective tissue disorder characterized by hypotonia and kyphoscoliosis at birth, joint hypermobility, and skin hyperelasticity and fragility.	The reference describes the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) as having kyphoscoliosis and hypotonia.	"{""explanation"": ""The reference describes the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) as having kyphoscoliosis and hypotonia."", ""reference"": ""PMID:18155911"", ""snippet"": ""The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) (OMIM 225400) is an inherited connective tissue disorder characterized by hypotonia and kyphoscoliosis at birth, joint hypermobility, and skin hyperelasticity and fragility."", ""supports"": ""SUPPORT""}"
2451	2289	101	Ehlers-Danlos Syndrome	Ehlers-Danlos_Syndrome.yaml	has_subtypes	3	evidence	1	PMID:20301635	SUPPORT		PLOD1-related kyphoscoliotic Ehlers-Danlos syndrome (PLOD1-kEDS) is characterized by hypotonia, generalized joint hypermobility, early-onset kyphoscoliosis, skin fragility, and ocular abnormality.	The reference explicitly lists kyphoscoliosis, hypotonia, and ocular abnormalities as characteristics of PLOD1-kEDS.	"{""explanation"": ""The reference explicitly lists kyphoscoliosis, hypotonia, and ocular abnormalities as characteristics of PLOD1-kEDS."", ""reference"": ""PMID:20301635"", ""snippet"": ""PLOD1-related kyphoscoliotic Ehlers-Danlos syndrome (PLOD1-kEDS) is characterized by hypotonia, generalized joint hypermobility, early-onset kyphoscoliosis, skin fragility, and ocular abnormality."", ""supports"": ""SUPPORT""}"
2712	2622	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	has_subtypes	0	evidence	0	PMID:25649364	NO_EVIDENCE		Familial Mediterranean Fever is an autosomal recessive inherited disease with a course of autoinflammation, which is characterized by the episodes of fever and serositis.	Although the literature describes Familial Mediterranean Fever having episodic fever and serositis, it does not define subtypes or a 'Type 1' specifically.	"{""explanation"": ""Although the literature describes Familial Mediterranean Fever having episodic fever and serositis, it does not define subtypes or a 'Type 1' specifically."", ""reference"": ""PMID:25649364"", ""snippet"": ""Familial Mediterranean Fever is an autosomal recessive inherited disease with a course of autoinflammation, which is characterized by the episodes of fever and serositis."", ""supports"": ""NO_EVIDENCE""}"
2713	2622	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	has_subtypes	0	evidence	1	PMID:23823268	NO_EVIDENCE		Periodic fevers are acquired or inherited disorders of innate immunity, which were first described in the 1940s. ... This clinical review focuses on a sample of autoinflammatory disorders including familial Mediterranean fever...	There is a general discussion of Familial Mediterranean Fever but no mention of subtypes or a classification system involving the term 'Type 1'.	"{""explanation"": ""There is a general discussion of Familial Mediterranean Fever but no mention of subtypes or a classification system involving the term 'Type 1'."", ""reference"": ""PMID:23823268"", ""snippet"": ""Periodic fevers are acquired or inherited disorders of innate immunity, which were first described in the 1940s. ... This clinical review focuses on a sample of autoinflammatory disorders including familial Mediterranean fever..."", ""supports"": ""NO_EVIDENCE""}"
2714	2622	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	has_subtypes	0	evidence	2	PMID:36889987	NO_EVIDENCE		MEFV gene mutation spectrum in patients with familial mediterranean fever.	This study discusses the gene mutations associated with FMF but does not describe subtypes of the disease.	"{""explanation"": ""This study discusses the gene mutations associated with FMF but does not describe subtypes of the disease."", ""reference"": ""PMID:36889987"", ""snippet"": ""MEFV gene mutation spectrum in patients with familial mediterranean fever."", ""supports"": ""NO_EVIDENCE""}"
2715	2623	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	has_subtypes	1	evidence	0	PMID:21358337	SUPPORT		Familial Mediterranean fever type 2 is characterized by amyloidosis as the first clinical manifestation of familial Mediterranean fever in an otherwise asymptomatic individual.	The literature directly states that FMF type 2 is characterized by amyloidosis without prior overt inflammatory episodes, aligning with the given statement.	"{""explanation"": ""The literature directly states that FMF type 2 is characterized by amyloidosis without prior overt inflammatory episodes, aligning with the given statement."", ""reference"": ""PMID:21358337"", ""snippet"": ""Familial Mediterranean fever type 2 is characterized by amyloidosis as the first clinical manifestation of familial Mediterranean fever in an otherwise asymptomatic individual."", ""supports"": ""SUPPORT""}"
2716	2623	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	has_subtypes	1	evidence	1	PMID:11053071	PARTIAL		Phenotype II in familial Mediterranean fever (FMF) is the onset of amyloidosis before the onset of FMF with its typical attacks, or as an isolated finding in a member of an FMF family.	While this states Type 2 can involve amyloidosis without typical attacks, it does not directly mention continuous subclinical inflammation.	"{""explanation"": ""While this states Type 2 can involve amyloidosis without typical attacks, it does not directly mention continuous subclinical inflammation."", ""reference"": ""PMID:11053071"", ""snippet"": ""Phenotype II in familial Mediterranean fever (FMF) is the onset of amyloidosis before the onset of FMF with its typical attacks, or as an isolated finding in a member of an FMF family."", ""supports"": ""PARTIAL""}"
2717	2623	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	has_subtypes	1	evidence	2	PMID:36161616	PARTIAL		Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance, however, it is not certain whether subclinical inflammation can sufficiently be inhibited with anti-IL-1 therapy in FMF patients with amyloidosis.	Reference to subclinical inflammation in amyloidosis supports part of the statement, but does not specifically mention Type 2 FMF.	"{""explanation"": ""Reference to subclinical inflammation in amyloidosis supports part of the statement, but does not specifically mention Type 2 FMF."", ""reference"": ""PMID:36161616"", ""snippet"": ""Anti IL-1 therapy is useful in suppressing attacks in FMF patients with colchicine resistance, however, it is not certain whether subclinical inflammation can sufficiently be inhibited with anti-IL-1 therapy in FMF patients with amyloidosis."", ""supports"": ""PARTIAL""}"
2718	2623	115	Familial Mediterranean Fever	Familial_Mediterranean_Fever.yaml	has_subtypes	1	evidence	3	PMID:37496356	PARTIAL		Recent studies have shown that cases of amyloidosis in patients with familial Mediterranean fever are decreasing	Though it implies a relationship between FMF and amyloidosis, it does not clearly distinguish between subtypes or mention continuous subclinical inflammation.	"{""explanation"": ""Though it implies a relationship between FMF and amyloidosis, it does not clearly distinguish between subtypes or mention continuous subclinical inflammation."", ""reference"": ""PMID:37496356"", ""snippet"": ""Recent studies have shown that cases of amyloidosis in patients with familial Mediterranean fever are decreasing"", ""supports"": ""PARTIAL""}"
2798	2677	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	0	evidence	0	PMID:31558676	SUPPORT	HUMAN_CLINICAL	Patients with FANCA mutations developed cancer at a significantly older age compared to patients with mutations in other Fanconi genes (mean 18.5 and 5.2 years, respectively, P=0.001)	Israeli cohort demonstrates later cancer onset in core complex (FANCA) vs downstream gene mutations.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Israeli cohort demonstrates later cancer onset in core complex (FANCA) vs downstream gene mutations."", ""reference"": ""PMID:31558676"", ""snippet"": ""Patients with FANCA mutations developed cancer at a significantly older age compared to patients with mutations in other Fanconi genes (mean 18.5 and 5.2 years, respectively, P=0.001)"", ""supports"": ""SUPPORT""}"
2799	2679	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	2	evidence	0	PMID:31558676	SUPPORT	HUMAN_CLINICAL	Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations.	Israeli cohort demonstrates more severe congenital anomaly profile in downstream pathway gene mutations.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Israeli cohort demonstrates more severe congenital anomaly profile in downstream pathway gene mutations."", ""reference"": ""PMID:31558676"", ""snippet"": ""Patients with downstream mutations were found to have significantly more skull anomalies (P<0.001), central nervous system (CNS) abnormalities (P=0.005) and genitourinary anomalies (P=0.03), compared with patients with core complex mutations."", ""supports"": ""SUPPORT""}"
2800	2680	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	3	evidence	0	PMID:31558676	SUPPORT	HUMAN_CLINICAL	two-thirds of genetically diagnosed patients had biallelic FANCA mutations. These numbers are similar to the International Fanconi Anemia Registry, in which 60% of the diagnosed patients had FANCA mutations	Israeli cohort confirms FANCA accounts for approximately 60-70% of FA cases.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Israeli cohort confirms FANCA accounts for approximately 60-70% of FA cases."", ""reference"": ""PMID:31558676"", ""snippet"": ""two-thirds of genetically diagnosed patients had biallelic FANCA mutations. These numbers are similar to the International Fanconi Anemia Registry, in which 60% of the diagnosed patients had FANCA mutations"", ""supports"": ""SUPPORT""}"
2801	2680	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	3	evidence	1	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms FANCA causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCA causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2802	2681	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	4	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	a hemizygous pathogenic variant in FANCB known to cause X-linked FA	GeneReviews confirms FANCB causes X-linked Fanconi anemia.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCB causes X-linked Fanconi anemia."", ""reference"": ""PMID:20301575"", ""snippet"": ""a hemizygous pathogenic variant in FANCB known to cause X-linked FA"", ""supports"": ""SUPPORT""}"
2803	2682	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	5	evidence	0	PMID:31558676	SUPPORT	HUMAN_CLINICAL	FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)	Israeli cohort shows FANCC accounts for 13% of genetically diagnosed FA cases.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Israeli cohort shows FANCC accounts for 13% of genetically diagnosed FA cases."", ""reference"": ""PMID:31558676"", ""snippet"": ""FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)"", ""supports"": ""SUPPORT""}"
2804	2683	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	6	evidence	0	PMID:31558676	SUPPORT	HUMAN_CLINICAL	one patient with a FANCD1 mutation developed medulloblastoma at the age of 3 years. Patients with FANCD1 mutations have been previously described as uniquely developing solid tumors early in life	Confirms early-onset solid tumors in FANCD1/BRCA2 patients.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Confirms early-onset solid tumors in FANCD1/BRCA2 patients."", ""reference"": ""PMID:31558676"", ""snippet"": ""one patient with a FANCD1 mutation developed medulloblastoma at the age of 3 years. Patients with FANCD1 mutations have been previously described as uniquely developing solid tumors early in life"", ""supports"": ""SUPPORT""}"
2805	2684	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	7	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms FANCD2 causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCD2 causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2806	2685	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	8	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms FANCE causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCE causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2807	2686	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	9	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms FANCF causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCF causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2808	2687	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	10	evidence	0	PMID:31558676	SUPPORT	HUMAN_CLINICAL	FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)	Israeli cohort shows FANCG accounts for 14% of genetically diagnosed FA cases.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Israeli cohort shows FANCG accounts for 14% of genetically diagnosed FA cases."", ""reference"": ""PMID:31558676"", ""snippet"": ""FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)"", ""supports"": ""SUPPORT""}"
2809	2688	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	11	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms FANCI causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCI causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2810	2689	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	12	evidence	0	PMID:31558676	SUPPORT	HUMAN_CLINICAL	FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)	Israeli cohort shows FANCJ accounts for 3% of genetically diagnosed FA cases.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Israeli cohort shows FANCJ accounts for 3% of genetically diagnosed FA cases."", ""reference"": ""PMID:31558676"", ""snippet"": ""FANCA (67%), FANCC (13%), FANCG (14%), FANCJ (3%) and FANCD1 (2%)"", ""supports"": ""SUPPORT""}"
2811	2690	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	13	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms FANCL causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms FANCL causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2812	2691	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	14	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms PALB2/FANCN causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms PALB2/FANCN causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2813	2692	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	15	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms RAD51C/FANCO causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms RAD51C/FANCO causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2814	2693	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	16	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms SLX4/FANCP causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms SLX4/FANCP causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2815	2694	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	17	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms ERCC4/FANCQ causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms ERCC4/FANCQ causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2816	2695	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	18	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	a heterozygous pathogenic variant in RAD51 known to cause autosomal dominant FA	GeneReviews confirms RAD51/FANCR causes autosomal dominant FA via de novo mutations.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms RAD51/FANCR causes autosomal dominant FA via de novo mutations."", ""reference"": ""PMID:20301575"", ""snippet"": ""a heterozygous pathogenic variant in RAD51 known to cause autosomal dominant FA"", ""supports"": ""SUPPORT""}"
2817	2696	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	19	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms BRCA1/FANCS causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms BRCA1/FANCS causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2818	2697	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	20	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms UBE2T/FANCT causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms UBE2T/FANCT causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2819	2698	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	21	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms XRCC2/FANCU causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms XRCC2/FANCU causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2820	2699	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	22	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms MAD2L2/FANCV causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms MAD2L2/FANCV causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
2821	2700	116	Fanconi_Anemia	Fanconi_Anemia.yaml	has_subtypes	23	evidence	0	PMID:20301575	SUPPORT	HUMAN_CLINICAL	biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA	GeneReviews confirms RFWD3/FANCW causes autosomal recessive FA.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""GeneReviews confirms RFWD3/FANCW causes autosomal recessive FA."", ""reference"": ""PMID:20301575"", ""snippet"": ""biallelic pathogenic variants in one of the 21 genes known to cause autosomal recessive FA"", ""supports"": ""SUPPORT""}"
3662	3697	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	has_subtypes	0	evidence	0	PMID:21289515	SUPPORT		There are three subtypes: types 1 and 3 represent quantitative variants and type 2 is a group of four qualitative variants:	The abstract notes type 1 as a quantitative subtype.	"{""explanation"": ""The abstract notes type 1 as a quantitative subtype."", ""reference"": ""PMID:21289515"", ""snippet"": ""There are three subtypes: types 1 and 3 represent quantitative variants and type 2 is a group of four qualitative variants:"", ""supports"": ""SUPPORT""}"
3663	3698	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	has_subtypes	1	evidence	0	PMID:21289515	SUPPORT		There are three subtypes: types 1 and 3 represent quantitative variants and type 2 is a group of four qualitative variants:	The abstract notes type 2 as a qualitative subtype group.	"{""explanation"": ""The abstract notes type 2 as a qualitative subtype group."", ""reference"": ""PMID:21289515"", ""snippet"": ""There are three subtypes: types 1 and 3 represent quantitative variants and type 2 is a group of four qualitative variants:"", ""supports"": ""SUPPORT""}"
3664	3699	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	has_subtypes	2	evidence	0	PMID:33497541	SUPPORT		Type 2N VWD is an uncommon recessive disorder that results from gene mutations located in the region coding for the binding site of VWF for factor VIII (FVIII).	The abstract describes type 2N as a qualitative defect affecting FVIII binding.	"{""explanation"": ""The abstract describes type 2N as a qualitative defect affecting FVIII binding."", ""reference"": ""PMID:33497541"", ""snippet"": ""Type 2N VWD is an uncommon recessive disorder that results from gene mutations located in the region coding for the binding site of VWF for factor VIII (FVIII)."", ""supports"": ""SUPPORT""}"
3665	3700	155	Hereditary von Willebrand Disease	Hereditary_von_Willebrand_Disease.yaml	has_subtypes	3	evidence	0	PMID:21289515	SUPPORT		There are three subtypes: types 1 and 3 represent quantitative variants and type 2 is a group of four qualitative variants:	The abstract notes type 3 as a quantitative subtype.	"{""explanation"": ""The abstract notes type 3 as a quantitative subtype."", ""reference"": ""PMID:21289515"", ""snippet"": ""There are three subtypes: types 1 and 3 represent quantitative variants and type 2 is a group of four qualitative variants:"", ""supports"": ""SUPPORT""}"
3700	3720	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	has_subtypes	0	evidence	0	PMID:9269974	SUPPORT		The extent of aganglionosis was as follows: short segment restricted to the rectosigmoid or descending colon (n = 44, 75%).	This statement directly supports that short-segment Hirschsprung Disease (HD) affects the rectum and a short segment of the distal colon.	"{""explanation"": ""This statement directly supports that short-segment Hirschsprung Disease (HD) affects the rectum and a short segment of the distal colon."", ""reference"": ""PMID:9269974"", ""snippet"": ""The extent of aganglionosis was as follows: short segment restricted to the rectosigmoid or descending colon (n = 44, 75%)."", ""supports"": ""SUPPORT""}"
3701	3720	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	has_subtypes	0	evidence	1	PMID:24168728	SUPPORT		Analysis of a series of rectosigmoid resections from patients with short-segment (>2-cm aganglionic, n  =  9) and very short-segment (</=2-cm aganglionic, n  =  9) Hirschsprung disease.	This excerpt confirms that short-segment HD involves the rectosigmoid area, supporting the claim that it affects the rectum and a short segment of the distal colon.	"{""explanation"": ""This excerpt confirms that short-segment HD involves the rectosigmoid area, supporting the claim that it affects the rectum and a short segment of the distal colon."", ""reference"": ""PMID:24168728"", ""snippet"": ""Analysis of a series of rectosigmoid resections from patients with short-segment (>2-cm aganglionic, n  =  9) and very short-segment (</=2-cm aganglionic, n  =  9) Hirschsprung disease."", ""supports"": ""SUPPORT""}"
3702	3720	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	has_subtypes	0	evidence	2	PMID:22985835	SUPPORT		Moreover, it reviews current outcomes to find consensus on management.	This literature discusses the differences in subtypes of Hirschsprung Disease, including short-segment HSCR involving the rectosigmoid colon, thus supporting the statement.	"{""explanation"": ""This literature discusses the differences in subtypes of Hirschsprung Disease, including short-segment HSCR involving the rectosigmoid colon, thus supporting the statement."", ""reference"": ""PMID:22985835"", ""snippet"": ""Moreover, it reviews current outcomes to find consensus on management."", ""supports"": ""SUPPORT""}"
3703	3721	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	has_subtypes	1	evidence	0	PMID:22985835	SUPPORT		Total colonic aganglionosis (TCA) is a relatively uncommon form of Hirschsprung disease (HSCR)... It can probably be classified as TCA (defined as aganglionosis extending from the anus to at least the ileocecal valve, but not >50 cm proximal to the ileocecal valve) and total colonic and small bowel aganglionosis, which may involve a very long segment of aganglionosis.	This reference supports the classification of long-segment Hirschsprung Disease, indicating that it involves a longer segment of the colon beyond the rectum.	"{""explanation"": ""This reference supports the classification of long-segment Hirschsprung Disease, indicating that it involves a longer segment of the colon beyond the rectum."", ""reference"": ""PMID:22985835"", ""snippet"": ""Total colonic aganglionosis (TCA) is a relatively uncommon form of Hirschsprung disease (HSCR)... It can probably be classified as TCA (defined as aganglionosis extending from the anus to at least the ileocecal valve, but not >50 cm proximal to the ileocecal valve) and total colonic and small bowel aganglionosis, which may involve a very long segment of aganglionosis."", ""supports"": ""SUPPORT""}"
3704	3721	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	has_subtypes	1	evidence	1	PMID:1514906	SUPPORT		We identified 21 children...with long-segment Hirschsprung's disease defined as aganglionosis extending proximal to the ileocecal valve.	This reference explicitly defines long-segment Hirschsprung's disease as affecting a longer segment of the colon beyond the rectum.	"{""explanation"": ""This reference explicitly defines long-segment Hirschsprung's disease as affecting a longer segment of the colon beyond the rectum."", ""reference"": ""PMID:1514906"", ""snippet"": ""We identified 21 children...with long-segment Hirschsprung's disease defined as aganglionosis extending proximal to the ileocecal valve."", ""supports"": ""SUPPORT""}"
3705	3722	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	has_subtypes	2	evidence	0	PMID:25367097	SUPPORT		Total colonic aganglionosis is a relatively uncommon form of Hirschsprung's disease (HSCR). It occurs in approximately 2-13 % of HSCR cases and involves the entire colon which is aganglionic but may extend proximally into varying lengths of small bowel.	This reference indicates that Total Colonic Aganglionosis (TCA) affects the entire colon and sometimes extends into the small intestine, supporting the statement.	"{""explanation"": ""This reference indicates that Total Colonic Aganglionosis (TCA) affects the entire colon and sometimes extends into the small intestine, supporting the statement."", ""reference"": ""PMID:25367097"", ""snippet"": ""Total colonic aganglionosis is a relatively uncommon form of Hirschsprung's disease (HSCR). It occurs in approximately 2-13 % of HSCR cases and involves the entire colon which is aganglionic but may extend proximally into varying lengths of small bowel."", ""supports"": ""SUPPORT""}"
3706	3722	156	Hirschsprung Disease	Hirschsprung_Disease.yaml	has_subtypes	2	evidence	1	PMID:10745745	SUPPORT		Absence of ganglion cells in the small intestine, a rare form of Hirschsprung's disease, is a condition found in newborns and associated with increased morbidity and mortality.	This reference supports the component of the statement indicating that the condition can involve the small intestine.	"{""explanation"": ""This reference supports the component of the statement indicating that the condition can involve the small intestine."", ""reference"": ""PMID:10745745"", ""snippet"": ""Absence of ganglion cells in the small intestine, a rare form of Hirschsprung's disease, is a condition found in newborns and associated with increased morbidity and mortality."", ""supports"": ""SUPPORT""}"
3813	3779	159	Huntington's Disease	Huntingtons_Disease.yaml	has_subtypes	0	evidence	0	PMID:26557176	SUPPORT		Huntington's disease (HD) is a rare dominantly inherited neurodegenerative disorder... As is expected in a case of childhood-onset HD, our patient is rapidly deteriorating and is currently in the terminal phase of his illness along with resistant convulsions.	The abstract describes a case of childhood-onset Huntington's disease that progresses rapidly, supporting the statement.	"{""explanation"": ""The abstract describes a case of childhood-onset Huntington's disease that progresses rapidly, supporting the statement."", ""reference"": ""PMID:26557176"", ""snippet"": ""Huntington's disease (HD) is a rare dominantly inherited neurodegenerative disorder... As is expected in a case of childhood-onset HD, our patient is rapidly deteriorating and is currently in the terminal phase of his illness along with resistant convulsions."", ""supports"": ""SUPPORT""}"
3814	3779	159	Huntington's Disease	Huntingtons_Disease.yaml	has_subtypes	0	evidence	1	PMID:36318082	SUPPORT		Juvenile-onset Huntington's disease (JOHD) is a rare form of Huntington's disease (HD) characterized by symptom onset before the age of 21 years... The mean annualized decrease in striatal volume in the JOHD group was -3.99% compared to -0.06% in the GNE.	The abstract confirms that Juvenile Huntington's Disease is rare, begins early, and progresses rapidly, supporting the statement.	"{""explanation"": ""The abstract confirms that Juvenile Huntington's Disease is rare, begins early, and progresses rapidly, supporting the statement."", ""reference"": ""PMID:36318082"", ""snippet"": ""Juvenile-onset Huntington's disease (JOHD) is a rare form of Huntington's disease (HD) characterized by symptom onset before the age of 21 years... The mean annualized decrease in striatal volume in the JOHD group was -3.99% compared to -0.06% in the GNE."", ""supports"": ""SUPPORT""}"
3815	3779	159	Huntington's Disease	Huntingtons_Disease.yaml	has_subtypes	0	evidence	2	PMID:14584235	SUPPORT		The presentation of juvenile Huntington's disease can cause diagnostic difficulties. The genetics and pathogenesis of the condition are discussed.	The abstract acknowledges the existence of juvenile Huntington's disease, which supports the statement.	"{""explanation"": ""The abstract acknowledges the existence of juvenile Huntington's disease, which supports the statement."", ""reference"": ""PMID:14584235"", ""snippet"": ""The presentation of juvenile Huntington's disease can cause diagnostic difficulties. The genetics and pathogenesis of the condition are discussed."", ""supports"": ""SUPPORT""}"
3816	3779	159	Huntington's Disease	Huntingtons_Disease.yaml	has_subtypes	0	evidence	3	PMID:2942452	SUPPORT		Of 195 cases of juvenile Huntington disease gathered from case descriptions... It is argued that juvenile Huntington disease should not be regarded as a separate clinical entity, but as a manifestation of the rigid variant of the disease.	The abstract discusses juvenile Huntington's disease and its characteristics, supporting the statement.	"{""explanation"": ""The abstract discusses juvenile Huntington's disease and its characteristics, supporting the statement."", ""reference"": ""PMID:2942452"", ""snippet"": ""Of 195 cases of juvenile Huntington disease gathered from case descriptions... It is argued that juvenile Huntington disease should not be regarded as a separate clinical entity, but as a manifestation of the rigid variant of the disease."", ""supports"": ""SUPPORT""}"
3817	3780	159	Huntington's Disease	Huntingtons_Disease.yaml	has_subtypes	1	evidence	0	PMID:28671137	PARTIAL		BACKGROUND: Although the typical age of onset for Huntington's disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age).	The statement that Huntington's Disease typically begins after the age of 50 is not entirely accurate. While late-onset Huntington's Disease (LoHD) does occur, the typical age of onset for HD is in the fourth decade. However, the statement is partially supported by the fact that some individuals do experience late onset, and LoHD may have a slower progression.	"{""explanation"": ""The statement that Huntington's Disease typically begins after the age of 50 is not entirely accurate. While late-onset Huntington's Disease (LoHD) does occur, the typical age of onset for HD is in the fourth decade. However, the statement is partially supported by the fact that some individuals do experience late onset, and LoHD may have a slower progression."", ""reference"": ""PMID:28671137"", ""snippet"": ""BACKGROUND: Although the typical age of onset for Huntington's disease (HD) is in the fourth decade, between 4.4-11.5% of individuals with HD have a late onset (over 60 years of age)."", ""supports"": ""PARTIAL""}"
3818	3780	159	Huntington's Disease	Huntingtons_Disease.yaml	has_subtypes	1	evidence	1	PMID:17390259	REFUTE		Huntington's disease may present at any age, but most typically manifests between the ages of 35 and 45 years as a slowly progressive neurodegenerative movement disorder with cognitive and behavioral impairment.	This reference refutes the statement that Huntington's Disease typically begins after the age of 50. It states that HD most typically manifests between the ages of 35 and 45 years.	"{""explanation"": ""This reference refutes the statement that Huntington's Disease typically begins after the age of 50. It states that HD most typically manifests between the ages of 35 and 45 years."", ""reference"": ""PMID:17390259"", ""snippet"": ""Huntington's disease may present at any age, but most typically manifests between the ages of 35 and 45 years as a slowly progressive neurodegenerative movement disorder with cognitive and behavioral impairment."", ""supports"": ""REFUTE""}"
3819	3780	159	Huntington's Disease	Huntingtons_Disease.yaml	has_subtypes	1	evidence	2	PMID:36318082	NO_EVIDENCE		Juvenile-onset Huntington's disease (JOHD) is a rare form of Huntington's disease (HD) characterized by symptom onset before the age of 21 years.	This reference discusses Juvenile-onset Huntington's Disease, which is not relevant to the claim about typical onset after the age of 50.	"{""explanation"": ""This reference discusses Juvenile-onset Huntington's Disease, which is not relevant to the claim about typical onset after the age of 50."", ""reference"": ""PMID:36318082"", ""snippet"": ""Juvenile-onset Huntington's disease (JOHD) is a rare form of Huntington's disease (HD) characterized by symptom onset before the age of 21 years."", ""supports"": ""NO_EVIDENCE""}"
3820	3780	159	Huntington's Disease	Huntingtons_Disease.yaml	has_subtypes	1	evidence	3	PMID:28087720	NO_EVIDENCE		Following predictive testing for Huntington disease (HD), knowledge of one's carrier status may have consequences on disease onset.	This reference does not provide information relevant to the typical age of onset or progression of Huntington's Disease.	"{""explanation"": ""This reference does not provide information relevant to the typical age of onset or progression of Huntington's Disease."", ""reference"": ""PMID:28087720"", ""snippet"": ""Following predictive testing for Huntington disease (HD), knowledge of one's carrier status may have consequences on disease onset."", ""supports"": ""NO_EVIDENCE""}"
3885	3808	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	has_subtypes	0	evidence	0	PMID:16097361	PARTIAL		Left ventricular hypertrophy (LVH) and diastolic dysfunction (CHF-D) are the early manifestations of cardiovascular target organ damage in patients with arterial hypertension and signify hypertensive heart disease.	The reference indicates that left ventricular hypertrophy (LVH) is a manifestation of hypertensive heart disease, but it does not explicitly state that LVH is a subtype of hypertensive heart disease. However, since it implies a direct relationship, partial support is inferred.	"{""explanation"": ""The reference indicates that left ventricular hypertrophy (LVH) is a manifestation of hypertensive heart disease, but it does not explicitly state that LVH is a subtype of hypertensive heart disease. However, since it implies a direct relationship, partial support is inferred."", ""reference"": ""PMID:16097361"", ""snippet"": ""Left ventricular hypertrophy (LVH) and diastolic dysfunction (CHF-D) are the early manifestations of cardiovascular target organ damage in patients with arterial hypertension and signify hypertensive heart disease."", ""supports"": ""PARTIAL""}"
3886	3809	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	has_subtypes	1	evidence	0	PMID:37739329	SUPPORT		Hypertension represents a major contributor to the development of coronary artery disease. The pathophysiological mechanisms underlying the link between hypertension and CAD are complex and include overactivation of neurohormones, accelerated development of the atherosclerotic plaque, endothelial dysfunction, altered intramyocardial coronary circulation, hypertension-mediated cardiac and vascular damage and the relationship between arterial stiffness and coronary perfusion.	The literature explicitly mentions the contribution of hypertension to the development of coronary artery disease, which involves narrowing of the blood vessels that supply the heart.	"{""explanation"": ""The literature explicitly mentions the contribution of hypertension to the development of coronary artery disease, which involves narrowing of the blood vessels that supply the heart."", ""reference"": ""PMID:37739329"", ""snippet"": ""Hypertension represents a major contributor to the development of coronary artery disease. The pathophysiological mechanisms underlying the link between hypertension and CAD are complex and include overactivation of neurohormones, accelerated development of the atherosclerotic plaque, endothelial dysfunction, altered intramyocardial coronary circulation, hypertension-mediated cardiac and vascular damage and the relationship between arterial stiffness and coronary perfusion."", ""supports"": ""SUPPORT""}"
3887	3810	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	has_subtypes	2	evidence	0	PMID:31472888	SUPPORT		Hypertensive heart disease represents a spectrum of illnesses from uncontrolled hypertension to heart failure.	The abstract indicates that heart failure can develop as part of hypertensive heart disease.	"{""explanation"": ""The abstract indicates that heart failure can develop as part of hypertensive heart disease."", ""reference"": ""PMID:31472888"", ""snippet"": ""Hypertensive heart disease represents a spectrum of illnesses from uncontrolled hypertension to heart failure."", ""supports"": ""SUPPORT""}"
3888	3810	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	has_subtypes	2	evidence	1	PMID:36030347	SUPPORT		Current evidence, based on cross-sectional and longitudinal observational studies as well as real-world registries and randomized controlled trials, suggests that women are more at risk of developing (and maintaining) LVH, concentric remodeling and subclinical LV dysfunction, namely the morpho-functional features of heart failure with preserved ejection fraction.	The study supports the presence of heart failure as an outcome of hypertensive heart disease.	"{""explanation"": ""The study supports the presence of heart failure as an outcome of hypertensive heart disease."", ""reference"": ""PMID:36030347"", ""snippet"": ""Current evidence, based on cross-sectional and longitudinal observational studies as well as real-world registries and randomized controlled trials, suggests that women are more at risk of developing (and maintaining) LVH, concentric remodeling and subclinical LV dysfunction, namely the morpho-functional features of heart failure with preserved ejection fraction."", ""supports"": ""SUPPORT""}"
3889	3810	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	has_subtypes	2	evidence	2	PMID:35679365	SUPPORT		Several factors chronically lead to HF, including cardiac volume and pressure overload that may result from hypertension.	Heart failure as a result of hypertension is explicitly mentioned.	"{""explanation"": ""Heart failure as a result of hypertension is explicitly mentioned."", ""reference"": ""PMID:35679365"", ""snippet"": ""Several factors chronically lead to HF, including cardiac volume and pressure overload that may result from hypertension."", ""supports"": ""SUPPORT""}"
3890	3810	160	Hypertensive Heart Disease	Hypertensive_Heart_Disease.yaml	has_subtypes	2	evidence	3	PMID:27884237	SUPPORT		Left ventricular (LV) diastolic dysfunction (LVDD) is characterized by alterations in LV diastolic filling, and is a strong predictor of cardiovascular events and heart failure. Hypertension is the most important risk factor for LVDD in the community and promotes LVDD through several mechanisms.	Hypertension leading to heart failure is supported via the mechanism of LV diastolic dysfunction.	"{""explanation"": ""Hypertension leading to heart failure is supported via the mechanism of LV diastolic dysfunction."", ""reference"": ""PMID:27884237"", ""snippet"": ""Left ventricular (LV) diastolic dysfunction (LVDD) is characterized by alterations in LV diastolic filling, and is a strong predictor of cardiovascular events and heart failure. Hypertension is the most important risk factor for LVDD in the community and promotes LVDD through several mechanisms."", ""supports"": ""SUPPORT""}"
3998	3856	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	has_subtypes	0	evidence	0	PMID:38368032	PARTIAL		Obstruction to left ventricular outflow occurs in approximately 60% of patients.	The provided literature states that obstruction occurs in approximately 60% of HCM patients, indicating that not all HCM cases are obstructive. Thus, the statement that the thickened heart muscle obstructs blood flow out of the left ventricle can be recognized as a subtype known as obstructive HCM but does not apply to all HCM patients.	"{""explanation"": ""The provided literature states that obstruction occurs in approximately 60% of HCM patients, indicating that not all HCM cases are obstructive. Thus, the statement that the thickened heart muscle obstructs blood flow out of the left ventricle can be recognized as a subtype known as obstructive HCM but does not apply to all HCM patients."", ""reference"": ""PMID:38368032"", ""snippet"": ""Obstruction to left ventricular outflow occurs in approximately 60% of patients."", ""supports"": ""PARTIAL""}"
3999	3856	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	has_subtypes	0	evidence	1	PMID:35555885	PARTIAL		Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM)...	The literature indicates that LV hypertrophy (LVH) occurs in HCM alongside various conditions. However, it characterizes different forms, not solely obstructive HCM, thereby acknowledging the partial correctness of the subtype Obstructive HCM but not exclusively.	"{""explanation"": ""The literature indicates that LV hypertrophy (LVH) occurs in HCM alongside various conditions. However, it characterizes different forms, not solely obstructive HCM, thereby acknowledging the partial correctness of the subtype Obstructive HCM but not exclusively."", ""reference"": ""PMID:35555885"", ""snippet"": ""Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM)..."", ""supports"": ""PARTIAL""}"
4000	3856	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	has_subtypes	0	evidence	2	PMID:20560010	SUPPORT		Left ventricular outflow tract obstruction (LVOTO) is one of the defining features of hypertrophic cardiomyopathy (HCM)...	This specific literature confirms that left ventricular outflow tract obstruction (LVOTO) is a defining feature of HCM, thereby supporting the statement regarding the thickened heart muscle obstructing blood flow out of the left ventricle.	"{""explanation"": ""This specific literature confirms that left ventricular outflow tract obstruction (LVOTO) is a defining feature of HCM, thereby supporting the statement regarding the thickened heart muscle obstructing blood flow out of the left ventricle."", ""reference"": ""PMID:20560010"", ""snippet"": ""Left ventricular outflow tract obstruction (LVOTO) is one of the defining features of hypertrophic cardiomyopathy (HCM)..."", ""supports"": ""SUPPORT""}"
4001	3857	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	has_subtypes	1	evidence	0	PMID:34126727	SUPPORT		Patients with non-obstructive HCM... According to the characteristics of cardiac morphology and function shown by echocardiography, the patients were divided into common type, dilated type, restricted type and reduced ejection fraction type.	The reference describes non-obstructive hypertrophic cardiomyopathy (HCM) as a subtype of HCM characterized by different clinical subtypes based on cardiac morphology and function, supporting the statement that non-obstructive HCM involves thickened heart muscle without significant obstruction of blood flow.	"{""explanation"": ""The reference describes non-obstructive hypertrophic cardiomyopathy (HCM) as a subtype of HCM characterized by different clinical subtypes based on cardiac morphology and function, supporting the statement that non-obstructive HCM involves thickened heart muscle without significant obstruction of blood flow."", ""reference"": ""PMID:34126727"", ""snippet"": ""Patients with non-obstructive HCM... According to the characteristics of cardiac morphology and function shown by echocardiography, the patients were divided into common type, dilated type, restricted type and reduced ejection fraction type."", ""supports"": ""SUPPORT""}"
4002	3857	161	Hypertrophic Cardiomyopathy	Hypertrophic_Cardiomyopathy.yaml	has_subtypes	1	evidence	1	PMID:35555885	SUPPORT		Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM)...Although various diseases share LV wall thickening as a common feature, the histologic changes that underscore each disease are distinct.	This reference supports the statement by acknowledging that hypertrophic cardiomyopathy can include conditions with thickened heart muscle where the histological features differ, indicating diverse subtypes including non-obstructive forms.	"{""explanation"": ""This reference supports the statement by acknowledging that hypertrophic cardiomyopathy can include conditions with thickened heart muscle where the histological features differ, indicating diverse subtypes including non-obstructive forms."", ""reference"": ""PMID:35555885"", ""snippet"": ""Left ventricular (LV) wall thickening, or LV hypertrophy (LVH), is common and occurs in diverse conditions including hypertrophic cardiomyopathy (HCM)...Although various diseases share LV wall thickening as a common feature, the histologic changes that underscore each disease are distinct."", ""supports"": ""SUPPORT""}"
4147	4087	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	has_subtypes	0	evidence	0	PMID:30082241	SUPPORT		Criteria for Jeavons syndrome included all of the following: (1) eyelid myoclonia with or without absences...	The criteria for diagnosing Jeavons syndrome include eyelid myoclonia with or without absences, supporting the statement's description.	"{""explanation"": ""The criteria for diagnosing Jeavons syndrome include eyelid myoclonia with or without absences, supporting the statement's description."", ""reference"": ""PMID:30082241"", ""snippet"": ""Criteria for Jeavons syndrome included all of the following: (1) eyelid myoclonia with or without absences..."", ""supports"": ""SUPPORT""}"
4148	4087	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	has_subtypes	0	evidence	1	PMID:37329145	SUPPORT		There was consensus that generalized tonic-clonic and absence seizures are typically or occasionally seen in patients.	The consensus specifies that absence seizures can be typically or occasionally seen in patients with Jeavons syndrome, supporting the statement.	"{""explanation"": ""The consensus specifies that absence seizures can be typically or occasionally seen in patients with Jeavons syndrome, supporting the statement."", ""reference"": ""PMID:37329145"", ""snippet"": ""There was consensus that generalized tonic-clonic and absence seizures are typically or occasionally seen in patients."", ""supports"": ""SUPPORT""}"
4149	4088	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	has_subtypes	1	evidence	0	PMID:35394968	SUPPORT		Epilepsy with eyelid myoclonia (EMA) is characterized by eyelid myoclonia, eyelid closure sensitivity, and photosensitivity.	This reference confirms that EMA, a defining feature of Jeavons Syndrome, includes photosensitivity as well as eyelid myoclonia and absences.	"{""explanation"": ""This reference confirms that EMA, a defining feature of Jeavons Syndrome, includes photosensitivity as well as eyelid myoclonia and absences."", ""reference"": ""PMID:35394968"", ""snippet"": ""Epilepsy with eyelid myoclonia (EMA) is characterized by eyelid myoclonia, eyelid closure sensitivity, and photosensitivity."", ""supports"": ""SUPPORT""}"
4150	4088	173	Jeavons Syndrome	Jeavons_Syndrome.yaml	has_subtypes	1	evidence	1	PMID:29722743	SUPPORT		Eyelid myoclonia with absences, generalized tonic-clonic seizures, and severe photosensitivity accompanied by eyelid myoclonia.	This case report discusses a patient with Jeavons Syndrome exhibiting eyelid myoclonia with absences and severe photosensitivity, supporting the subtype EMA+ described in the statement.	"{""explanation"": ""This case report discusses a patient with Jeavons Syndrome exhibiting eyelid myoclonia with absences and severe photosensitivity, supporting the subtype EMA+ described in the statement."", ""reference"": ""PMID:29722743"", ""snippet"": ""Eyelid myoclonia with absences, generalized tonic-clonic seizures, and severe photosensitivity accompanied by eyelid myoclonia."", ""supports"": ""SUPPORT""}"
4280	4221	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	has_subtypes	0	evidence	0	PMID:10369869	SUPPORT		"VS is characterized by papular and honeycomb keratoderma associated with constrictions of digits leading to autoamputation, distinctive starfish-like acral keratoses and moderate degrees of deafness.
"	This landmark paper identified the D66H mutation in GJB2 as causative for classic Vohwinkel syndrome with the characteristic triad.	"{""explanation"": ""This landmark paper identified the D66H mutation in GJB2 as causative for classic Vohwinkel syndrome with the characteristic triad."", ""reference"": ""PMID:10369869"", ""snippet"": ""VS is characterized by papular and honeycomb keratoderma associated with constrictions of digits leading to autoamputation, distinctive starfish-like acral keratoses and moderate degrees of deafness.\n"", ""supports"": ""SUPPORT""}"
4281	4222	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	has_subtypes	1	evidence	0	PMID:9326398	SUPPORT		"Vohwinkel's keratoderma is thus clinically and genetically heterogeneous. Only the variant with ichthyosis appears to be due to loricrin mutation.
"	This paper established that loricrin mutations cause the ichthyotic variant without hearing loss.	"{""explanation"": ""This paper established that loricrin mutations cause the ichthyotic variant without hearing loss."", ""reference"": ""PMID:9326398"", ""snippet"": ""Vohwinkel's keratoderma is thus clinically and genetically heterogeneous. Only the variant with ichthyosis appears to be due to loricrin mutation.\n"", ""supports"": ""SUPPORT""}"
4282	4222	178	Keratoderma Hereditarium Mutilans	Keratoderma_Hereditarium_Mutilans.yaml	has_subtypes	1	evidence	1	PMID:12072018	SUPPORT		"Functional studies in transgenic mice have shown that the accumulation of mutant loricrin in the nucleus appears to interfere with the later stages of epidermal differentiation, thereby explaining the clinical manifestations of ichthyosis, keratoderma and pseudoainhum.
"	Confirms loricrin mutations underlie the ichthyotic variant of Vohwinkel syndrome.	"{""explanation"": ""Confirms loricrin mutations underlie the ichthyotic variant of Vohwinkel syndrome."", ""reference"": ""PMID:12072018"", ""snippet"": ""Functional studies in transgenic mice have shown that the accumulation of mutant loricrin in the nucleus appears to interfere with the later stages of epidermal differentiation, thereby explaining the clinical manifestations of ichthyosis, keratoderma and pseudoainhum.\n"", ""supports"": ""SUPPORT""}"
4465	4362	183	Leishmaniasis	Leishmaniasis.yaml	has_subtypes	0	evidence	0	PMID:19634705	SUPPORT		It manifests mainly in 3 clinical forms; visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL)	The review lists visceral leishmaniasis as a main clinical form.	"{""explanation"": ""The review lists visceral leishmaniasis as a main clinical form."", ""reference"": ""PMID:19634705"", ""snippet"": ""It manifests mainly in 3 clinical forms; visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL)"", ""supports"": ""SUPPORT""}"
4466	4363	183	Leishmaniasis	Leishmaniasis.yaml	has_subtypes	1	evidence	0	PMID:19634705	SUPPORT		It manifests mainly in 3 clinical forms; visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL)	The review lists cutaneous leishmaniasis as a main clinical form.	"{""explanation"": ""The review lists cutaneous leishmaniasis as a main clinical form."", ""reference"": ""PMID:19634705"", ""snippet"": ""It manifests mainly in 3 clinical forms; visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL)"", ""supports"": ""SUPPORT""}"
4467	4364	183	Leishmaniasis	Leishmaniasis.yaml	has_subtypes	2	evidence	0	PMID:19634705	SUPPORT		It manifests mainly in 3 clinical forms; visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL)	The review lists mucocutaneous leishmaniasis as a main clinical form.	"{""explanation"": ""The review lists mucocutaneous leishmaniasis as a main clinical form."", ""reference"": ""PMID:19634705"", ""snippet"": ""It manifests mainly in 3 clinical forms; visceral leishmaniasis (VL), cutaneous leishmaniasis (CL) and mucocutaneous leishmaniasis (MCL)"", ""supports"": ""SUPPORT""}"
4591	4510	190	Lung Carcinoma	Lung_Carcinoma.yaml	has_subtypes	0	evidence	0	PMID:19445746	SUPPORT		Small cell lung cancer accounts for 20% of all cases, and is usually treated with chemotherapy.	The abstract identifies small cell lung cancer as a major subtype and notes chemotherapy treatment.	"{""explanation"": ""The abstract identifies small cell lung cancer as a major subtype and notes chemotherapy treatment."", ""reference"": ""PMID:19445746"", ""snippet"": ""Small cell lung cancer accounts for 20% of all cases, and is usually treated with chemotherapy."", ""supports"": ""SUPPORT""}"
4592	4511	190	Lung Carcinoma	Lung_Carcinoma.yaml	has_subtypes	1	evidence	0	PMID:19445746	SUPPORT		Adenocarcinoma is the main non-small cell pathology, and is treated initially with surgery.	The abstract notes adenocarcinoma as the main NSCLC subtype and its initial surgical treatment.	"{""explanation"": ""The abstract notes adenocarcinoma as the main NSCLC subtype and its initial surgical treatment."", ""reference"": ""PMID:19445746"", ""snippet"": ""Adenocarcinoma is the main non-small cell pathology, and is treated initially with surgery."", ""supports"": ""SUPPORT""}"
4638	4569	193	Lymphoma	Lymphoma.yaml	has_subtypes	0	evidence	0	PMID:31894937	SUPPORT		It is traditionally classified broadly as non-Hodgkin or Hodgkin lymphoma.	The abstract states lymphoma is classified as non-Hodgkin or Hodgkin.	"{""explanation"": ""The abstract states lymphoma is classified as non-Hodgkin or Hodgkin."", ""reference"": ""PMID:31894937"", ""snippet"": ""It is traditionally classified broadly as non-Hodgkin or Hodgkin lymphoma."", ""supports"": ""SUPPORT""}"
4639	4570	193	Lymphoma	Lymphoma.yaml	has_subtypes	1	evidence	0	PMID:31894937	SUPPORT		It is traditionally classified broadly as non-Hodgkin or Hodgkin lymphoma.	The abstract states lymphoma is classified as non-Hodgkin or Hodgkin.	"{""explanation"": ""The abstract states lymphoma is classified as non-Hodgkin or Hodgkin."", ""reference"": ""PMID:31894937"", ""snippet"": ""It is traditionally classified broadly as non-Hodgkin or Hodgkin lymphoma."", ""supports"": ""SUPPORT""}"
4679	4592	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	0	evidence	0	PMID:19466295	SUPPORT		Lynch syndrome represents 1-7% of all cases of colorectal cancer and is an autosomal-dominant inherited cancer predisposition syndrome caused by germline mutations in deoxyribonucleic acid (DNA) mismatch repair genes	The literature confirms that Lynch Syndrome is caused by germline mutations in DNA mismatch repair genes, including MLH1.	"{""explanation"": ""The literature confirms that Lynch Syndrome is caused by germline mutations in DNA mismatch repair genes, including MLH1."", ""reference"": ""PMID:19466295"", ""snippet"": ""Lynch syndrome represents 1-7% of all cases of colorectal cancer and is an autosomal-dominant inherited cancer predisposition syndrome caused by germline mutations in deoxyribonucleic acid (DNA) mismatch repair genes"", ""supports"": ""SUPPORT""}"
4680	4592	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	0	evidence	1	PMID:38003003	SUPPORT		MLH1 hypermethylation is an epigenetic alteration in the tumorigenesis of colorectal cancer (CRC) and endometrial cancer (EC), causing gene silencing, and, as a consequence, microsatellite instability.	The literature discusses MLH1 gene involvement in Lynch Syndrome, supporting its significant role.	"{""explanation"": ""The literature discusses MLH1 gene involvement in Lynch Syndrome, supporting its significant role."", ""reference"": ""PMID:38003003"", ""snippet"": ""MLH1 hypermethylation is an epigenetic alteration in the tumorigenesis of colorectal cancer (CRC) and endometrial cancer (EC), causing gene silencing, and, as a consequence, microsatellite instability."", ""supports"": ""SUPPORT""}"
4681	4592	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	0	evidence	2	PMID:34091457	SUPPORT		Deleterious heterozygous mutation of the MLH1 gene is an important cause of Lynch syndrome (LS), an autosomal dominant cancer caused by functional defects in the DNA mismatch repair (MMR) complex.	The abstract confirms that mutations in the MLH1 gene are a significant cause of Lynch Syndrome.	"{""explanation"": ""The abstract confirms that mutations in the MLH1 gene are a significant cause of Lynch Syndrome."", ""reference"": ""PMID:34091457"", ""snippet"": ""Deleterious heterozygous mutation of the MLH1 gene is an important cause of Lynch syndrome (LS), an autosomal dominant cancer caused by functional defects in the DNA mismatch repair (MMR) complex."", ""supports"": ""SUPPORT""}"
4682	4593	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	1	evidence	0	PMID:19466295	SUPPORT		Lynch syndrome represents 1-7% of all cases of colorectal cancer and is an autosomal-dominant inherited cancer predisposition syndrome caused by germline mutations in deoxyribonucleic acid (DNA) mismatch repair genes. Since the discovery of the major human genes with DNA mismatch repair function, mutations in five of them have been correlated with susceptibility to Lynch syndrome: mutS homolog 2 (MSH2); mutL homolog 1 (MLH1); mutS homolog 6 (MSH6); postmeiotic segregation increased 2 (PMS2); and postmeiotic segregation increased 1 (PMS1).	The literature indicates that MSH2 is one of the genes whose mutation is correlated with susceptibility to Lynch syndrome.	"{""explanation"": ""The literature indicates that MSH2 is one of the genes whose mutation is correlated with susceptibility to Lynch syndrome."", ""reference"": ""PMID:19466295"", ""snippet"": ""Lynch syndrome represents 1-7% of all cases of colorectal cancer and is an autosomal-dominant inherited cancer predisposition syndrome caused by germline mutations in deoxyribonucleic acid (DNA) mismatch repair genes. Since the discovery of the major human genes with DNA mismatch repair function, mutations in five of them have been correlated with susceptibility to Lynch syndrome: mutS homolog 2 (MSH2); mutL homolog 1 (MLH1); mutS homolog 6 (MSH6); postmeiotic segregation increased 2 (PMS2); and postmeiotic segregation increased 1 (PMS1)."", ""supports"": ""SUPPORT""}"
4683	4593	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	1	evidence	1	PMID:34302852	SUPPORT		Lynch syndrome (LS) is caused by a pathogenic heterozygous germline variant in one of the DNA mismatch repair (MMR) genes: MLH1, MSH2, MSH6 or PMS2.	This directly supports the statement that Lynch syndrome subtypes include those caused by mutations in the MSH2 gene.	"{""explanation"": ""This directly supports the statement that Lynch syndrome subtypes include those caused by mutations in the MSH2 gene."", ""reference"": ""PMID:34302852"", ""snippet"": ""Lynch syndrome (LS) is caused by a pathogenic heterozygous germline variant in one of the DNA mismatch repair (MMR) genes: MLH1, MSH2, MSH6 or PMS2."", ""supports"": ""SUPPORT""}"
4684	4593	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	1	evidence	2	PMID:36434153	SUPPORT		Patients with the heritable cancer disease, Lynch syndrome, carry germline variants in the MLH1, MSH2, MSH6 and PMS2 genes, encoding the central components of the DNA mismatch repair system.	This provides further confirmation that mutations in MSH2 can cause Lynch syndrome, supporting the statement.	"{""explanation"": ""This provides further confirmation that mutations in MSH2 can cause Lynch syndrome, supporting the statement."", ""reference"": ""PMID:36434153"", ""snippet"": ""Patients with the heritable cancer disease, Lynch syndrome, carry germline variants in the MLH1, MSH2, MSH6 and PMS2 genes, encoding the central components of the DNA mismatch repair system."", ""supports"": ""SUPPORT""}"
4685	4594	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	2	evidence	0	PMID:19466295	SUPPORT		Since the discovery of the major human genes with DNA mismatch repair function, mutations in five of them have been correlated with susceptibility to Lynch syndrome: mutS homolog 2 (MSH2); mutL homolog 1 (MLH1); mutS homolog 6 (MSH6); postmeiotic segregation increased 2 (PMS2); and postmeiotic segregation increased 1 (PMS1).	The literature confirms that Lynch syndrome can be caused by mutations in the MSH6 gene, which is involved in DNA mismatch repair.	"{""explanation"": ""The literature confirms that Lynch syndrome can be caused by mutations in the MSH6 gene, which is involved in DNA mismatch repair."", ""reference"": ""PMID:19466295"", ""snippet"": ""Since the discovery of the major human genes with DNA mismatch repair function, mutations in five of them have been correlated with susceptibility to Lynch syndrome: mutS homolog 2 (MSH2); mutL homolog 1 (MLH1); mutS homolog 6 (MSH6); postmeiotic segregation increased 2 (PMS2); and postmeiotic segregation increased 1 (PMS1)."", ""supports"": ""SUPPORT""}"
4686	4594	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	2	evidence	1	PMID:25430799	SUPPORT		Sixty-seven (59%) families had mutations in MSH2, 20 (18%) in MSH6, 19 (17%) in MLH1 and 7 (6%) in PMS2.	The study identifies MSH6 as one of the genes with mutations found in Lynch syndrome patients.	"{""explanation"": ""The study identifies MSH6 as one of the genes with mutations found in Lynch syndrome patients."", ""reference"": ""PMID:25430799"", ""snippet"": ""Sixty-seven (59%) families had mutations in MSH2, 20 (18%) in MSH6, 19 (17%) in MLH1 and 7 (6%) in PMS2."", ""supports"": ""SUPPORT""}"
4687	4595	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	3	evidence	0	PMID:24027009	SUPPORT		Lynch syndrome (LS) is a common cancer predisposition caused by an inactivating mutation in one of four DNA mismatch repair (MMR) genes.	Further detail is provided in the study focusing on PMS2 gene's role in MMR and its link to Lynch Syndrome.	"{""explanation"": ""Further detail is provided in the study focusing on PMS2 gene's role in MMR and its link to Lynch Syndrome."", ""reference"": ""PMID:24027009"", ""snippet"": ""Lynch syndrome (LS) is a common cancer predisposition caused by an inactivating mutation in one of four DNA mismatch repair (MMR) genes."", ""supports"": ""SUPPORT""}"
4688	4595	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	3	evidence	1	PMID:18602922	SUPPORT		Although the clinical phenotype of Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer) has been well described, little is known about disease in PMS2 mutation carriers.	The study confirms PMS2 mutations contribute to Lynch Syndrome.	"{""explanation"": ""The study confirms PMS2 mutations contribute to Lynch Syndrome."", ""reference"": ""PMID:18602922"", ""snippet"": ""Although the clinical phenotype of Lynch syndrome (also known as hereditary nonpolyposis colorectal cancer) has been well described, little is known about disease in PMS2 mutation carriers."", ""supports"": ""SUPPORT""}"
4689	4596	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	4	evidence	0	PMID:23411950	SUPPORT		Germline mutations of 4 MMR genes, e.g., MLH1, MSH2, MSH6 and PMS2, had been identified as the cause of this disease, however, a novel mechanism, epigenetic inactivation of MSH2 gene due to hypermethylation of promotor region by the deletion of 3'part of epithelial cell adhesion molecule(EPCAM) gene which is located upstream of the MSH2 gene, has been reported in recent years.	This reference describes the mechanism by which EPCAM gene deletion causes epigenetic inactivation of the MSH2 gene, supporting the statement.	"{""explanation"": ""This reference describes the mechanism by which EPCAM gene deletion causes epigenetic inactivation of the MSH2 gene, supporting the statement."", ""reference"": ""PMID:23411950"", ""snippet"": ""Germline mutations of 4 MMR genes, e.g., MLH1, MSH2, MSH6 and PMS2, had been identified as the cause of this disease, however, a novel mechanism, epigenetic inactivation of MSH2 gene due to hypermethylation of promotor region by the deletion of 3'part of epithelial cell adhesion molecule(EPCAM) gene which is located upstream of the MSH2 gene, has been reported in recent years."", ""supports"": ""SUPPORT""}"
4690	4596	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	4	evidence	1	PMID:30461124	SUPPORT		Monoallelic deletions of the 3' end of EPCAM that silence the downstream gene, MSH2, cause a form of Lynch syndrome, which is a cancer predisposition syndrome associated with loss of DNA mismatch repair.	This reference further supports the statement by specifying that deletions of the EPCAM gene silence the MSH2 gene, leading to Lynch syndrome.	"{""explanation"": ""This reference further supports the statement by specifying that deletions of the EPCAM gene silence the MSH2 gene, leading to Lynch syndrome."", ""reference"": ""PMID:30461124"", ""snippet"": ""Monoallelic deletions of the 3' end of EPCAM that silence the downstream gene, MSH2, cause a form of Lynch syndrome, which is a cancer predisposition syndrome associated with loss of DNA mismatch repair."", ""supports"": ""SUPPORT""}"
4691	4596	194	Lynch Syndrome	Lynch_Syndrome.yaml	has_subtypes	4	evidence	2	PMID:23264089	SUPPORT		These patients carry deletions of the 3' end of the EPCAM gene, including its polyadenylation signal. Due to concomitant transcriptional read-through of EPCAM, the promoter of MSH2 15 kb further downstream becomes inactivated through hypermethylation.	This reference describes the specific mechanism by which EPCAM deletions lead to the inactivation of MSH2, supporting the statement.	"{""explanation"": ""This reference describes the specific mechanism by which EPCAM deletions lead to the inactivation of MSH2, supporting the statement."", ""reference"": ""PMID:23264089"", ""snippet"": ""These patients carry deletions of the 3' end of the EPCAM gene, including its polyadenylation signal. Due to concomitant transcriptional read-through of EPCAM, the promoter of MSH2 15 kb further downstream becomes inactivated through hypermethylation."", ""supports"": ""SUPPORT""}"
4757	4654	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	has_subtypes	0	evidence	0	PMID:15340260	SUPPORT		Colorectal cancers resulting from defective DNA mismatch repair can occur in both hereditary non-polyposis colon cancer (HNPCC) and in the sporadic setting.	Study confirms that MSI-H colorectal cancers can arise from hereditary (HNPCC/Lynch syndrome) or sporadic causes.	"{""explanation"": ""Study confirms that MSI-H colorectal cancers can arise from hereditary (HNPCC/Lynch syndrome) or sporadic causes."", ""reference"": ""PMID:15340260"", ""snippet"": ""Colorectal cancers resulting from defective DNA mismatch repair can occur in both hereditary non-polyposis colon cancer (HNPCC) and in the sporadic setting."", ""supports"": ""SUPPORT""}"
4758	4655	197	MSI-High Colorectal Cancer	MSI_High_Colorectal_Cancer.yaml	has_subtypes	1	evidence	0	PMID:15340260	SUPPORT		BRAF mutations were detected in 74% of sporadic tumours but none of the HNPCC cancers tested.	Study demonstrates that BRAF mutations distinguish sporadic MSI-H CRC from Lynch syndrome-associated tumors.	"{""explanation"": ""Study demonstrates that BRAF mutations distinguish sporadic MSI-H CRC from Lynch syndrome-associated tumors."", ""reference"": ""PMID:15340260"", ""snippet"": ""BRAF mutations were detected in 74% of sporadic tumours but none of the HNPCC cancers tested."", ""supports"": ""SUPPORT""}"
4767	4678	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	has_subtypes	0	evidence	0	PMID:15340260	SUPPORT		Colorectal cancers resulting from defective DNA mismatch repair can occur in both hereditary non-polyposis colon cancer (HNPCC) and in the sporadic setting.	This study establishes that MMR-deficient cancers can arise from hereditary (Lynch syndrome) or sporadic causes, applicable to endometrial cancer as well.	"{""explanation"": ""This study establishes that MMR-deficient cancers can arise from hereditary (Lynch syndrome) or sporadic causes, applicable to endometrial cancer as well."", ""reference"": ""PMID:15340260"", ""snippet"": ""Colorectal cancers resulting from defective DNA mismatch repair can occur in both hereditary non-polyposis colon cancer (HNPCC) and in the sporadic setting."", ""supports"": ""SUPPORT""}"
4768	4679	198	MSI-High Endometrial Cancer	MSI_High_Endometrial_Cancer.yaml	has_subtypes	1	evidence	0	PMID:15340260	SUPPORT		significant differences can be demonstrated at the molecular level including widespread promoter hypermethylation and BRAF -activating mutations which occur significantly less often in HNPCC	Study demonstrates that sporadic MSI-H tumors are characterized by promoter hypermethylation, distinguishing them from Lynch syndrome cases.	"{""explanation"": ""Study demonstrates that sporadic MSI-H tumors are characterized by promoter hypermethylation, distinguishing them from Lynch syndrome cases."", ""reference"": ""PMID:15340260"", ""snippet"": ""significant differences can be demonstrated at the molecular level including widespread promoter hypermethylation and BRAF -activating mutations which occur significantly less often in HNPCC"", ""supports"": ""SUPPORT""}"
4819	4792	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	has_subtypes	0	evidence	0	PMID:27373929	SUPPORT		In the classic form of MSUD256, BCKDH enzyme only has 25% normal activity.	Confirms classic form has very low residual enzyme activity.	"{""explanation"": ""Confirms classic form has very low residual enzyme activity."", ""reference"": ""PMID:27373929"", ""snippet"": ""In the classic form of MSUD256, BCKDH enzyme only has 25% normal activity."", ""supports"": ""SUPPORT""}"
4820	4793	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	has_subtypes	1	evidence	0	PMID:27373929	SUPPORT		In addition to the classic form, there are intermediate78 (1525% BCKDH activity), intermittent (asymptomatic until 1016 months or later) and thiamine-responsive910 MSUD diseases.	Confirms intermediate form has higher residual enzyme activity.	"{""explanation"": ""Confirms intermediate form has higher residual enzyme activity."", ""reference"": ""PMID:27373929"", ""snippet"": ""In addition to the classic form, there are intermediate78 (1525% BCKDH activity), intermittent (asymptomatic until 1016 months or later) and thiamine-responsive910 MSUD diseases."", ""supports"": ""SUPPORT""}"
4821	4794	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	has_subtypes	2	evidence	0	PMID:27373929	SUPPORT		In addition to the classic form, there are intermediate78 (1525% BCKDH activity), intermittent (asymptomatic until 1016 months or later) and thiamine-responsive910 MSUD diseases.	Confirms intermittent form patients are asymptomatic until later in life.	"{""explanation"": ""Confirms intermittent form patients are asymptomatic until later in life."", ""reference"": ""PMID:27373929"", ""snippet"": ""In addition to the classic form, there are intermediate78 (1525% BCKDH activity), intermittent (asymptomatic until 1016 months or later) and thiamine-responsive910 MSUD diseases."", ""supports"": ""SUPPORT""}"
4822	4795	203	Maple Syrup Urine Disease	Maple_Syrup_Urine_Disease.yaml	has_subtypes	3	evidence	0	PMID:27373929	SUPPORT		Thiamine responsivity is associated with a specific mutation in the thiamine binding site in the E1b subunit, or due to the stabilization of BCKDH via an allosteric interaction	Confirms thiamine-responsive form is due to specific mutations affecting thiamine binding.	"{""explanation"": ""Confirms thiamine-responsive form is due to specific mutations affecting thiamine binding."", ""reference"": ""PMID:27373929"", ""snippet"": ""Thiamine responsivity is associated with a specific mutation in the thiamine binding site in the E1b subunit, or due to the stabilization of BCKDH via an allosteric interaction"", ""supports"": ""SUPPORT""}"
5188	5092	214	Migraine	Migraine.yaml	has_subtypes	0	evidence	0	PMID:1525797	SUPPORT		Lifetime prevalence of MA was 5%, male:female ratio 1:2.	Population study establishes migraine with aura as a distinct subtype with 5% lifetime prevalence.	"{""explanation"": ""Population study establishes migraine with aura as a distinct subtype with 5% lifetime prevalence."", ""reference"": ""PMID:1525797"", ""snippet"": ""Lifetime prevalence of MA was 5%, male:female ratio 1:2."", ""supports"": ""SUPPORT""}"
5189	5092	214	Migraine	Migraine.yaml	has_subtypes	0	evidence	1	PMID:1525797	SUPPORT		Visual disturbances were the most common aura phenomenon occurring in 90% of subjects with MA.	Visual symptoms are the predominant aura type, occurring in 90% of migraine with aura cases.	"{""explanation"": ""Visual symptoms are the predominant aura type, occurring in 90% of migraine with aura cases."", ""reference"": ""PMID:1525797"", ""snippet"": ""Visual disturbances were the most common aura phenomenon occurring in 90% of subjects with MA."", ""supports"": ""SUPPORT""}"
5190	5093	214	Migraine	Migraine.yaml	has_subtypes	1	evidence	0	PMID:1525797	SUPPORT		Lifetime prevalence of MO was 8%, M:F ratio 1:7.	Migraine without aura is the most common form with 8% lifetime prevalence and strong female predominance.	"{""explanation"": ""Migraine without aura is the most common form with 8% lifetime prevalence and strong female predominance."", ""reference"": ""PMID:1525797"", ""snippet"": ""Lifetime prevalence of MO was 8%, M:F ratio 1:7."", ""supports"": ""SUPPORT""}"
5191	5093	214	Migraine	Migraine.yaml	has_subtypes	1	evidence	1	PMID:1525797	SUPPORT		Women, but not men, were significantly more likely to have MO than MA.	Migraine without aura shows stronger female predominance than migraine with aura.	"{""explanation"": ""Migraine without aura shows stronger female predominance than migraine with aura."", ""reference"": ""PMID:1525797"", ""snippet"": ""Women, but not men, were significantly more likely to have MO than MA."", ""supports"": ""SUPPORT""}"
5192	5094	214	Migraine	Migraine.yaml	has_subtypes	2	evidence	0	PMID:30893319	SUPPORT		For chronic migraine, propranolol was more likely to reduce headaches by at least 50% (RR: 2.0, 95% CI: 1.0-4.3).	Chronic migraine is recognized as a distinct subtype requiring different treatment approaches.	"{""explanation"": ""Chronic migraine is recognized as a distinct subtype requiring different treatment approaches."", ""reference"": ""PMID:30893319"", ""snippet"": ""For chronic migraine, propranolol was more likely to reduce headaches by at least 50% (RR: 2.0, 95% CI: 1.0-4.3)."", ""supports"": ""SUPPORT""}"
5193	5095	214	Migraine	Migraine.yaml	has_subtypes	3	evidence	0	PMID:38619053	SUPPORT		Vestibular migraine is an underdiagnosed migraine phenotype that shares the pathophysiological mechanisms of migraine, with growing interest in recent years.	Vestibular migraine is established as a distinct underdiagnosed migraine phenotype.	"{""explanation"": ""Vestibular migraine is established as a distinct underdiagnosed migraine phenotype."", ""reference"": ""PMID:38619053"", ""snippet"": ""Vestibular migraine is an underdiagnosed migraine phenotype that shares the pathophysiological mechanisms of migraine, with growing interest in recent years."", ""supports"": ""SUPPORT""}"
5248	5144	216	Monkeypox	Monkeypox.yaml	has_subtypes	0	evidence	0	PMID:36607751	SUPPORT		Monkeypox is a variola poxvirus that is related to smallpox, but monkeypox symptoms (fever, painful vesicular or pustular rash, and lymphadenopathy) are milder and fatalities are rare.	The abstract mentions that monkeypox symptoms are milder and fatalities are rare, which aligns with the statement that the West African Clade typically causes milder illness with lower mortality rates.	"{""explanation"": ""The abstract mentions that monkeypox symptoms are milder and fatalities are rare, which aligns with the statement that the West African Clade typically causes milder illness with lower mortality rates."", ""reference"": ""PMID:36607751"", ""snippet"": ""Monkeypox is a variola poxvirus that is related to smallpox, but monkeypox symptoms (fever, painful vesicular or pustular rash, and lymphadenopathy) are milder and fatalities are rare."", ""supports"": ""SUPPORT""}"
5249	5144	216	Monkeypox	Monkeypox.yaml	has_subtypes	0	evidence	1	PMID:36801633	SUPPORT		In addition to identified transmission mediators through animal-to-human and human-to-human, especially sexual transmission among men who have sex with men came to prominence in the 2022 global outbreak. Although the severity and prevalence of the disease differ depending on age and gender, some symptoms are commonly observed.	While the snippet predominantly discusses transmission and general symptomatology, the phrase 'the severity and prevalence of the disease differ' suggests variation among clades, implicitly supporting that the West African Clade, by comparison, is known for milder illness.	"{""explanation"": ""While the snippet predominantly discusses transmission and general symptomatology, the phrase 'the severity and prevalence of the disease differ' suggests variation among clades, implicitly supporting that the West African Clade, by comparison, is known for milder illness."", ""reference"": ""PMID:36801633"", ""snippet"": ""In addition to identified transmission mediators through animal-to-human and human-to-human, especially sexual transmission among men who have sex with men came to prominence in the 2022 global outbreak. Although the severity and prevalence of the disease differ depending on age and gender, some symptoms are commonly observed."", ""supports"": ""SUPPORT""}"
5250	5144	216	Monkeypox	Monkeypox.yaml	has_subtypes	0	evidence	2	PMID:36604361	NO_EVIDENCE		Monkeypox is a systemic exanthematous viral disease presenting with fever, lymphadenopathy, and vesicular rash.	This abstract provides an overview of monkeypox symptoms but does not distinguish between different clades or mention their severity or mortality rates.	"{""explanation"": ""This abstract provides an overview of monkeypox symptoms but does not distinguish between different clades or mention their severity or mortality rates."", ""reference"": ""PMID:36604361"", ""snippet"": ""Monkeypox is a systemic exanthematous viral disease presenting with fever, lymphadenopathy, and vesicular rash."", ""supports"": ""NO_EVIDENCE""}"
5251	5145	216	Monkeypox	Monkeypox.yaml	has_subtypes	1	evidence	0	PMID:36066176	SUPPORT		Despite with a close genetic similarity between the two clades, the Central African strain is comparatively very virulent with high mortality.	The abstract clearly distinguishes the Central African clade as having higher virulence and mortality compared to the West African clade.	"{""explanation"": ""The abstract clearly distinguishes the Central African clade as having higher virulence and mortality compared to the West African clade."", ""reference"": ""PMID:36066176"", ""snippet"": ""Despite with a close genetic similarity between the two clades, the Central African strain is comparatively very virulent with high mortality."", ""supports"": ""SUPPORT""}"
5252	5145	216	Monkeypox	Monkeypox.yaml	has_subtypes	1	evidence	1	PMID:36328951	SUPPORT		High fatality rates associated with monkeypox virus clade I also are a local and international concern.	Clade I corresponds to the Central African clade, and the abstract reports high fatality rates associated with it, supporting the statement.	"{""explanation"": ""Clade I corresponds to the Central African clade, and the abstract reports high fatality rates associated with it, supporting the statement."", ""reference"": ""PMID:36328951"", ""snippet"": ""High fatality rates associated with monkeypox virus clade I also are a local and international concern."", ""supports"": ""SUPPORT""}"
5253	5145	216	Monkeypox	Monkeypox.yaml	has_subtypes	1	evidence	2	PMID:20643162	SUPPORT		the MPXV Congo Basin clade viruses are endemic in the Congo Basin, human illness typically presents with symptoms similar to discrete, ordinary smallpox and has a case fatality rate of approximately 10% in unvaccinated populations	This reference describes the Congo Basin clade (Central African clade) as having a high case fatality rate, supporting the claim about more severe clinical manifestations and higher mortality.	"{""explanation"": ""This reference describes the Congo Basin clade (Central African clade) as having a high case fatality rate, supporting the claim about more severe clinical manifestations and higher mortality."", ""reference"": ""PMID:20643162"", ""snippet"": ""the MPXV Congo Basin clade viruses are endemic in the Congo Basin, human illness typically presents with symptoms similar to discrete, ordinary smallpox and has a case fatality rate of approximately 10% in unvaccinated populations"", ""supports"": ""SUPPORT""}"
5562	5332	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	has_subtypes	1	evidence	0	PMID:21674519	SUPPORT		Eighty-five percent were female, with disease onset typically in the fourth decade. Ocular and/or bulbar symptoms were present at onset in 79% of those studied.	Large cohort study confirms MuSK-MG has prominent bulbar involvement and female predominance.	"{""explanation"": ""Large cohort study confirms MuSK-MG has prominent bulbar involvement and female predominance."", ""reference"": ""PMID:21674519"", ""snippet"": ""Eighty-five percent were female, with disease onset typically in the fourth decade. Ocular and/or bulbar symptoms were present at onset in 79% of those studied."", ""supports"": ""SUPPORT""}"
5563	5332	222	Myasthenia Gravis	Myasthenia_Gravis.yaml	has_subtypes	1	evidence	1	PMID:21674519	SUPPORT		Eighty-five percent were MGFA class III or greater, and crisis occurred in 28%.	MuSK-MG tends to be more severe with higher rates of myasthenic crisis.	"{""explanation"": ""MuSK-MG tends to be more severe with higher rates of myasthenic crisis."", ""reference"": ""PMID:21674519"", ""snippet"": ""Eighty-five percent were MGFA class III or greater, and crisis occurred in 28%."", ""supports"": ""SUPPORT""}"
5630	5460	229	Nephronophthisis	Nephronophthisis.yaml	has_subtypes	0	evidence	0	PMID:16966065	SUPPORT		Infantile nephronophtisis is a recessive autosomic tubulo-interstitial nephritis with cortical microcysts which progress to end stage renal failure before age 5.	The source indicates that infantile nephronophthisis is characterized by early onset and rapid progression to end-stage renal disease, supporting the statement.	"{""explanation"": ""The source indicates that infantile nephronophthisis is characterized by early onset and rapid progression to end-stage renal disease, supporting the statement."", ""reference"": ""PMID:16966065"", ""snippet"": ""Infantile nephronophtisis is a recessive autosomic tubulo-interstitial nephritis with cortical microcysts which progress to end stage renal failure before age 5."", ""supports"": ""SUPPORT""}"
5631	5461	229	Nephronophthisis	Nephronophthisis.yaml	has_subtypes	1	evidence	0	PMID:16966065	SUPPORT		Juvenile nephronophtisis, the most frequent, progress to end stage renal failure before age 15.	The provided excerpt states that juvenile nephronophthisis is the most frequent subtype and typically progresses to end-stage renal failure by adolescence.	"{""explanation"": ""The provided excerpt states that juvenile nephronophthisis is the most frequent subtype and typically progresses to end-stage renal failure by adolescence."", ""reference"": ""PMID:16966065"", ""snippet"": ""Juvenile nephronophtisis, the most frequent, progress to end stage renal failure before age 15."", ""supports"": ""SUPPORT""}"
5632	5461	229	Nephronophthisis	Nephronophthisis.yaml	has_subtypes	1	evidence	1	PMID:35570616	SUPPORT		Nephronophthisis is the most common genetic cause of kidney failure in childhood... outcomes of kidney transplant recipients with primary diagnosis of juvenile nephronophthisis...	The excerpt indicates that juvenile nephronophthisis is a common pediatric kidney failure cause, aligning with 'most common form with onset in childhood'.	"{""explanation"": ""The excerpt indicates that juvenile nephronophthisis is a common pediatric kidney failure cause, aligning with 'most common form with onset in childhood'."", ""reference"": ""PMID:35570616"", ""snippet"": ""Nephronophthisis is the most common genetic cause of kidney failure in childhood... outcomes of kidney transplant recipients with primary diagnosis of juvenile nephronophthisis..."", ""supports"": ""SUPPORT""}"
5633	5462	229	Nephronophthisis	Nephronophthisis.yaml	has_subtypes	2	evidence	0	PMID:16966065	SUPPORT		Adolescent nephronophtisis is a less frequent form of nephronophtisis.	The term 'adolescent nephronophthisis' is noted, and it is described as a less frequent form of nephronophthisis which is consistent with later onset.	"{""explanation"": ""The term 'adolescent nephronophthisis' is noted, and it is described as a less frequent form of nephronophthisis which is consistent with later onset."", ""reference"": ""PMID:16966065"", ""snippet"": ""Adolescent nephronophtisis is a less frequent form of nephronophtisis."", ""supports"": ""SUPPORT""}"
5634	5462	229	Nephronophthisis	Nephronophthisis.yaml	has_subtypes	2	evidence	1	PMID:16966065	SUPPORT		Medullary cystic disease is transmitted as an autosomic dominant trait. Clinical and histological signs are similar to nephronophthisis, but the disease progress later to terminal renal failure and is not accompanied by extra-renal symptoms.	Medullary cystic disease presents similar signs but progresses later, implying a slower progression to renal failure, corroborating the adolescent nephronophthisis description.	"{""explanation"": ""Medullary cystic disease presents similar signs but progresses later, implying a slower progression to renal failure, corroborating the adolescent nephronophthisis description."", ""reference"": ""PMID:16966065"", ""snippet"": ""Medullary cystic disease is transmitted as an autosomic dominant trait. Clinical and histological signs are similar to nephronophthisis, but the disease progress later to terminal renal failure and is not accompanied by extra-renal symptoms."", ""supports"": ""SUPPORT""}"
5706	5545	233	Neuromyelitis Optica Spectrum Disorder	Neuromyelitis_Optica_Spectrum_Disorder.yaml	has_subtypes	0	evidence	0	PMID:26092914	SUPPORT		The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG).	The 2015 international diagnostic criteria formally stratify NMOSD by AQP4-IgG serostatus.	"{""explanation"": ""The 2015 international diagnostic criteria formally stratify NMOSD by AQP4-IgG serostatus."", ""reference"": ""PMID:26092914"", ""snippet"": ""The new nomenclature defines the unifying term NMO spectrum disorders (NMOSD), which is stratified further by serologic testing (NMOSD with or without AQP4-IgG)."", ""supports"": ""SUPPORT""}"
5747	5579	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	0	evidence	0	PMID:37681230	SUPPORT		Adenosquamous carcinoma of the lung is a characteristic tumor that has both adenocarcinoma and squamous cell carcinoma components.	This excerpt confirms that adenosquamous carcinoma displays features of both adenocarcinoma and squamous cell carcinoma.	"{""explanation"": ""This excerpt confirms that adenosquamous carcinoma displays features of both adenocarcinoma and squamous cell carcinoma."", ""reference"": ""PMID:37681230"", ""snippet"": ""Adenosquamous carcinoma of the lung is a characteristic tumor that has both adenocarcinoma and squamous cell carcinoma components."", ""supports"": ""SUPPORT""}"
5748	5579	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	0	evidence	1	PMID:20004040	SUPPORT		Adenocarcinomas (AC), squamous cell carcinomas (SCC) and adenosquamous carcinomas (ASC) are three histological subtypes of non-small-cell lung carcinomas (NSCLC). ASC are morphologically mixed tumours that contain the two cell components AC and SCC.	This literature supports the statement by explaining that adenosquamous carcinoma (ASC) contains both adenocarcinoma (AC) and squamous cell carcinoma (SCC) components.	"{""explanation"": ""This literature supports the statement by explaining that adenosquamous carcinoma (ASC) contains both adenocarcinoma (AC) and squamous cell carcinoma (SCC) components."", ""reference"": ""PMID:20004040"", ""snippet"": ""Adenocarcinomas (AC), squamous cell carcinomas (SCC) and adenosquamous carcinomas (ASC) are three histological subtypes of non-small-cell lung carcinomas (NSCLC). ASC are morphologically mixed tumours that contain the two cell components AC and SCC."", ""supports"": ""SUPPORT""}"
5749	5580	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	1	evidence	0	PMID:27637426	SUPPORT		An early result of this search was the discovery of NSCLC driven by activating rearrangements of the anaplastic lymphoma kinase (ALK) gene. In an astoundingly brief period following the recognition of ALK-positive NSCLC, details of the biology, clinicopathologic features, development of targeted inhibitors, mechanisms of therapeutic resistance, and new generations of treatment were elucidated.	This reference supports that NSCLC with ALK gene rearrangements is a subtype that is responsive to ALK inhibitors.	"{""explanation"": ""This reference supports that NSCLC with ALK gene rearrangements is a subtype that is responsive to ALK inhibitors."", ""reference"": ""PMID:27637426"", ""snippet"": ""An early result of this search was the discovery of NSCLC driven by activating rearrangements of the anaplastic lymphoma kinase (ALK) gene. In an astoundingly brief period following the recognition of ALK-positive NSCLC, details of the biology, clinicopathologic features, development of targeted inhibitors, mechanisms of therapeutic resistance, and new generations of treatment were elucidated."", ""supports"": ""SUPPORT""}"
5750	5580	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	1	evidence	1	PMID:21233671	SUPPORT		The significance of EGFR and ALK mutations in NSCLC and the impact of these genotypes on pathology and clinical practice are also reviewed.	This article mentions the impact of ALK mutations and the necessity to identify NSCLCs harboring these mutations due to their sensitivity to specific agents like ALK inhibitors.	"{""explanation"": ""This article mentions the impact of ALK mutations and the necessity to identify NSCLCs harboring these mutations due to their sensitivity to specific agents like ALK inhibitors."", ""reference"": ""PMID:21233671"", ""snippet"": ""The significance of EGFR and ALK mutations in NSCLC and the impact of these genotypes on pathology and clinical practice are also reviewed."", ""supports"": ""SUPPORT""}"
5751	5580	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	1	evidence	2	PMID:24998601	SUPPORT		The accelerated approval of the first ALK-inhibitor, Crizotinib and more recently Ceritinib, without a Phase III randomized, clinical trial, has been an amazing success story in lung cancer research, marking the beginning of a new decade of targeted drugs development.	This reference discusses the success and approval of ALK inhibitors like Crizotinib and Ceritinib for the treatment of ALK-rearranged NSCLC, supporting the claim.	"{""explanation"": ""This reference discusses the success and approval of ALK inhibitors like Crizotinib and Ceritinib for the treatment of ALK-rearranged NSCLC, supporting the claim."", ""reference"": ""PMID:24998601"", ""snippet"": ""The accelerated approval of the first ALK-inhibitor, Crizotinib and more recently Ceritinib, without a Phase III randomized, clinical trial, has been an amazing success story in lung cancer research, marking the beginning of a new decade of targeted drugs development."", ""supports"": ""SUPPORT""}"
5752	5580	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	1	evidence	3	PMID:31720561	SUPPORT		Similarly to anaplastic lymphoma kinase (ALK)-positive NSCLC, patients with ROS1+ NSCLC tend to have minimal smoking and be of the female sex. In most cases, adenocarcinoma is the dominant histology.	This indirectly supports that ALK-rearranged NSCLC is a recognized subtype as it compares ROS1+ NSCLC to ALK-positive NSCLC in terms of patient characteristics and histology.	"{""explanation"": ""This indirectly supports that ALK-rearranged NSCLC is a recognized subtype as it compares ROS1+ NSCLC to ALK-positive NSCLC in terms of patient characteristics and histology."", ""reference"": ""PMID:31720561"", ""snippet"": ""Similarly to anaplastic lymphoma kinase (ALK)-positive NSCLC, patients with ROS1+ NSCLC tend to have minimal smoking and be of the female sex. In most cases, adenocarcinoma is the dominant histology."", ""supports"": ""SUPPORT""}"
5753	5580	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	1	evidence	4	PMID:33387080	SUPPORT		Anaplastic lymphoma kinase (ALK) rearrangements represent a seldom event in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK targeting represents the main therapeutic strategy.	This recent review discusses the targeting of ALK rearrangements as a therapeutic strategy, supporting that ALK-rearranged NSCLC is a recognized subtype responsive to ALK inhibitors.	"{""explanation"": ""This recent review discusses the targeting of ALK rearrangements as a therapeutic strategy, supporting that ALK-rearranged NSCLC is a recognized subtype responsive to ALK inhibitors."", ""reference"": ""PMID:33387080"", ""snippet"": ""Anaplastic lymphoma kinase (ALK) rearrangements represent a seldom event in non-small cell lung cancer (NSCLC). Given the oncogene alteration, ALK targeting represents the main therapeutic strategy."", ""supports"": ""SUPPORT""}"
5754	5581	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	2	evidence	0	PMID:28017789	SUPPORT		Although the most common EGFR mutations-exon 19 deletions or L858R mutations-predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs)...	This excerpt confirms that NSCLC with activating EGFR mutations (such as exon 19 deletions or L858R mutations) are responsive to EGFR TKIs.	"{""explanation"": ""This excerpt confirms that NSCLC with activating EGFR mutations (such as exon 19 deletions or L858R mutations) are responsive to EGFR TKIs."", ""reference"": ""PMID:28017789"", ""snippet"": ""Although the most common EGFR mutations-exon 19 deletions or L858R mutations-predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs)..."", ""supports"": ""SUPPORT""}"
5755	5581	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	2	evidence	1	PMID:15946581	SUPPORT		A genetic mutation in EGFR has also been correlated with an increase in response.	This statement supports the idea that NSCLC with EGFR mutations are responsive to EGFR inhibitors.	"{""explanation"": ""This statement supports the idea that NSCLC with EGFR mutations are responsive to EGFR inhibitors."", ""reference"": ""PMID:15946581"", ""snippet"": ""A genetic mutation in EGFR has also been correlated with an increase in response."", ""supports"": ""SUPPORT""}"
5756	5581	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	2	evidence	2	PMID:35993098	SUPPORT		Osimertinib is the current standard-of-care for the first-line treatment of EGFR-mutant NSCLC.	Osimertinib, an EGFR inhibitor, being the standard-of-care for EGFR-mutant NSCLC indicates that this subtype is responsive to EGFR inhibitors.	"{""explanation"": ""Osimertinib, an EGFR inhibitor, being the standard-of-care for EGFR-mutant NSCLC indicates that this subtype is responsive to EGFR inhibitors."", ""reference"": ""PMID:35993098"", ""snippet"": ""Osimertinib is the current standard-of-care for the first-line treatment of EGFR-mutant NSCLC."", ""supports"": ""SUPPORT""}"
5757	5581	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	2	evidence	3	PMID:24857124	SUPPORT		Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC.	This excerpt specifically notes the responsiveness of NSCLC with TKI-sensitizing EGFR mutations to EGFR inhibitors.	"{""explanation"": ""This excerpt specifically notes the responsiveness of NSCLC with TKI-sensitizing EGFR mutations to EGFR inhibitors."", ""reference"": ""PMID:24857124"", ""snippet"": ""Somatic TKI-sensitizing EGFR mutations (such as exon 19 deletions and L858R substitutions) are the most robust predictive biomarker for symptom improvement, radiographic response, and increment in progression-free survival (PFS) when EGFR TKIs (gefitinib, erlotinib, and afatinib) are used for patients with advanced NSCLC."", ""supports"": ""SUPPORT""}"
5758	5581	235	Non-Small Cell Lung Cancer	Non-Small_Cell_Lung_Cancer.yaml	has_subtypes	2	evidence	4	PMID:25145405	SUPPORT		Several large Phase III trials have shown that EGFR-TKIs improved the progression-free survival of patients with EGFR mutant NSCLC compared to conventional chemotherapy.	This indicates the effectiveness of EGFR inhibitors in treating EGFR-mutant NSCLC.	"{""explanation"": ""This indicates the effectiveness of EGFR inhibitors in treating EGFR-mutant NSCLC."", ""reference"": ""PMID:25145405"", ""snippet"": ""Several large Phase III trials have shown that EGFR-TKIs improved the progression-free survival of patients with EGFR mutant NSCLC compared to conventional chemotherapy."", ""supports"": ""SUPPORT""}"
6027	5925	251	Pars Planitis	Pars_Planitis.yaml	has_subtypes	0	evidence	0	PMID:39360991	SUPPORT		Pars planitis is the term used for idiopathic intermediate uveitis that presents with snowballs and snowbanks.	This represents the classic form of pars planitis where no underlying cause can be identified.	"{""explanation"": ""This represents the classic form of pars planitis where no underlying cause can be identified."", ""reference"": ""PMID:39360991"", ""snippet"": ""Pars planitis is the term used for idiopathic intermediate uveitis that presents with snowballs and snowbanks."", ""supports"": ""SUPPORT""}"
6028	5926	251	Pars Planitis	Pars_Planitis.yaml	has_subtypes	1	evidence	0	PMID:39360991	SUPPORT		Etiology can be infectious, associated with a systemic disease, neoplastic or idiopathic.	Secondary pars planitis occurs when intermediate uveitis is linked to an underlying systemic or infectious condition.	"{""explanation"": ""Secondary pars planitis occurs when intermediate uveitis is linked to an underlying systemic or infectious condition."", ""reference"": ""PMID:39360991"", ""snippet"": ""Etiology can be infectious, associated with a systemic disease, neoplastic or idiopathic."", ""supports"": ""SUPPORT""}"
6323	6167	261	Pick Disease	Pick_Disease.yaml	has_subtypes	0	evidence	0	PMID:32440921	SUPPORT		Behavioral variant FTD (bvFTD; 12/21) was the most common phenotype... bvFTD and PPA are the most common clinical phenotypes associated with PiD...	The reference identifies that behavioral variant FTD (bvFTD) is a common presentation of Pick's disease, implying that PiD can be characterized by bvFTD symptoms.	"{""explanation"": ""The reference identifies that behavioral variant FTD (bvFTD) is a common presentation of Pick's disease, implying that PiD can be characterized by bvFTD symptoms."", ""reference"": ""PMID:32440921"", ""snippet"": ""Behavioral variant FTD (bvFTD; 12/21) was the most common phenotype... bvFTD and PPA are the most common clinical phenotypes associated with PiD..."", ""supports"": ""SUPPORT""}"
6324	6167	261	Pick Disease	Pick_Disease.yaml	has_subtypes	0	evidence	1	PMID:21881831	SUPPORT		Some present with behavioral variant frontotemporal dementia (bvFTD)... predominantly apathetic with less florid social disinhibition and eating disturbances, and were more anxious than bvFTD(Pick's) patients.	The study confirms that some patients with corticobasal degeneration (CBD) pathology showing bvFTD symptoms have similar trait overlaps with those having Pick's disease.	"{""explanation"": ""The study confirms that some patients with corticobasal degeneration (CBD) pathology showing bvFTD symptoms have similar trait overlaps with those having Pick's disease."", ""reference"": ""PMID:21881831"", ""snippet"": ""Some present with behavioral variant frontotemporal dementia (bvFTD)... predominantly apathetic with less florid social disinhibition and eating disturbances, and were more anxious than bvFTD(Pick's) patients."", ""supports"": ""SUPPORT""}"
6325	6168	261	Pick Disease	Pick_Disease.yaml	has_subtypes	1	evidence	0	PMID:27025090	SUPPORT		Pick's disease is currently defined by the presence of tau-positive Pick bodies... The clinical phenotypes of Pick's disease include behavioral variant FTD (bvFTD), progressive nonfluent aphasia (PNFA) and semantic dementia (SD).	This reference confirms that Pick's disease includes subtypes such as progressive nonfluent aphasia and semantic dementia, which are associated with prominent language deterioration as an initial symptom.	"{""explanation"": ""This reference confirms that Pick's disease includes subtypes such as progressive nonfluent aphasia and semantic dementia, which are associated with prominent language deterioration as an initial symptom."", ""reference"": ""PMID:27025090"", ""snippet"": ""Pick's disease is currently defined by the presence of tau-positive Pick bodies... The clinical phenotypes of Pick's disease include behavioral variant FTD (bvFTD), progressive nonfluent aphasia (PNFA) and semantic dementia (SD)."", ""supports"": ""SUPPORT""}"
6326	6168	261	Pick Disease	Pick_Disease.yaml	has_subtypes	1	evidence	1	PMID:24966676	SUPPORT		Four clinical subtypes characterize the predominant presentations of this illness: behavioral or frontal variant FTD, progressive nonfluent aphasia, semantic dementia, and logopenic primary progressive aphasia.	This reference specifies that frontotemporal dementia, which includes Pick's disease, has subtypes including progressive nonfluent aphasia and semantic dementia, both associated with prominent initial language deterioration.	"{""explanation"": ""This reference specifies that frontotemporal dementia, which includes Pick's disease, has subtypes including progressive nonfluent aphasia and semantic dementia, both associated with prominent initial language deterioration."", ""reference"": ""PMID:24966676"", ""snippet"": ""Four clinical subtypes characterize the predominant presentations of this illness: behavioral or frontal variant FTD, progressive nonfluent aphasia, semantic dementia, and logopenic primary progressive aphasia."", ""supports"": ""SUPPORT""}"
6567	6411	273	Primary Progressive Aphasia	Primary_Progressive_Aphasia.yaml	has_subtypes	0	evidence	0	PMID:21666264	SUPPORT		Primary progressive aphasia is a clinical syndrome that encompasses three major phenotypes: non-fluent/agrammatic, semantic and logopenic.	The abstract lists nonfluent/agrammatic PPA as a major phenotype.	"{""explanation"": ""The abstract lists nonfluent/agrammatic PPA as a major phenotype."", ""reference"": ""PMID:21666264"", ""snippet"": ""Primary progressive aphasia is a clinical syndrome that encompasses three major phenotypes: non-fluent/agrammatic, semantic and logopenic."", ""supports"": ""SUPPORT""}"
6568	6412	273	Primary Progressive Aphasia	Primary_Progressive_Aphasia.yaml	has_subtypes	1	evidence	0	PMID:21666264	SUPPORT		Primary progressive aphasia is a clinical syndrome that encompasses three major phenotypes: non-fluent/agrammatic, semantic and logopenic.	The abstract lists semantic PPA as a major phenotype.	"{""explanation"": ""The abstract lists semantic PPA as a major phenotype."", ""reference"": ""PMID:21666264"", ""snippet"": ""Primary progressive aphasia is a clinical syndrome that encompasses three major phenotypes: non-fluent/agrammatic, semantic and logopenic."", ""supports"": ""SUPPORT""}"
6569	6413	273	Primary Progressive Aphasia	Primary_Progressive_Aphasia.yaml	has_subtypes	2	evidence	0	PMID:21666264	SUPPORT		Primary progressive aphasia is a clinical syndrome that encompasses three major phenotypes: non-fluent/agrammatic, semantic and logopenic.	The abstract lists logopenic PPA as a major phenotype.	"{""explanation"": ""The abstract lists logopenic PPA as a major phenotype."", ""reference"": ""PMID:21666264"", ""snippet"": ""Primary progressive aphasia is a clinical syndrome that encompasses three major phenotypes: non-fluent/agrammatic, semantic and logopenic."", ""supports"": ""SUPPORT""}"
6806	6713	287	Retinoblastoma	Retinoblastoma.yaml	has_subtypes	0	evidence	0	PMID:5279523	SUPPORT		In the dominantly inherited form, one mutation is inherited via the germinal cells and the second occurs in somatic cells.	Knudson's analysis established that hereditary retinoblastoma involves germline inheritance of the first mutation.	"{""explanation"": ""Knudson's analysis established that hereditary retinoblastoma involves germline inheritance of the first mutation."", ""reference"": ""PMID:5279523"", ""snippet"": ""In the dominantly inherited form, one mutation is inherited via the germinal cells and the second occurs in somatic cells."", ""supports"": ""SUPPORT""}"
6807	6714	287	Retinoblastoma	Retinoblastoma.yaml	has_subtypes	1	evidence	0	PMID:5279523	SUPPORT		In the nonhereditary form, both mutations occur in somatic cells.	Knudson established that sporadic retinoblastoma requires two somatic mutations in the same cell.	"{""explanation"": ""Knudson established that sporadic retinoblastoma requires two somatic mutations in the same cell."", ""reference"": ""PMID:5279523"", ""snippet"": ""In the nonhereditary form, both mutations occur in somatic cells."", ""supports"": ""SUPPORT""}"
6894	6772	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	has_subtypes	0	evidence	0	PMID:28451788	SUPPORT		Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation. The presence of autoantibodies in the sera of RA patients has provided many clues to the underlying disease pathophysiology. Based on the presence of several autoantibodies like rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA)... RA can be subdivided into seropositive and seronegative disease.	The literature indicates that RA can be subdivided into seropositive and seronegative types based on the presence of RF and/or ACPAs in the sera of the patients, which supports the given statement.	"{""explanation"": ""The literature indicates that RA can be subdivided into seropositive and seronegative types based on the presence of RF and/or ACPAs in the sera of the patients, which supports the given statement."", ""reference"": ""PMID:28451788"", ""snippet"": ""Rheumatoid arthritis (RA) is an autoimmune disease characterized by joint inflammation. The presence of autoantibodies in the sera of RA patients has provided many clues to the underlying disease pathophysiology. Based on the presence of several autoantibodies like rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPA)... RA can be subdivided into seropositive and seronegative disease."", ""supports"": ""SUPPORT""}"
6895	6773	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	has_subtypes	1	evidence	0	PMID:33329548	SUPPORT		Traditionally, RA is divided into seropositive (SP) and seronegative (SN) disease forms, the latter consisting of an array of unrelated diseases with joint involvement.	This study discusses SN-RA as a form characterized by the absence of anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF), supporting the statement.	"{""explanation"": ""This study discusses SN-RA as a form characterized by the absence of anti-citrullinated peptide antibody (ACPA) and rheumatoid factor (RF), supporting the statement."", ""reference"": ""PMID:33329548"", ""snippet"": ""Traditionally, RA is divided into seropositive (SP) and seronegative (SN) disease forms, the latter consisting of an array of unrelated diseases with joint involvement."", ""supports"": ""SUPPORT""}"
6896	6773	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	has_subtypes	1	evidence	1	PMID:3266362	SUPPORT		We became increasingly concerned with the problem of defining properly patients with seronegative RA. Both the statement of seronegativity with regard to rheumatoid factors (RF), the diagnosis of RA, and particularly the exclusion of cases of seronegative arthritis other than RA were difficult.	This study acknowledges the existence of seronegative RA defined by the absence of RF.	"{""explanation"": ""This study acknowledges the existence of seronegative RA defined by the absence of RF."", ""reference"": ""PMID:3266362"", ""snippet"": ""We became increasingly concerned with the problem of defining properly patients with seronegative RA. Both the statement of seronegativity with regard to rheumatoid factors (RF), the diagnosis of RA, and particularly the exclusion of cases of seronegative arthritis other than RA were difficult."", ""supports"": ""SUPPORT""}"
6897	6773	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	has_subtypes	1	evidence	2	PMID:32678001	PARTIAL		Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays.	This supports the seronegative classification based on the absence of RF and anti-CCP antibodies but points out the complexity and variability within seronegative RA.	"{""explanation"": ""This supports the seronegative classification based on the absence of RF and anti-CCP antibodies but points out the complexity and variability within seronegative RA."", ""reference"": ""PMID:32678001"", ""snippet"": ""Rheumatoid arthritis (RA) is classified as seropositive or seronegative, depending on the presence/absence of rheumatoid factor (RF), primarily IgM RF, and/or anti-citrullinated protein antibodies (ACPA), commonly detected using anti-cyclic citrullinated peptide (CCP) assays."", ""supports"": ""PARTIAL""}"
6898	6773	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	has_subtypes	1	evidence	3	PMID:38251565	SUPPORT		The subset of rheumatoid arthritis that does not have autoantibodies (such as rheumatoid factor and anti-citrullinated protein autoantibodies) remains less well defined in its pathogenic mechanisms.	Refers to RA without autoantibodies, supporting the statement that such a subtype exists.	"{""explanation"": ""Refers to RA without autoantibodies, supporting the statement that such a subtype exists."", ""reference"": ""PMID:38251565"", ""snippet"": ""The subset of rheumatoid arthritis that does not have autoantibodies (such as rheumatoid factor and anti-citrullinated protein autoantibodies) remains less well defined in its pathogenic mechanisms."", ""supports"": ""SUPPORT""}"
6899	6774	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	has_subtypes	2	evidence	0	PMID:35087087	PARTIAL		Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting for >6 weeks with onset before 16 years of age.	The literature specifies that JIA is defined as arthritis lasting for more than 6 weeks with onset before 16 years, aligning with the statement. However, JIA is not a subtype of Rheumatoid Arthritis but rather a distinct condition.	"{""explanation"": ""The literature specifies that JIA is defined as arthritis lasting for more than 6 weeks with onset before 16 years, aligning with the statement. However, JIA is not a subtype of Rheumatoid Arthritis but rather a distinct condition."", ""reference"": ""PMID:35087087"", ""snippet"": ""Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting for >6 weeks with onset before 16 years of age."", ""supports"": ""PARTIAL""}"
6900	6774	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	has_subtypes	2	evidence	1	PMID:23763801	NO_EVIDENCE		To determine the spectrum of clinical presentation, laboratory parameters and drug therapy in patients with Juvenile Rheumatoid Arthritis (JRA).	The study focuses on Juvenile Rheumatoid Arthritis (JRA), a term which is sometimes used synonymously with Juvenile Idiopathic Arthritis (JIA) but does not explicitly define it as a subtype of Rheumatoid Arthritis.	"{""explanation"": ""The study focuses on Juvenile Rheumatoid Arthritis (JRA), a term which is sometimes used synonymously with Juvenile Idiopathic Arthritis (JIA) but does not explicitly define it as a subtype of Rheumatoid Arthritis."", ""reference"": ""PMID:23763801"", ""snippet"": ""To determine the spectrum of clinical presentation, laboratory parameters and drug therapy in patients with Juvenile Rheumatoid Arthritis (JRA)."", ""supports"": ""NO_EVIDENCE""}"
6901	6774	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	has_subtypes	2	evidence	2	PMID:37700346	PARTIAL		Childhood-onset rheumatoid arthritis (CORA), known as rheumatoid factor (RF)-positive juvenile idiopathic arthritis is a type of juvenile idiopathic arthritis that shares the same genetic factors and clinical features as adult-onset rheumatoid arthritis.	This literature mentions that RF-positive juvenile idiopathic arthritis is a type of JIA sharing features with adult RA. It confirms that JIA has clinical overlap with RA but does not support that JIA is a subtype of RA.	"{""explanation"": ""This literature mentions that RF-positive juvenile idiopathic arthritis is a type of JIA sharing features with adult RA. It confirms that JIA has clinical overlap with RA but does not support that JIA is a subtype of RA."", ""reference"": ""PMID:37700346"", ""snippet"": ""Childhood-onset rheumatoid arthritis (CORA), known as rheumatoid factor (RF)-positive juvenile idiopathic arthritis is a type of juvenile idiopathic arthritis that shares the same genetic factors and clinical features as adult-onset rheumatoid arthritis."", ""supports"": ""PARTIAL""}"
6902	6774	290	Rheumatoid Arthritis	Rheumatoid_Arthritis.yaml	has_subtypes	2	evidence	3	PMID:8465574	NO_EVIDENCE		Ten to thirty-three per cent of all cases of rheumatoid arthritis (RA) develop after sixty years of age. Late-onset RA patients are more likely to be male, to have faster onset of symptoms...	The literature provided does not discuss JIA or its relation as a subtype of RA.	"{""explanation"": ""The literature provided does not discuss JIA or its relation as a subtype of RA."", ""reference"": ""PMID:8465574"", ""snippet"": ""Ten to thirty-three per cent of all cases of rheumatoid arthritis (RA) develop after sixty years of age. Late-onset RA patients are more likely to be male, to have faster onset of symptoms..."", ""supports"": ""NO_EVIDENCE""}"
7041	6849	293	Salla Disease	Salla_Disease.yaml	has_subtypes	0	evidence	0	PMID:37713976	SUPPORT	HUMAN_CLINICAL	Disease onset occurred within the first six months of life in both patients. Early childhood development was delayed with achievement of some milestones followed by a developmental plateau in late childhood. After this, both patients began a slow and progressive neurological regression in adolescence.	Longitudinal study characterizes clinical course of intermediate-severe Salla disease as distinct from classic form with progressive regression.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Longitudinal study characterizes clinical course of intermediate-severe Salla disease as distinct from classic form with progressive regression."", ""reference"": ""PMID:37713976"", ""snippet"": ""Disease onset occurred within the first six months of life in both patients. Early childhood development was delayed with achievement of some milestones followed by a developmental plateau in late childhood. After this, both patients began a slow and progressive neurological regression in adolescence."", ""supports"": ""SUPPORT""}"
7042	6849	293	Salla Disease	Salla_Disease.yaml	has_subtypes	0	evidence	1	PMID:28662915	SUPPORT	HUMAN_CLINICAL	Likely pathogenic variants in SLC17A5 results in allelic disorders of free sialic acid metabolism including (1) infantile free sialic acid storage disease with severe global developmental delay, coarse facial features, hepatosplenomegaly, and cardiomegaly; (2) intermediate severe Salla disease with moderate to severe global developmental delay, hypotonia, and hypomyelination with or without coarse facial features, and (3) Salla disease with normal appearance, mild cognitive dysfunction, and spasticity.	Comprehensive literature review and case report of intermediate-severe Salla disease identifies hypomyelination, developmental delay, and hypotonia as characteristic features, with compound heterozygous SLC17A5 variants. Demonstrates that normal or marginally elevated urine sialic acid cannot exclude this phenotype.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""Comprehensive literature review and case report of intermediate-severe Salla disease identifies hypomyelination, developmental delay, and hypotonia as characteristic features, with compound heterozygous SLC17A5 variants. Demonstrates that normal or marginally elevated urine sialic acid cannot exclude this phenotype."", ""reference"": ""PMID:28662915"", ""snippet"": ""Likely pathogenic variants in SLC17A5 results in allelic disorders of free sialic acid metabolism including (1) infantile free sialic acid storage disease with severe global developmental delay, coarse facial features, hepatosplenomegaly, and cardiomegaly; (2) intermediate severe Salla disease with moderate to severe global developmental delay, hypotonia, and hypomyelination with or without coarse facial features, and (3) Salla disease with normal appearance, mild cognitive dysfunction, and spasticity."", ""supports"": ""SUPPORT""}"
7498	7283	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	has_subtypes	0	evidence	0	PMID:35084720	SUPPORT		GAD antibody-spectrum disorders (GAD-SD) that include Cerebellar Ataxia, Autoimmune Epilepsy, Limbic Encephalitis, PERM and eye movement disorder. In spite of the unique clinical phenotype that each of these disorders has, there is significant overlapping symptomatology characterized by autoimmune neuronal excitability.	The paper defines classic SPS as part of a broader spectrum of GAD antibody-associated disorders with unique clinical phenotypes.	"{""explanation"": ""The paper defines classic SPS as part of a broader spectrum of GAD antibody-associated disorders with unique clinical phenotypes."", ""reference"": ""PMID:35084720"", ""snippet"": ""GAD antibody-spectrum disorders (GAD-SD) that include Cerebellar Ataxia, Autoimmune Epilepsy, Limbic Encephalitis, PERM and eye movement disorder. In spite of the unique clinical phenotype that each of these disorders has, there is significant overlapping symptomatology characterized by autoimmune neuronal excitability."", ""supports"": ""SUPPORT""}"
7499	7284	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	has_subtypes	1	evidence	0	PMID:35084720	SUPPORT		In spite of the unique clinical phenotype that each of these disorders has, there is significant overlapping symptomatology characterized by autoimmune neuronal excitability.	Clinical heterogeneity in GAD-spectrum disorders includes focal variants like stiff limb syndrome.	"{""explanation"": ""Clinical heterogeneity in GAD-spectrum disorders includes focal variants like stiff limb syndrome."", ""reference"": ""PMID:35084720"", ""snippet"": ""In spite of the unique clinical phenotype that each of these disorders has, there is significant overlapping symptomatology characterized by autoimmune neuronal excitability."", ""supports"": ""SUPPORT""}"
7500	7285	316	Stiff Person Syndrome	Stiff_Person_Syndrome.yaml	has_subtypes	2	evidence	0	PMID:35084720	SUPPORT		GAD antibody-spectrum disorders (GAD-SD) that include Cerebellar Ataxia, Autoimmune Epilepsy, Limbic Encephalitis, PERM and eye movement disorder.	PERM is explicitly listed as part of the GAD antibody-spectrum disorders.	"{""explanation"": ""PERM is explicitly listed as part of the GAD antibody-spectrum disorders."", ""reference"": ""PMID:35084720"", ""snippet"": ""GAD antibody-spectrum disorders (GAD-SD) that include Cerebellar Ataxia, Autoimmune Epilepsy, Limbic Encephalitis, PERM and eye movement disorder."", ""supports"": ""SUPPORT""}"
7565	7337	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	0	evidence	0	PMID:30988213	SUPPORT		The representatives of the chronic and acute types are discoid lupus erythematosus (DLE) and butterfly rash, respectively. Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE). Chronic LE eruptions tend to be seen in cutaneous-limited LE, and acute LE eruptions mainly appear in SLE.	Discoid Lupus Erythematosus (DLE) is a chronic cutaneous form of lupus erythematosus primarily affecting the skin.	"{""explanation"": ""Discoid Lupus Erythematosus (DLE) is a chronic cutaneous form of lupus erythematosus primarily affecting the skin."", ""reference"": ""PMID:30988213"", ""snippet"": ""The representatives of the chronic and acute types are discoid lupus erythematosus (DLE) and butterfly rash, respectively. Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE). Chronic LE eruptions tend to be seen in cutaneous-limited LE, and acute LE eruptions mainly appear in SLE."", ""supports"": ""SUPPORT""}"
7566	7337	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	0	evidence	1	PMID:7763220	SUPPORT		Discoid lupus erythematosus is a manifestation of chronic cutaneous lupus erythematosus with a small risk of systemic involvement.	This reference confirms that Discoid Lupus Erythematosus primarily affects the skin.	"{""explanation"": ""This reference confirms that Discoid Lupus Erythematosus primarily affects the skin."", ""reference"": ""PMID:7763220"", ""snippet"": ""Discoid lupus erythematosus is a manifestation of chronic cutaneous lupus erythematosus with a small risk of systemic involvement."", ""supports"": ""SUPPORT""}"
7567	7337	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	0	evidence	2	PMID:28941498	SUPPORT		Cutaneous lupus erythematosus, specifically discoid lupus erythematosus, disproportionately affects those with skin of color and may result in greater dyspigmentation and scarring in darker skin types.	This reference confirms the primary cutaneous impact of Discoid Lupus Erythematosus.	"{""explanation"": ""This reference confirms the primary cutaneous impact of Discoid Lupus Erythematosus."", ""reference"": ""PMID:28941498"", ""snippet"": ""Cutaneous lupus erythematosus, specifically discoid lupus erythematosus, disproportionately affects those with skin of color and may result in greater dyspigmentation and scarring in darker skin types."", ""supports"": ""SUPPORT""}"
7568	7338	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	1	evidence	0	PMID:9287379	SUPPORT		neonatal lupus erythematosus is likely the result of fetal or neonatal tissue damage caused by maternally transmitted IgG autoantibodies.	This describes neonatal lupus erythematosus as a subtype of lupus erythematosus affecting newborns due to the transplacental transfer of maternal autoantibodies.	"{""explanation"": ""This describes neonatal lupus erythematosus as a subtype of lupus erythematosus affecting newborns due to the transplacental transfer of maternal autoantibodies."", ""reference"": ""PMID:9287379"", ""snippet"": ""neonatal lupus erythematosus is likely the result of fetal or neonatal tissue damage caused by maternally transmitted IgG autoantibodies."", ""supports"": ""SUPPORT""}"
7569	7338	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	1	evidence	1	PMID:24763535	SUPPORT		Another complication may be neonatal lupus (NL), mediated by the presence of maternal antibodies (anti-Ro/SSA and anti-La/SSB).	The reference notes that neonatal lupus is mediated by maternal autoantibodies, supporting the statement.	"{""explanation"": ""The reference notes that neonatal lupus is mediated by maternal autoantibodies, supporting the statement."", ""reference"": ""PMID:24763535"", ""snippet"": ""Another complication may be neonatal lupus (NL), mediated by the presence of maternal antibodies (anti-Ro/SSA and anti-La/SSB)."", ""supports"": ""SUPPORT""}"
7570	7338	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	1	evidence	2	PMID:15744116	SUPPORT		Neonatal lupus syndrome is a passively acquired autoimmune syndrome in which pathogenic autoantibodies (anti-SSA/Ro, anti-SSB/La... antibodies) are transmitted from a mother to her fetus through the placenta.	This confirms that neonatal lupus is a result of the transplacental transfer of maternal antibodies.	"{""explanation"": ""This confirms that neonatal lupus is a result of the transplacental transfer of maternal antibodies."", ""reference"": ""PMID:15744116"", ""snippet"": ""Neonatal lupus syndrome is a passively acquired autoimmune syndrome in which pathogenic autoantibodies (anti-SSA/Ro, anti-SSB/La... antibodies) are transmitted from a mother to her fetus through the placenta."", ""supports"": ""SUPPORT""}"
7571	7338	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	1	evidence	3	PMID:3521977	SUPPORT		Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus...	This supports the classification of neonatal lupus erythematosus as a subtype affecting children due to maternal factors.	"{""explanation"": ""This supports the classification of neonatal lupus erythematosus as a subtype affecting children due to maternal factors."", ""reference"": ""PMID:3521977"", ""snippet"": ""Lupus erythematosus in childhood comprises the following distinctive lupus subsets: neonatal lupus erythematosus..."", ""supports"": ""SUPPORT""}"
7572	7338	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	1	evidence	4	PMID:22832822	PARTIAL		Cardiac manifestations of neonatal lupus include anti-SSA/Ro-SSB/La-mediated conduction system disease and endocardial/myocardial damage resulting in cardiomyopathy.	This reference implies that neonatal lupus caused by maternal autoantibodies affects the heart but doesn't explicitly say it's a systemic lupus erythematosus subtype.	"{""explanation"": ""This reference implies that neonatal lupus caused by maternal autoantibodies affects the heart but doesn't explicitly say it's a systemic lupus erythematosus subtype."", ""reference"": ""PMID:22832822"", ""snippet"": ""Cardiac manifestations of neonatal lupus include anti-SSA/Ro-SSB/La-mediated conduction system disease and endocardial/myocardial damage resulting in cardiomyopathy."", ""supports"": ""PARTIAL""}"
7573	7339	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	2	evidence	0	PMID:1356074	SUPPORT		The epidemiologic characteristics of medication-induced SLE (MI-SLE) are different from those of idiopathic SLE... Hydralazine and procainamide are the most commonly recognized medications for inducing SLE.	This indicates that there is a distinct subtype of SLE induced by medications.	"{""explanation"": ""This indicates that there is a distinct subtype of SLE induced by medications."", ""reference"": ""PMID:1356074"", ""snippet"": ""The epidemiologic characteristics of medication-induced SLE (MI-SLE) are different from those of idiopathic SLE... Hydralazine and procainamide are the most commonly recognized medications for inducing SLE."", ""supports"": ""SUPPORT""}"
7574	7339	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	2	evidence	1	PMID:23164669	SUPPORT		Drug-induced lupus erythematosus (DILE) refers to a condition whose clinical, histological, and immunological features are similar to those seen in idiopathic lupus erythematosus but that occurs when certain drugs are taken and resolves after their withdrawal.	This explicitly states that drug-induced lupus erythematosus (DILE) is caused by certain medications and is usually reversible after discontinuation of the drug.	"{""explanation"": ""This explicitly states that drug-induced lupus erythematosus (DILE) is caused by certain medications and is usually reversible after discontinuation of the drug."", ""reference"": ""PMID:23164669"", ""snippet"": ""Drug-induced lupus erythematosus (DILE) refers to a condition whose clinical, histological, and immunological features are similar to those seen in idiopathic lupus erythematosus but that occurs when certain drugs are taken and resolves after their withdrawal."", ""supports"": ""SUPPORT""}"
7575	7339	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	2	evidence	2	PMID:1751313	SUPPORT		All physicians should be alerted to the many drugs and other agents that are associated with drug-related lupus, as there is an increasing number of such drugs... Continued study of this human experimental model of lupus will help to clarify the etiology and mechanisms of systemic lupus erythematosus itself.	This literature mentions that certain drugs are associated with drug-related lupus, providing further support to the statement.	"{""explanation"": ""This literature mentions that certain drugs are associated with drug-related lupus, providing further support to the statement."", ""reference"": ""PMID:1751313"", ""snippet"": ""All physicians should be alerted to the many drugs and other agents that are associated with drug-related lupus, as there is an increasing number of such drugs... Continued study of this human experimental model of lupus will help to clarify the etiology and mechanisms of systemic lupus erythematosus itself."", ""supports"": ""SUPPORT""}"
7576	7339	318	Systemic Lupus Erythematosus	Systemic_Lupus_Erythematosus.yaml	has_subtypes	2	evidence	3	PMID:25037258	SUPPORT		This article discusses the clinical presentation, time frames, reported culprit medications, pathophysiology and management of drug-induced lupus...	This article covers drug-induced lupus, affirming the existence of this subtype linked to medications.	"{""explanation"": ""This article covers drug-induced lupus, affirming the existence of this subtype linked to medications."", ""reference"": ""PMID:25037258"", ""snippet"": ""This article discusses the clinical presentation, time frames, reported culprit medications, pathophysiology and management of drug-induced lupus..."", ""supports"": ""SUPPORT""}"
7803	7547	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	has_subtypes	0	evidence	0	PMID:21633166	SUPPORT		BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin.	The Lehmann et al. study identified basal-like subtypes (BL1 and BL2) with high cell cycle and DNA damage response gene expression, consistent with high proliferation and BRCA1 mutations.	"{""explanation"": ""The Lehmann et al. study identified basal-like subtypes (BL1 and BL2) with high cell cycle and DNA damage response gene expression, consistent with high proliferation and BRCA1 mutations."", ""reference"": ""PMID:21633166"", ""snippet"": ""BL1 and BL2 subtypes had higher expression of cell cycle and DNA damage response genes, and representative cell lines preferentially responded to cisplatin."", ""supports"": ""SUPPORT""}"
7804	7548	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	has_subtypes	1	evidence	0	PMID:21633166	SUPPORT		M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition, and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/src inhibitor).	The Lehmann et al. study confirmed mesenchymal subtypes are enriched for EMT and growth factor pathways, responding to PI3K/mTOR inhibition.	"{""explanation"": ""The Lehmann et al. study confirmed mesenchymal subtypes are enriched for EMT and growth factor pathways, responding to PI3K/mTOR inhibition."", ""reference"": ""PMID:21633166"", ""snippet"": ""M and MSL subtypes were enriched in GE for epithelial-mesenchymal transition, and growth factor pathways and cell models responded to NVP-BEZ235 (a PI3K/mTOR inhibitor) and dasatinib (an abl/src inhibitor)."", ""supports"": ""SUPPORT""}"
7805	7549	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	has_subtypes	2	evidence	0	PMID:21633166	SUPPORT		The LAR subtype includes patients with decreased relapse-free survival and was characterized by androgen receptor (AR) signaling. LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist).	The Lehmann et al. study identified the LAR subtype characterized by AR signaling and sensitivity to AR antagonists.	"{""explanation"": ""The Lehmann et al. study identified the LAR subtype characterized by AR signaling and sensitivity to AR antagonists."", ""reference"": ""PMID:21633166"", ""snippet"": ""The LAR subtype includes patients with decreased relapse-free survival and was characterized by androgen receptor (AR) signaling. LAR cell lines were uniquely sensitive to bicalutamide (an AR antagonist)."", ""supports"": ""SUPPORT""}"
7806	7550	330	Triple-Negative Breast Cancer	Triple_Negative_Breast_Cancer.yaml	has_subtypes	3	evidence	0	PMID:21633166	SUPPORT		Cluster analysis identified 6 TNBC subtypes displaying unique GE and ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype.	The Lehmann et al. study identified the immunomodulatory (IM) subtype as one of the six TNBC subtypes with unique gene expression profiles.	"{""explanation"": ""The Lehmann et al. study identified the immunomodulatory (IM) subtype as one of the six TNBC subtypes with unique gene expression profiles."", ""reference"": ""PMID:21633166"", ""snippet"": ""Cluster analysis identified 6 TNBC subtypes displaying unique GE and ontologies, including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL), and a luminal androgen receptor (LAR) subtype."", ""supports"": ""SUPPORT""}"
8167	7782	338	Vitiligo	Vitiligo.yaml	has_subtypes	0	evidence	0	PMID:20540698	SUPPORT	HUMAN_CLINICAL	Non segmental vitiligo (NSV) is the most common form of the disease: it is usually progressive and may be associated with familiarity and autoimmunity.	The reference confirms that Non-Segmental Vitiligo (NSV) is the most common form of vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The reference confirms that Non-Segmental Vitiligo (NSV) is the most common form of vitiligo."", ""reference"": ""PMID:20540698"", ""snippet"": ""Non segmental vitiligo (NSV) is the most common form of the disease: it is usually progressive and may be associated with familiarity and autoimmunity."", ""supports"": ""SUPPORT""}"
8168	7782	338	Vitiligo	Vitiligo.yaml	has_subtypes	0	evidence	1	PMID:22237197	SUPPORT	HUMAN_CLINICAL	Generalized vitiligo was the most common type (n=132, 57.4%) followed by focal (n=53, 23%) and acro-facial vitiligo (n=16, 7%).	This reference identifies generalized vitiligo as the most common, which is a subtype of NSV, supporting the statement.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This reference identifies generalized vitiligo as the most common, which is a subtype of NSV, supporting the statement."", ""reference"": ""PMID:22237197"", ""snippet"": ""Generalized vitiligo was the most common type (n=132, 57.4%) followed by focal (n=53, 23%) and acro-facial vitiligo (n=16, 7%)."", ""supports"": ""SUPPORT""}"
8169	7782	338	Vitiligo	Vitiligo.yaml	has_subtypes	0	evidence	2	PMID:33431938	SUPPORT	HUMAN_CLINICAL	Non-segmental vitiligo (NSV) is the most common type of vitiligo, which is characterized by chronic and progressive loss of melanocytes.	The reference directly states that NSV is the most common type of vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The reference directly states that NSV is the most common type of vitiligo."", ""reference"": ""PMID:33431938"", ""snippet"": ""Non-segmental vitiligo (NSV) is the most common type of vitiligo, which is characterized by chronic and progressive loss of melanocytes."", ""supports"": ""SUPPORT""}"
8170	7782	338	Vitiligo	Vitiligo.yaml	has_subtypes	0	evidence	3	PMID:37062442	SUPPORT	HUMAN_CLINICAL	The concomitance of autoimmune disease in vitiligo patients demands the investigation of immune-mediated inner ear disease (IMIED) as a cause of SNHL in NSV.	The reference indicates the association of autoimmune conditions with NSV, characterizing it as a common subtype.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The reference indicates the association of autoimmune conditions with NSV, characterizing it as a common subtype."", ""reference"": ""PMID:37062442"", ""snippet"": ""The concomitance of autoimmune disease in vitiligo patients demands the investigation of immune-mediated inner ear disease (IMIED) as a cause of SNHL in NSV."", ""supports"": ""SUPPORT""}"
8171	7782	338	Vitiligo	Vitiligo.yaml	has_subtypes	0	evidence	4	PMID:30988213	PARTIAL	OTHER	Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE).	This reference mainly discusses lupus erythematosus but indirectly aligns with autoimmune connections similar to NSV.	"{""evidence_source"": ""OTHER"", ""explanation"": ""This reference mainly discusses lupus erythematosus but indirectly aligns with autoimmune connections similar to NSV."", ""reference"": ""PMID:30988213"", ""snippet"": ""Based on the systemic manifestations, we can classify LE into cutaneous-limited LE and systemic LE (SLE)."", ""supports"": ""PARTIAL""}"
8172	7782	338	Vitiligo	Vitiligo.yaml	has_subtypes	0	evidence	5	PMID:7593796	NO_EVIDENCE	OTHER	The term 'trichrome vitiligo' has been used to describe lesions of vitiligo that have an intermediate level of color between the achromic center and the peripheral unaffected skin.	This reference discusses trichrome vitiligo, which is not directly about NSV or its commonality.	"{""evidence_source"": ""OTHER"", ""explanation"": ""This reference discusses trichrome vitiligo, which is not directly about NSV or its commonality."", ""reference"": ""PMID:7593796"", ""snippet"": ""The term 'trichrome vitiligo' has been used to describe lesions of vitiligo that have an intermediate level of color between the achromic center and the peripheral unaffected skin."", ""supports"": ""NO_EVIDENCE""}"
8173	7783	338	Vitiligo	Vitiligo.yaml	has_subtypes	1	evidence	0	PMID:28317524	SUPPORT	HUMAN_CLINICAL	Segmental vitiligo is characterized by its early onset, rapid stabilization, and unilateral distribution.	The provided description is consistent with the characterization of segmental vitiligo mentioned in the literature.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The provided description is consistent with the characterization of segmental vitiligo mentioned in the literature."", ""reference"": ""PMID:28317524"", ""snippet"": ""Segmental vitiligo is characterized by its early onset, rapid stabilization, and unilateral distribution."", ""supports"": ""SUPPORT""}"
8174	7783	338	Vitiligo	Vitiligo.yaml	has_subtypes	1	evidence	1	PMID:35094387	SUPPORT	HUMAN_CLINICAL	Mixed vitiligo (MV) is the coexistence of segmental vitiligo (SV) and non-segmental vitiligo (NSV)...As compared to SV, MV had significantly lower mean age of onset of segmental component (SC) (13.33  9.01 vs. 15.70  8.60 years, P = 0.03) and significantly higher proportion of patients with more than 1% body surface involvement by SC (66.2% vs. 51.5%, P = 0.03)	The text mentions segmental vitiligo and supports characteristics such as early onset.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The text mentions segmental vitiligo and supports characteristics such as early onset."", ""reference"": ""PMID:35094387"", ""snippet"": ""Mixed vitiligo (MV) is the coexistence of segmental vitiligo (SV) and non-segmental vitiligo (NSV)...As compared to SV, MV had significantly lower mean age of onset of segmental component (SC) (13.33  9.01 vs. 15.70  8.60 years, P = 0.03) and significantly higher proportion of patients with more than 1% body surface involvement by SC (66.2% vs. 51.5%, P = 0.03)"", ""supports"": ""SUPPORT""}"
8175	7784	338	Vitiligo	Vitiligo.yaml	has_subtypes	2	evidence	0	PMID:17241584	SUPPORT	HUMAN_CLINICAL	OBSERVATION: We report four more cases of mixed vtiligo, segmental with generalized type	The provided literature discusses cases where segmental and generalized vitiligo occur together in the same individual, which supports the existence of mixed vitiligo.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""The provided literature discusses cases where segmental and generalized vitiligo occur together in the same individual, which supports the existence of mixed vitiligo."", ""reference"": ""PMID:17241584"", ""snippet"": ""OBSERVATION: We report four more cases of mixed vtiligo, segmental with generalized type"", ""supports"": ""SUPPORT""}"
8176	7784	338	Vitiligo	Vitiligo.yaml	has_subtypes	2	evidence	1	PMID:34780118	PARTIAL	HUMAN_CLINICAL	The overlaps between segmental vitiligo (SV) and nonsegmental vitiligo (NSV) suggest the underlying features of SV, which may be helpful for treating SV...The clinical and immunological similarities between SV and M-NSV presented a deeper autoimmune understanding of SV.	This reference discusses overlaps and similarities between segmental and non-segmental vitiligo but does not specifically confirm the simultaneous or sequential occurrence in the same individual.	"{""evidence_source"": ""HUMAN_CLINICAL"", ""explanation"": ""This reference discusses overlaps and similarities between segmental and non-segmental vitiligo but does not specifically confirm the simultaneous or sequential occurrence in the same individual."", ""reference"": ""PMID:34780118"", ""snippet"": ""The overlaps between segmental vitiligo (SV) and nonsegmental vitiligo (NSV) suggest the underlying features of SV, which may be helpful for treating SV...The clinical and immunological similarities between SV and M-NSV presented a deeper autoimmune understanding of SV."", ""supports"": ""PARTIAL""}"
